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ABSTRACT
HIGH-THROUGHPUT ENGINEERING AND ANALYSIS OF CLASS II
MHC/PEPTIDE BINDING BY YEAST CO-DISPLAY
Wei Jiang
Eric T. Boder
Polymorphisms of major histocompatibility complex (MHC) and molecular mechanisms
of their antigen-presenting specificity and promiscuity have great impact on T cellmediated immune responses and related diseases.

Challenges in elucidating the

characteristics of antigenic peptide binding by MHC motivate the development of high
throughput experimental tools to quantitatively analyze interactions between hundreds of
MHC allelic proteins and various peptide sequences. We demonstrated such a method
by co-displaying target peptides and class II MHC (MHC-II) on the yeast surface in an
intracellular association-dependent manner.

The optimized yeast co-display system

enabled quantitative mapping of side-chain preferences and general motifs for peptides
binding to MHC-II by site-directed mutagenesis or peptide library screening, and also
allowed rapid tailoring of MHC-II peptide binding specificity by directed evolution
approaches, which derived MHC-II allelic mutants with altered peptide binding
specificity or hyper-promiscuity.

Comparison of these experimentally engineered

mutants with naturally discovered MHC-II proteins recovered valuable information
about structure-function relationship in the evolutionary mechanisms for polymorphic
MHC-II molecules, which could direct future immunotherapeutic innovation.
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Chapter 1. Background and significance
1.1. Overview
Biological evolution makes creatures on the earth more and more sophisticated as
well as better and better developed. For example, to protect against diseases caused by
various agents in the surrounding, organisms have developed a defending bio-system
called immune system1-3 by gradually accumulating and coordinating subtle helpful
immunological features supplied by specifically differentiated cells and naturally
evolved molecules over thousands or millions of generations. Natural evolution is slow
and results are determined by complex fitness constraints existing in nature.
Nonetheless, evolution remains a powerful paradigm for optimizing biological systems.
Thus, in vitro methods for directed evolution4, 5, wherein researchers can control fitness
drivers guiding change, have garnered substantial interest in the last two decades. These
methods are commonly and most simply applied to proteins6, 7, the basic unit of
biological function.
Most highly developed vertebrates, such as mammals and humans, have a relatively
complicated immune system consisting of many types of organs, tissues, cells, and
proteins, which connect with each other in an elaborate and dynamic process. Within
this network, CD4+ T cell, a sub-group of lymphocytes, serves as a director to control
and optimize the function of other immune effector cells8 and a booster to maximize the
efficacy of immunity. The role of these lymphocytes is so important that dysfunction or
deficiency of functional CD4+ T cells in human individuals will result in fatal immune
disorders, such as severe combined immunodeficiency (SCID)9 and acquired immune
1

deficiency syndrome (AIDS) caused by a notorious virus, HIV10.

It is of great

importance to understand the mechanism for stimulation of CD4+ T cell responses and
find a possible way to modulate their activation and function. Studies of CD4+ T cells at
the molecular level indicate that two signals are involved in the process of their epitope
specific activation11, 12. The primary pathway for transmitting signal 1 is predominantly
determined by the molecular interaction between T cell receptor (TCR) and class II
major histocompatibility complex (MHC-II) associated with antigenic peptide processed
and presented by professional antigen-presenting cells (APCs)11, 13. Therefore, peptidebinding specificity of MHC-II proteins plays an important role in defining the epitope
specificity of T cell activation and evolution of MHC-II for altered specificity implicates
potentials in regulation of helper T cell-mediated immune responses.
As one of the most polymorphic membrane proteins14, 15, MHC has already been
selected for millennia by nature16, 17 so that each MHC-II allele is poly-specific for a
large set of antigenic peptides derived from both endocytosed pathogens and cytosolic
proteins18-22 and only a few alleles are required and expressed by each individual for
presentation of peptides and initiation of T cell responses to overwhelm a verity of
foreign invaders. However, environmental changes enforce improvement of MHC’s
peptide selectivity such that CD4+ T cell mediated immune responses could function
against mutagenic pathogens. Laboratorial protein engineering techniques enable an
initial evaluation of these evolutionary processes experimentally, which not only help to
understand structure-function relationship for naturally evolved MHC-II molecules but
also shed light on artificially modulating immune responses for therapeutic purpose.

2

This thesis work is focused on 1) development of a quantitative, high throughput in
vitro protein engineering methodology – yeast co-display, for studying the interaction
between various peptides and diverse MHC-II molecules (Chapter 2 and 3); 2)
characterization at the molecular level of peptide binding specificity for selected MHC-II
allele (HLA-DR1), determination of side chain preference for some pocket-like region in
the binding site of DR1 (or pocket profile23), and prediction of DR1 specific ligands
using the novel technology (Chapter 4); 3) modification of pockets within the peptide
binding groove of DR1 for improved and/or altered peptide binding specificity by
directed evolution, which has a potential to regulate T cell activation (Chapter 5).

1.2. Central role of CD4+ T cells in adaptive immune responses
1.2.1. Brief introduction for Immune system and lymphocytes
The immune system that most vertebrates have not only inherits the oldest innate
immunity, but also develops a more evolved adaptive immunity, first appeared in jawed
vertebrates2 and became increasingly specialized with further evolution.

Adaptive

immune system consists of macrophages and other phagocytic cells, lymphocytes and
their derivatives such as antibodies1, 3, 24. Lymphocytes are the only cell types in the
body capable of specifically recognizing and distinguishing different antigenic
determinants and are responsible for the adaptive immune response, specificity and
memory25.

A lot of congenital and acquired immunodeficiencies are related to

molecular defects in the development and function of lymphocytes or their products9.
Therefore, many immunotherapeutic approaches and vaccinations aim at modifying and
optimizing the performance of lymphocytes or its mediators26-28.
3

There are three major subsets of lymphocytes25: 1) Natural killer (NK) cells, a part of
innate immune system, can recognize and kill infected cells directly without a need for
additional activation; 2) B cells, main components of adaptive immune system, are
responsible for secreting antibodies, which stimulate humoral immune responses by
directly capturing antigens; 3) T cells, another group of main components in adaptive
immune system, only respond to antigens processed and presented by APCs via a MHCinvoked secretory pathway and stimulate cell-mediated immune responses.

Two

important effector cells differentiated from T lymphocytes involved in MHC-restricted
activations are T helper cells (Th cells, expressing CD4 coreceptors for MHC-II binding)
and CD8+ cytotoxic T lymphocytes (CTLs, expressing CD8 coreceptors for MHC-I
binding).

1.2.2. Differentiation and Function of CD4+ T cells
Not like NK cells, antibodies or CTLs, Th cells do not have the ability to eliminate
infected pathogens by themselves, however, taking up almost half of the lymphocyte
population in human body, they do play an important role in adaptive immunity or even
innate immunity. Because of their regulatory function, these effector cells of CD4+ T
cells are usually designated as helper cells. Of particular interest is that CD4+ T cells
may differentiate into two different subsets of effector cells, Th1 and Th2, which produce
distinct cytokines and perform distinct effector functions. Once being activated, Th1 cells
are essential in stimulating antibody secretion and determining B cell antibody class
switch, in promoting the activation and proliferation of CTLs8, and in regulating activity
of phagocytes such as macrophages, neutrophils, and other leukocytes responsible for
4

cell-mediated immunity (Figure 1-1).

Th2 cells on the hand mainly function as

suppressers for these effector cell-mediate responses. Both cell subsets are involved in
formation of tissue injury and inflammation as well as generation of memory T cells,
which may persist for years after acute immune responses are down-regulated and
disappeear25.

Figure 1-1 Proliferation and function of CD4+ T cells. CD4+ T cells are activated by antigenic peptide
presented by professional APCs and driven to the clonal expansion by cytokines (e.g. interleukin-2). The
activated and differentiated Th cells can further activate and differentiate macrophages, CD8+ T cells, and
B cells, or introduce inflammation. The main function of activated macrophages, CD8+ T cells, and B
cells are to lyse phagocytosed antigens, to kill antigen-infected cells or tumor cells, and to secrete antigenspecific antibodies, respectively. Once antigens are eliminated, Th cells will be down regulated and
entering a memory phase. (Adapted from Abbas, A.K., Lichtman, A.H. & Pober, J.S. Cellular and
molecular Immunology, 4/e (Saunders, philadelphia, 2000)).

Both B cell and macrophages are professional APCs for Th cells29, so immature B
cells or macrophages can process and present antigen fragments to specifically activate
CD4+ cells, which in turn will fully activate B cells and macrophages by cytokines (e.g.,
interferon-γ (IFN-γ)30,

31

) or CD40-mediated signaling32-34 (Figure 1-2) for antibody

secretion and phagocytosis respectively (Figure 1-1).
5

In contrast, CD8+ T cells do not serve as professional APCs to Th cells and their
development and function do not necessarily require presence of Th cells. In a strong
innate immune response, the primary activation of CD8+ T cells can be elicited by
dendritic cells (DCs), if microbe directly infects DCs35, or if cross-presentation36, 37 of
microbial antigens is sufficient.

However, the participation of Th cells is usually

required for CD8+ T cell responses to tumor cells38, viral infections39,

40

and for

expansion of memory CD8+ T cells41, 42. Communication between these two types of T
cells is largely mediated by professional APCs, such as DCs43, via interleukin-2 (IL-2)
signaling41 (Figure 1-1) or costimulatory signaling mediated by CD40:CD40 ligand39, 44,
45

or CD28:B7-1/B7-2 pathway42 (Figure 1-2).
Thus, CD4+ helper T cell actually plays a central role in adaptive immunity. The

possibility of controlling or adjusting CD4+ T cell development and function at
molecular level would present intriguing potential for immunotherapy of numerous
diseases related to Th cell-mediated responses46-48.

6

Figure 1-2 Signaling pathways between CD4+ T cell and APCs.

1.2.3. Activation of CD4+ T cells by APCs
In order to enter the functional stage, naïve T cells need to be activated and
differentiated into effector T cells by specialized APCs, called “professional APCs”
(Figure 1-1). As mentioned earlier, DCs, B cells and macrophages can all serve as
professional APCs to present antigenic peptides for CD4+ T cell recognition and
activation29, 35. However, the amount of MHC-II and cotimulators they can express, the
phase of adaptive immune responses at which they can activate CD4+ T cells, the
locations where they meet with T cells, and the functional feedback received from Th
cells are all different25.
B cells and macrophages with lower levels of MHC-II mainly present antigen to
differentiated effector Th cells, and the process of antigen presentation mostly takes
place in lymphoid organs. Other than those places, macrophages can also mediate T cell
7

responses in tissues, which might cause delayed type hypersensitivity.

The main

purpose of this antigen presenting process is to further activate B cells and macrophages
themselves and fully accomplish their function.

DCs on the contrary, resident in

epithelia and tissues, can capture antigens and transport them to secondary lymphoid
organs, including lymph nodes and spleen and present them to naïve CD4+ T cells.
They can express large amount of MHC-II and costimulators on the surface and are the
most effective APCs for initiating primary T cell responses.
Adoptive transplantation of autologous APCs such as DCs has been used in
immunotherapy to generate more effective T cell-mediated immune responses26,

49

.

However, the labor intensity and high expense on producing APCs and the unreliable
quality and quantity of the available APCs that can be used in adoptive immunotherapy
all limit their usage in clinical applications. Therefore, investigators have started to
develop various artificial APCs (aAPCs) to enhance the generation of antigen specific T
cells27. No matter which method is going to be used, first of all, it is critical to clarify
the molecular mechanism that leads to the activation of CD4+ T cells by APCs.

1.2.4. Signaling pathways for CD4+ T cell activation
T cell activation needs both antigen recognition and costimulation. After antigens
are specifically processed and presented by professional APCs to CD4+ T cells, T cells
will receive both “signal 1” through TCRs and “signal 2” via costimulator receptors
from professional APCs11, 12.
The primary signaling pathway, which determines the specificity of CD4+ T cellmediated adaptive immune responses, is formed by the interaction between CD3 and
8

ζ protein-associated TCRs (TCR complexes) and APC-processed antigenic peptidecoupled MHC-II molecules (peptide/MHC-II complexes) along with the CD4
coreceptor12,

13

(Figure 1-2).

The antigen specificity of T cell response is greatly

dependent on antigenic peptides processing and presentation by APCs and peptide-MHC
complex recognition of TCRs on the T cell surface.
Other than the first signaling pathway, there are several intermolecular ligandreceptor interactions that function to deliver the second signal which is necessary for
optimization of T cell activation and differentiation: CD28:B7-1/B7-2, the principal
pathway for delivering second signals for T cell activation12, 13; CD2: CD58, signal
transducer as well as intercellular adhesion molecules. Some other ligand-receptor pairs
might only serve as adhesion molecules, such as integrin LFA-150: ICAM-1/ICAM-2,
however, they are necessary for keeping T cells and APCs in close contacting with each
other for signaling transduction25 (Figure 1-2).
Although the appearance of costimulatory molecules is substantial, specialized
MHC-II proteins on the surface of APCs perform the main task of displaying cellassociated antigens for recognition by CD4+ T cells. Therefore, intensive studies using
in vivo and in vitro methods have been carried out and will keep focusing on elucidating
the cellular and molecular basis of antigen processing inside APCs as well as interaction
between antigenic peptide and MHC molecules, which is also a key to the construction
of aAPCs and to the design of vaccines for modulating T cell responses. One purpose of
this thesis work is trying to develop a quantitative, high throughput method for better
understanding the characteristics of MHC-II molecules that determine their selectivity
for peptides.
9

1.3. MHC-II and antigenic peptide binding
1.3.1. Classification and evolution of polymorphic MHC
The MHC locus is a large gene cluster found in the genome of most vertebrates. The
main products encoded by these diverse genes are expressed as trans-membrane
glycoproteins on the surface of APCs, which have the ability to degrade and process
antigens into short fragments (peptides) and transport them using MHC proteins to the
surface for recognition by antigen-specific T cells. Two well-known subgroups of MHC
proteins are 1) class I (MHC-I), expressed on the surface of all nucleated cells and
responsible for presenting intracellular peptides to CD8+ T cells, and 2) class II (MHCII), expressed on the surface of professional APCs, such as DCs, macrophages and B
cells and responsible for presenting extracellular peptides to CD4+ T cells51. In humans,
MHC proteins are referred to as human leukocyte antigen (HLA), and most intensely
studied HLA alleles are HLA-A, HLA-B, HLA-C (for class I) and HLA-DR, HLA-DP,
HLA-DQ (fcor class II).
MHC is the most polymorphic gene in the human genome. Up till today, multiple
alleles have been found for all the nine classical genes (the heavy chain for each of class
I alleles and two chains for each of class II alleles), among which the most
conspicuously diverse loci, HLA-A, HLA-B, HLA-C and HLA-DRB, have 893, 1431,
569 and 814 known gene alleles that can encoding 681, 1165, 431 and 637 proteins
respectively (Table 1-1).
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Table 1-1 HLA alleles numbers (adapted From IMGT/HLA Database, assigned October 2009)
HLA class I

Gene

HLA class II

A

B

C

DRA

DRB

DQA1

DQB1

DPA1

DPB1

Alleles

893

1,431

569

3

814

35

106

28

136

Proteins

681

1,165

431

2*

637

26

77

16

118

HLA-DRB Alleles
Gene
DRB1

DRB2

DRB3

DRB4

DRB5

DRB6

DRB7

DRB8

DRB9

Alleles

722

1

52

13

19

3

2

1

1

Proteins

572

0

42

7

16

0

0

0

0

* The two DRA proteins have only one difference at the cytoplasmic tail.

The evolutionary force that has created and maintained such astounding allelic
diversity is postulated to be balancing selection52, 53, a broad term that identifies any kind
of natural selection in which no single allele is absolutely most fit. This striking feature
of MHC genes as well as proteins not only creates fertile grounds for evolutionary
biologists but also provides resourceful platforms for protein engineers. Although a high
degree of MHC polymorphism is found in human population, an individual can only
express approximately 18 class I or class II proteins, which are usually individually
specific, so transplantation rejection and autoimmune diseases might occur when trying
to transplant organs or tissues between individuals.

Because of these limitations,

immunologists and bioengineers would always like to investigate the common and
distinct molecular properties of MHC proteins and develop methods for monitoring the
evolution of MHC molecules for improved immune tolerance as well as diversity. The
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in vitro methodology we will talk about in this thesis allows discovery of the molecular
relationship among MHC-II alleles in a functionality-dependent manner.

1.3.2. Structure of MHC-II proteins
An MHC-II protein is a non-covalently associated heterodimer consist of an α chain
(32-34kDa) and a β chain (29-32kDa).

Each subunit contains two extracellular

domains54-59 (Figure 1-3A), a trans-membrane spanning domain and a cytoplasmic tail.
The N-terminal α1 and β1 domains interact to form the peptide-binding groove,
composed of two α-helical walls and a floor formed by eight strands of anti-parallel βsheets (Figure 1-3B). Polymorphisms of MHC-II are mainly due to the existence of
various possible residues at the same position within the peptide binding groove15. In
contrast with class I, the class II molecules leave both ends of the peptide-binding
groove open for accommodating longer peptides up to 30 residues59, 60. This peptide
binding domain is responsible for loading peptides and presenting them to T cells61. The
α2 and β2 domains fold into immunoglobulin (Ig) domains, responsible for CD4
coreceptor binding and are relatively conserved among various alleles of a particular
gene62.
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Figure 1-3 Three-dimensional structure of human leukocyte antigen-DR1 in complex with FLU
peptide54. A. Extra-cellular domains of DR1 associated with FLU peptide (derived from influenza
hemagglutinin residues 306-318: PKYVKQNTLKLAT, also known as HA306-318 elsewhere54; and we
use “FLU” henceforward in order to distinguish it from another HA epitope tag derived from the same
protein). B. Top view of the peptide-binding site formed by α1 and β1 domains. Images were made using
PyMOL software (Delano, W.L., The PyMOL Molecular Graphics System (2002) on world wide web
http://www.pymol.org) by rendering molecular coordinates in the code file 1DHL.

1.3.3. MHC-II pathway of antigen processing in APC
The maturation of MHC-II and the peptide binding and transport by MHC-II take
place inside professional APCs upon the exposure to foreign antigens29, 63 (Figure 1-4).
After capturing antigens, these specialized APCs will internalize the extracellular
proteins into vesicular compartments, such as endosomes and lysosomes, where
proteolytic enzymes degrade antigens into short fragments (peptides) under the acidic
condition. Newly assembled MHC-II in endoplasmic reticulum (ER) are transported
through Golgi complex to late endosomes and lysosomes with the help of invariant chain
(Ii), which weakly occupies the peptide-binding groove of immature MHC-II. After
13

membrane fusion of different endosomes and lysosomes, MHC-II and antigenic peptides
enter the same vesicle, called the MHC class II compartment, or MIIC64, which contains
all components required for peptide/MHC-II association such as enzymes, MHC-II, the
Ii (or invariant chain-derived peptides), and HLA-DM (product of a non-polymorphic
gene located at the locus of MHC-II gene cluster) with the ability to catalyze peptide
binding65. To remove Ii from the peptide-binding site, proteolytic enzymes first cleave Ii
into class II-asociated invariant chain peptide (CLIP), and then DM helps to catalyze the
conformational change66 of MHC-II for peptide exchange between CLIP and high
affinity antigenic peptides.

Once mature MHC-II molecules are associated and

stabilized by antigenic peptides66-69, the peptide/MHC-II complex can be delivered by
exocytic vesicles to the surface of APC for recognition by CD4+ T cells.

Figure 1-4 Peptide processing in APC via MHC-II maturation pathway.
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1.3.4. Peptide binding characteristics of MHC-II
There are several important features of the interaction between MHC-II proteins and
specific peptides21, 70. First of all, even though each MHC-II molecule contains a single
peptide binding groove capable of accommodating one peptide at a time, it has the
ability to specifically recognize and present a large set of peptides derived from
enormous numbers of antigens18-20. This explains why each individual expressing only a
few different MHC-II alleles (normally less than 12) could defend against infections of
various foreign agents.
Secondly, peptides bound to MHC-II share common structural features that favor
their interaction. The optimal length of specific peptides is between 12 to 16 residues,
with 9 consecutive residues directly contacting with the binding groove59. Some have
their side chains pointing down to pocket-like region within the groove serving as
anchors for MHC-II binding, whereas the rest face up with their side chains away from
the groove for recognition by TCRs (Figure 4-1). This feature reflects the antigen
specificity of both MHC-II and TCRs.
Thirdly, the association is relatively stable with a very low off-rate and the peptide
binding affinity of MHC-II is higher than the peptide/MHC-II complex binding affinity
of TCR25. This allows peptide/MHC complexes to persist long enough on the surface of
APCs for T cell recognition.
Fourthly, MHC-II shows a broader specificity (promiscuity) for peptide binding than
the specificity of antigen recognition by TCRs25. They can bind different sources of
peptides derived from both self and foreign antigens, which TCRs will distinguish for T
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cell stimulation. This actually increases the chance of autoimmunity and the tolerance of
self-like foreign antigens.
All the information about peptide/MHC-II interactions may be used in vaccine
design for enhancing CD4+ T cell-mediated adaptive immunity or in immunotherapy for
treating T cell-related diseases26-28, 38, 46-49, 71, 72. However, most of these strategies based
on applying known T cell specific epitopes presented by self MHC-II molecules for
stimulating CD4+ T cell activation, which are limited by the restricted set of epitopes
recognized by the few types of self expressed MHC-II alleles found in each individual.
Therefore, there will always be some nonspecific epitope or mutated epitope bearing
antigens with the capability of escaping the recognition of MHC-II as well as CD4+ T
cells and causing sever immune diseases to certain MHC-II alleles expressing
individuals. In these cases, immunotherapeutic methods relying on MHC-II-specific
antigens will become less effective, and alternative strategies such as improving the
range of peptides presentable by MHC-II or changing the specificity of certain alleles
could be useful.
Even though each individual could only bear a few MHC alleles and will inevitably
come across with the problem of transplantation rejection when a foreign allele showing
up in their bodies, hundreds or even thousands of alleles do exist in nature among
different individuals and their protein products share similar structures and functions.
This large freedom of the balancing selection for MHC-II in nature suggests that any
self-MHC allele has the potential of being mutated or modified subtly without affecting
most of its characteristics, possibly including self-tolerance. Furthermore, if a selection
mechanism is properly set up, the peptide binding properties such as specificity and
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affinity of an MHC-II molecule should be able to be “directedly” edited or evolved by
introducing subtle changes such as single mutations in the protein sequence leaving most
of the other properties and functions unchanged. Creating and applying this kind of selfderived or self-evolved tolerant MHC-II molecules in the development of vaccines and
aAPCs would become a breakthrough in vaccination and immunotherapy.
In this thesis work, we will take the first step of this big project on evaluating the
possibility of developing novel MHC-II molecules with minimum residue substitutions,
which can specifically recognize and present targeted peptides for T cell activation.

1.4. Protein engineering technologies in this thesis work
1.4.1. Cell-surface display for target proteins
Display of recombinant proteins on the surface of cells or viral particles not only
serves as an expression system for correct assembly of proteins but also provides a
platform for directly exploring and improving protein functions such as immunogenicity,
ligand binding specificity and enzymatic activities, etc. by directed evolution73-89. Up till
today, various cellular systems such as bacteriophages, bacteria, yeast, baculovirusinsect cells and baculovirus/retrovirus-mammalian cells have been developed and widely
used for displaying and engineering proteins of interest. There is no expression system
perfectly suitable for all kinds of in vitro engineering applications, so advantages and
disadvantages usually need to be considered and compromised for acquiring a specific
accomplishment.
Phage display90, 91 and bacterial display79, 80, 92 are largely applied for expressing
short peptides and simple polypeptides, which require more relaxed folding
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environments and less modifications, because these prokaryotic organisms are normally
lack of the post-translational machinery that helps properly assembling eukaryotic
especially human proteins. However, the simplicity of culturing and cloning these lower
hierarchy single-cell systems make them priorities for engineering a great number of
well studied eukaryotic polypeptides by construction and screening of libraries of
variants with a size of 108~1010. Investigation of large pool of variants and screening for
better fitness has become more and more useful via directed evolution for understanding
function of various proteins nowadays, thus, other than cellular platform based
displaying system, ribosome display93 or even mRNA display94-96 have been derived for
expression of even larger libraries for protein engineering in a cell-free environment
without limitation of transfection and/or transformation efficiency.

The latter two

systems are very useful for screening a large variety of short peptides in some cases, but
less preferred for polypeptides, whose function relies on tertiary structure.
On the other hand, insect cell display76, 97 and mammalian cell display75, 82, 98, 99
inherit the advantage of eukaryotic expression systems, which provide more accurate
protein folding regulatory and auxiliary mechanism and better similarity to in vivo
conditions.

As a result, large membrane proteins with sophisticated structures or

membrane protein complexes consist of multiple non-covalently associated monomers
are better to be studied within these higher-level organisms. For the cost, one must
sacrifice diversity and the number of protein variants that can be tested, or, labor
intensity as well as time and expense cost has to be increased dramatically to obtain
similar library of protein mutants for screening novel functionality, which sometimes is
difficult and impossible for these multicellular organisms even with modern
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biotechnology.

Additionally, even with the help of baculoviral100 or retroviral89

technology, the difficulty of applying mammalian cells to engineer heterologous proteins
make them less commonly used than other displaying systems. The ability of producing
viral particles (e.g. baculovirus or retrovirus) for displaying interest polypeptides though
provides more flexibility to extend the application of these two kinds of virus infected
eukaryotic displaying systems84, 89.
In a lot of cases, diversity and complexity of certain eukaryotic protein are both
desired when performing specific structure-function analysis, such as the one in this
thesis work; hence, yeast display73, 74, 101 represents an ideal in vitro research platform,
which has the ability to translate and modify proteins under control of eukaryotic
expression though a little different from mammalian cells, while lose little molecular
cloning advantage as a single cellular expression system.

Theoretically, one can

generate a combinatorial library with up to 109 individual clones using yeast, which is
able to cover combinations of 20 standard amino acids in 7 different sites within a
relatively complex protein. It is for sure that this single-cell eukaryotic displaying
system has its potential on occupying more and more research fields in protein
engineering.
In this thesis, we are going to display proteins of interest on the surface of yeast and
extend the display technology to fully utilize yeast to characterize interaction between
two or more proteins, e.g. peptides and DR1 heterodimer.
To display a protein of interest on the surface of yeast, the gene coding for protein of
interest can be cloned to upstream102 or downstream74 of AGA2 gene in a yeast shuttle
vector. After being transformed into an engineered yeast Saccharomyces cerevisiae
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strain EBY10074 (a GAL1-AGA1::URA3 ura3-52 trp1 leu2Δ1 his3Δ200 pep4::HIS2
prb1Δ1.6R can1 GAL), heterologous genes in the vector will be translated to protein of
interest fused by Aga2 protein (Aga2p), which is the subunit of a native yeast surface
protein, a-agglutinin103, 104. Directed by a signal peptide, the protein fusion will enter
protein secretory pathway, where Aga2p will associate with the other subunit of aagglutinin (Aga1p) by forming two disulfide bonds. Once transported outside yeast, the
assembled a-agglutinin will anchor protein of interest on the surface by the designed
covalent linkage between Aga2p and protein of interest (Figure 1-5).

Figure 1-5 Classical yeast surface display of target protein. Protein of interest can be covalently linked
to either N-terminus or C-terminus of Aga2p, which serves as the anchor for surface-displaying protein of
interest.

1.4.2. Analyzing immunofluorescently labeled cells by flow
cytometry
Detection of protein on yeast surface is mainly carried out by applying
immunofluorescenty labeled yeast to a fluorescence detector – flow cytometer. To label
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proteins on the surface of yeast, cells are usually enriched in growth media and then
switched to induction media for a certain time for optimal protein expression.
Consequently, cells are collected by centrifugation and labeled with a primary labeling
reagent specific for protein of interest displayed on yeast surface. In some cases, the
primary reagent is conjugated with a fluorophore for direct fluorescent labeling. In other
cases, a secondary reagent conjugated with a fluorescent dye is used for indirect
fluorescent labeling.

These conjugated fluorescent dyes can be detected via flow

cytometry. All labeling work performed in this thesis work used indirect labeling, which
normally gives the stronger signal.
Other than proteins of interest themselves, small epitope tags such as HA, V5, 6His,
c-Myc, etc., are wildly used and fused to nonfunctional ends of target protein enabling
indirect checking of expression and presentation of protein of interest on the surface of
yeast. Due to the small size (5-20 residues), epitope tags will not affect the tagged
protein’s biochemical properties, but can be recognized by epitope-specific antibodies,
which also allows immunofluorescent labeling. Fluorescent labeling can be performed
for one epitope or more at the same time as long as primary and secondary reagents have
lowest cross-reactivity against each other. Double labeling by using an antibody specific
for protein of interest and another one specific for a fused epitope tag was used
frequently in this thesis work.
Flow cytometer allows suspension of labeled yeast cells flowing dropwise through a
detecting area at a high speed, where fluorophores coupled on yeast surface can be
excited by a laser beam, and emit fluorescent light with certain wavelength, intensity of
which can be recorded in fluorescent detector with a specific wavelength cut-off half
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mirror. At the same time, forward light scattering (FSC) and 90° side light scattering
(SSC) can also be observed, which correlate with volume of yeast cells and their
intracellular complexity, respectively. The dot-plot of these two parameters always
shows a certain pattern (e.g. Figure 3-1 (i)), which is significantly different from that of
bacteria or mammalian cells, allowing a first validation for properly cultivation of yeast
and an easy checking for contamination.
Sometimes, yeast displaying target protein is desired to be recovered from a large
pool of yeast cells, a more developed flow cytometer, called cell sorter, will make this
possible. Cell sorter can isolate individual cells via an electronic field and direct them
into the corresponding collection tubes. This process is usually called fluorescentactivated cell sorting (FACS).
After flow cytometry or cell sorting, flow cytometric data can be analyzed in
different plots. The simplest is using a one-dimensional histogram by cell events (or cell
numbers) vs. fluorescence intensity of the fluorophore used for labeling protein of
interest (e.g. Figure 2-4 (i) and (ii)). This histogram will normally exhibit a distribution
of cell numbers at different intensities, the mean of which statistically represents how
well the labeled protein is displayed on the surface of yeast.

Usually, yeast cells

themselves will give an auto-fluorescent background in most flow data, which can be
determined by preparing a few unlabeled or irrelevant yeast controls in parallel. If
double labeling of two proteins on yeast surface is performed, other than histograms, a
two-dimensional dot-plot can be generated by plotting the fluorescence intensity of one
fluorophore against the other (e.g. Figure 2-4 (iii)). The dot-pot will normally display
cell populations with different fluorescence intensities, where information of two
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proteins or epitopes displayed on yeast surface can be examined simultaneously. It is
critical to set up appropriate compensation when running a double-labeled sample,
because a lot of times, the emission from one fluorophore can overflow into channels
used to detect other fluorophores, especially for some strong signals. In those cases,
single labeled controls need to be used to adjust the compensation so that no signal
interfering occurs.
Most recent flow cytometers are equipped with at least two lasers, which can excite
fluorophores with excitation wavelengths in a fairly large range, thus, if properly
selected, two fluorophores with excitation wavelengths far from each other can be used
for double labeling and excited by two lasers respectively on flow cytometer without any
compensation. This will greatly increase the efficacy and accuracy of flow detection. In
this thesis work, we are going to take advantage of this feature so that no compensation
is needed most of times.
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Chapter 2. Development of yeast co-display – a novel
methodology for characterizing MHC-II/peptide binding
2.1. Introduction
Antigen specificity of CD4+ T cell-mediated immune response is primarily
determined by peptide presented by MHC-II molecules on the surface of APCs. In depth
characterization of peptide binding by MHC-II is critical to understanding issues in
vaccine design, autoimmune disease, infectious disease progression, and transplantation
rejection28, 46, 72.
MHC-II is a transmembrane protein, whose extracellular portion consists of two
heterologous chains, α and β, each of which containing two domains54. Mature MHC-II
proteins function to capture antigenic peptides processed inside professional antigenpresenting cells (APCs) and present them on the surface of APCs for recognition by
CD4+ T cells to mediate adaptive immunity. The peptide-binding site of MHC-II
formed by α1 and β1 domains contains several pocket-like regions, which prefer to
accommodate specific side chains of anchor residues on peptides58, 59. The engaged
peptides are always heterogeneous in size with both termini extended beyond the
binding groove60. Even though a lot of common features for peptide binding have
already been discovered, the majority of peptide binding motif and anchor preference
information for distinct alleles of MHC-II still needs to be further characterized so that
specific target peptide/MHC-II pairs can be applied for immunotherapeutic application
via activating specific T cell clone.
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MHCs are the most polymorphic glycoproteins known in nature, out of which each
individual only expresses a few alleles, so it is challenging to investigate peptide-binding
properties of all these trans-membrane proteins in vivo or ex vivo. Therefore a variety of
in vitro methods have been developed for studying the interaction between peptide and
MHC-II.

A routinely used in vitro approach entails purifying soluble recombinant

MHC-II molecules from different expression systems such as B cell lines105, insect
cells106, yeast107, or Escherichia coli108-112 and then characterizing binding of these
molecules to different peptides generated either chemically by solid-phase synthesis113,
114

or genetically by cell or non-cell display technologies.

The former one using

synthesized peptides enables coupling of all kinds of quantitative assays for acquiring
binding affinity and kinetics18, 112, 115-123, whereas the latter allows construction of big
libraries of peptide sequences for a high throughput screening and investigation90.
However, the labor-intensive preparation of soluble MHC-II proteins and lengthy
binding assays limit the efficacy and throughput of these methods for mapping MHC-II
binding specificities across the large number of existing alleles. Other attempts focused
on assaying binding of soluble peptide by MHC-II expressed natively on mammalian
cell surface124-128, which still did not completely get away from the difficulty of
manipulating MHC-II proteins.
Alternatively, engineered cell-surface display systems such as phage129-131, yeast102,
132-134

, baculovirus-insect cells76, and mammalian cells98,

135

have been tried for

displaying recombinant extracellular domain of MHC molecules, suggesting a potential
to engineer MHC-II proteins by directed evolution such that any possible allele can be
examined for peptide binding. However, to stabilize the recombinant MHC proteins, an
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antigenic peptide was always genetically introduced by covalent linkage, which not only
brings in unknown artificial effects but also restrain the flexibility of using these
methods to quantify peptide binding. Sometimes, acid/base half of leucine zipper was
attached to C-terminus of either chain of MHC-II to facilitate protein association and
surface anchorage76, which was not necessary in other display system but could alter
MHC-II native folding. These limitations make current cell-surface display system less
proper for characterizing the interaction between peptides and MHCs. The lack of a
rapid, efficient, robust, and quantitative methodology for characterizing the peptide
binding specificity and promiscuity of MHC-II alleles remains a bottleneck. Several
two-hybrid expression systems76,

81, 88, 102, 136-141

suggest a way to manipulate multi-

proteins in their native forms within the same cell and a possibility to improve current
cell-surface display technology to study interaction between peptide and MHC-II.
Herein, we report a novel, quantitative, high throughput methodology, yeast codisplay (Figure 2-1), for characterizing and engineering peptide-binding specificity of
MHC-II. As a model system, the extracellular domains of the MHC-II human leukocyte
antigen HLA-DR1 were expressed as a secreted heterodimer in Saccharomyces
cerevisiae.

Simultaneously, an antigenic peptide known to bind to HLA-DR1 was

surface-displayed. Intracellular binding between the MHC-II and the peptide antigen
thus anchored the soluble MHC-II to the cell surface upon secretion, allowing detection
by immunofluorescence. The relative abundance of MHC-II compared to peptide on the
cell surface depended on the strength of binding between these species. Accordingly,
the relative binding of different peptides and/or MHC-II variants can be assayed by
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genetically manipulating either partner, enabling the application of directed evolution
approaches for high throughput characterization or engineering.

Figure 2-1 Design of the yeast co-display system for HLA-DR1. Two plasmids direct the expression of
MHC-II ectodomain heterodimer and a peptide respectively in Saccharomyces cerevisiae yeast stain
EBY100 (URA+, trp-, leu-). Aga2p-fused FLU peptide (derived from influenza hemagglutinin residues
306-318: PKYVKQNTLKLAT) is expressed flanked by HA tag (influenza hemagglutinin 98-106:
YPYDVPDYA, different from FLU) and V5 tag (short peptide: GKPIPNPLLGLDST), enabling detection
of peptide levels by immunofluorescent staining with antibodies specific for either tag. The α and β chain
of HLA-DR1 ectodomain are expressed from separate cassettes and assembled in endoplasmic reticulum
(ER) as a soluble non-covalently associated heterodimer. FLU peptide is anchored to the cell surface via
native processing and secretion of the assembled a-agglutinin protein (composed of the Aga1p and Aga2p
subunits) as described74, and the HLA-DR1 heterodimer is anchored by noncovalent binding to FLU.
Relative fluorescence levels of different fluorophores coupled to anti-tag and anti-DR reagents indicate the
level of saturation of available peptides by bound HLA-DR1. GPI: glycosyl phosphatidylinositol, an
anchor helping a-agglutinin to transport through the secretory pathway104.

2.2. Materials and Methods
2.2.1. Construction of plasmids
Primers or oligonucleotides were synthesized commercially either by Invitrogen
(Carlsbad, CA) or by Integrated DNA Technologies, Inc. (Coralville, Iowa). Other than
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stated, most enzymes were purchased from New England Biolabs (NEB, Ipswich, MA).
Taq (Qiagen, Germantown, MD or NEB) or Vent DNA polymerase catalyzed
amplification of polymerase chain reaction (PCR) products. Enzymatic digested PCR
products and plasmids were all confirmed by gel electrophoresis and purified before
ligation, which was catalyzed by T4 DNA Ligase (NEB or Invitrogen). Either QIAquick
Gel Extraction Kit (Qiagen) or Wizard SV Gel and PCR Cleanup System (Promega,
Madison, WI) was used for purification of DNA or PCR products without significant
differences. Either chemical- or electro- transformation in Escherichia coli strain DH5α
(Invitrogen) was performed for cloning and amplifying plasmids, which can be isolated
by using QIAprep Spin Miniprep Kit (Qiagen) and confirmed by DNA sequencing
(DNA Sequencing Facility, Department of Genetics, University of Pennsylvania, PA or
Molecular Biology Resource Facility, Division of Biology, University of Tennessee,
TN)


Plasmids for classical surface display of HLA-DR1
The gene expressing the extracellular domain of HLA-DR1 β chain allele

DRB1*010101 (1-190) was cloned from plasmid pDLM1-drb1s (kindly provided by Dr.
L. Sten, Umass) by PCR using N-terminal primer W3 (5’–TAATCCCGGGGACCTAA
GTATGTGAAGCAGAATACACTGAAGCTGGCAACCGGAGGTGGTTCACTAGT
GCCACGGGGCTCTGGAGGAAAGCTTGGAGACACCCGACCACGTTTCTT)

and

C-terminal primer W4 (5’–TACTGGATCCAGAACCACCACCACCAGAACCACCAC
CACCAGAACCACCACCACCGCTAGCTGCTCTCCATTCCACTGTGAG), such that
sequence encoding the 13-residue FLU peptide (derived from influenza hemagglutinin
residues 306-318: PKYVKQNTLKLAT) and a thrombin recognition site were added at
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the N-terminus. The PCR product was ligated into plasmid Z47102 in place of the
original expression cassette coding for allele DRB1*0401 via annealing of sticky ends
obtained by XmaI/BamHI double digest, to create pfluDR1 for surface-displaying FLUfused HLA-DR1 (Figure 2-2). Another vector pDR1 expressing “empty” HLA-DR1
was constructed likewise but without adding FLU peptide by using another N-terminal
primer W1 (5’–AGCTCCCGGGGAGACACCCGACCACGTTTCTT) instead of W3.


Plasmids for classical surface display of FLU peptide
The entire expression cassette (GAL1-10//AGA2//HA//scFv 4-4-20//MFα Term.)

was excised from pCT30274 by double digest using KpnI and SacI and cloned into
KpnI/SacI partially digested yeast shuttle vector pRS315142 to create a plasmid with a
LEU2 selectable marker. Expression cassette (scFv 4-4-20 //MFα Term.) within NheI
and SacI sites in this plasmid was substituted by a PCR product encoding
(FLU//SphI//MFα

Term.),

obtained

by

using

N-terminal

primer

W20

(5’–

TCTAGCTAGCCCTAAGTATGTGAAGCAGAATACACTGAAGCTGGCAACCTAA
GCATGCCAACAGTGTAGATGTAACAA)

and

C-terminal

primer

W21

(5’–

CTGTGAGCTCAATTCTCTTAGGATTCG), to construct pFLU. Similarly, W34 (5’–
TCTAGCTAGCCCTAAGGCGGTGAAGCAGAATACACTGAAGCTGGCAACCTA
AGCATGCCAACAGTGTAGATGTAACAA)

was

used

instead

of

W20

for

constructing pFLUA, which directs expression of a FLU analogue with Tyr308
substituted by Ala (encoded by underlined GCG) at the putative anchor position P1
(refer to Figure 4-1).
To add V5 epitope tag at C-terminus of FLU or its analogues, an oligonucleotide
encoding FLU followed by a short spacer (GGGP) and V5-tag was generated by PCR
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using N-terminal primer 0118 (5’–AAGGACAATAGCTCGACGATT) and C-terminal
primer W48 (5’–TCTAGCATGCTTAAGTAGAATCGAGACCGAGGAGTGGATTTG
GTATAGGCTTCCCGGGTCCACCTCCGGTTGCCAGCTTCAGTGTATTC),

and

inserted into vectors pFLU and pFLUA via annealing of sticky ends generated by
PstI/SphI double digest, for constructing ptFLU (Figure 2-6A, construct a) and ptFLUA
respectively.
In order to clone FLU to the N-terminus of Aga2p, a restriction site EcoRI in
ptFLUD was changed to AatII by site directed mutagenesis for future cloning. Briefly,
A pair of reverse complementary oligos W95 (5’–ACCCCGGATCGACGTCCCTACTT
CAT) / W96 (5’–ATGAAGTAGGGACGTCGATCCGGGGT) carrying the mutagenic
site was designed to prime the synthesis of mutant strand by PCR following the
manufacturer’s recommended procedures in QuikChange II site directed mutagenesis kit
(Stratagene, La Jolla, CA). After being digested by DpnI for 1 h, mutant plasmids were
transformed into electro-competent DH5α using the MicroPulser Electroporation
Apparatus (BIO-RAD, Hercules, CA) and recovered by Miniprep kit. Following that, an
AatII/SphI fragment was amplified from a modified surface display plasmid (will be
referred to again in next paragraph) by W97 (5’–CGTCGACGTCATGAAGGTTTTGA
TTGTC) and W98 (5’–ATGAGCATGCTTAAGCGTAGTCTGGAACG) and inserted
into AatII/SphI sites of the mutant plasmid for introducing an expression cassette (SynPre-Pro leader//XmaI//an irrelevant protein//speI//6His//AGA2//HA), which allows
target protein followed by a polyhistidine tag to attach to Aga2p N-terminus. Finally,
gene encoding the irrelevant protein was replaced by a PCR product encoding FLU
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peptide, generated using primers 0115 (5’–CAACAAAAAATTGTTAATATACCT) and
W106 (5’–TAATGACTAGTGGTTGCCAGCTTCAGTGTATTCTGCTTCACATACT
TAGGACCCCGGGCTTCTCTCTTGTCCAAAG), to construct ptNFLU (Figure 2-6A,
costruct b).


Plasmids for expressing soluble HLA-DR1
Z47 was modified first for displaying an irrelevant heterodimeric protein. In the

resulting plasmid, XhoI recognition site at the downstream of gene cassette promoted by
GAL1 promoter was removed and replaced by a Myc-tag (EQKLISEEDL) flanked by
two unique restriction sites NcoI and SphI, thus, the other XhoI left in the plasmid also
became unique for later cloning work. Two expression cassettes (DRB1*010101 (1190)//Flag-tag (DYKDDDDK)) and (DRA*0101 (1-192)//6His) were synthesized by
PCR

using

corresponding

primer

pairs

W38

(5’–

CACGCGGCCGATCAAAGAAGAACATGTGATCATCC) / W43 (5’–TACTCCATG
GGTGGTGGTGGTGGTGGTGACCACCGTCGACGTTCTCTGTAGTCTCTGGGAG)
and W1 / W44 (5’–TAGACTCGAGTTACTTATCGTCATCATCCTTGTAATCTCCA
CCACTAGTTGCTCTCCATTCCACTGTGAG), and cloned into the modified plasmid
sequentially via annealing XmaI/XhoI and EagI/NcoI digested cohesive ends
respectively, to create plasmid ptsDR1 (Figure 2-6B).

2.2.2. Buffers and media for yeast cultivation and treatment
Other than stated, most chemicals and reagents mentioned below were purchased
from Fisher Scientific (Fair Lawn, New Jersey). Buffers used in this chapter include:
phosphate buffer (5.4 g/l Na2HPO4, 9.70 g/l NaH2PO4·2H2O, pH 6.0); citrate buffer
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(14.7 g/l sodium citrate (Sigma-Aldrich Inc., St. Louis, MO), 4.29 g/l citric acid
monohydrate, pH 5.0); phosphate buffered saline (PBS; 137mM NaCl, 2.7mM KCl,
10.1mM Na2HPO4, 1.8mM KH2PO4, pH 7.4); Tris buffered saline (TBS; 137 mM NaCl,
20mM Tric-Cl, pH 7.6); Factor Xa buffer (100mM NaCl, 2mM CaCl, 20mM Tris-Cl,
pH 8.0).
Glucose (Dextrose) is used as carbon source in all growth media: rich medium such
as YPD (10 g/l Yeast extract (BD Diagnostics Systems, Sparks, MD), 20 g/l Peptone
(BD Diagnostic Systems), 20 g/l Glucose) can be used for enriching all strains without
selectivity, which is suitable for preparing competent cells; minimal media allowed yeast
growing under different nutrient dropout conditions. For example, SD-CAA (20 g/l
glucose, 6.7 g/l Yeast N2 Base w/o Amino Acids (BD Diagnostic Systems), 5.4 g/l
Na2HPO4, 9.70 g/l NaH2PO4·2H2O, 5g/l Bacto Casaminoacids (CAA, Difco)) was used
for cells requiring ura- and trp- condition and SD-SCAA (Bacto Casaminoacids in SDCAA was replaced by 0.62 g/l Leu/Trp/Ura dropout supplement mixtures of amino acids
(Clontech, Mountain View, CA)) provided ura-, trp- and leu- condition. D-Tryptophan
(Sigma) was sometimes added in above minimal media to make those conditions
suitable for trp- yeast strains. For induction of protein expression promoted by GAL110 promoter, glucose was replaced by galactose as the carbon source, while all other
nutrients stay the same. Induction media used in this chapter include rich medium YPG
and minimal media SG-CAA and SG-SCAA for corresponding nutrient dropout
condition as stated above.
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2.2.3. Antibodies and labeling reagents
Mouse anti-DR monoclonal antibody (mAb) L243 (BD Biosciences, San Jose, CA),
rabbit anti-HA polyclonal antibody H6908 (Sigma) and mouse anti-V5 Mab (Invitrogen,
Carlsbad, CA) were used for specifically labeling HLA-DR1, HA-tag and V5-tag on the
surface of yeast. Alexa Fluor 488 or 647 fluorophore conjugated goat anti-rabbit, Alexa
Fluor 647 or tandem dye PE-Alexa Fluor 647 conjugated goat anti-mouse (Invitrogen),
and R-phycoerythrin (PE) conjugated goat anti-mouse (Sigma) antibodies were used as
secondary labeling reagents for primary antibodies from corresponding species.
Streptavidin-PE (Sigma-Aldrich) was used to label biotinylated peptides.

2.2.4. Generation and cultivation of yeast strains
Saccharomyces cerevisiae yeast stain EBY100 (URA+, trp-, leu-) was used as the
parent strain to accommodate plasmids with either TRP1 or LEU2 nutrient marker. In
this thesis work, all plasmids directing expression of HLA-DR1 have TRP1 marker, and
all plasmids expressing peptide fusions contain LEU2 marker. Plasmids were
transformed into electro-competent EBY100 (lab made) by electroporation following
‘MicroPulser Electroporation Guide’ (BIO-RAD) and transformants were selectively
grown up under corresponding nutrient dropout condition on glucose containing minimal
medium agar plates (containing 1 M sorbitol) by incubating at 30 °C for 3–5 days. For
example, EBY100 transformed with pfluDR1, pDR1 or ptsDR1 were selected under ura, trp- and LEU+ condition on SD-CAA medium agar plates. Transformants with ptFLU
were able to grown up under ura-, TRP+ and leu- condition on SD-SCAA agar plates
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with D-tryptophan (TRP; 20µg/ml) added. Co-displaying strains can grow under ura-,
trp- and leu- condition on SD-SCAA agar plates.
A single colony was picked from agar plates and inoculated into 2–3 ml
corresponding glucose-containing liquid minimal medium and enriched to a cell density
around OD600 of 3.0–7.0 in a 30 °C shaker for 16–24 h. After that, enough cells were
pelleted by centrifugation and transferred to 2–3 ml corresponding galactose-containing
liquid medium to an initial OD600 around 1.0 to induce the expression of target proteins
in yeast. Induction using minimal medium was usually performed at 30 °C for 16–24 h,
while that using rich medium was usually carried out at 20 °C for 48 h.

2.2.5. Peptide binding assay for classical surface displayed HLADR1
Yeast strain EBY100 bearing pDR1 was cultured under ura-, trp- and LEU+
condition as described previously. 4 × 106 galactose-induced yeast were collected by
centrifugation and resuspended in 40 µl of one of the following solutions: YPG (pH
6.5), PBS (pH 7.4), citrate buffer (pH 5.0), citrate buffered SG-CAA (pH 5.0, using
citrate buffer instead of phosphate buffer). Biotinylated FLU peptide and β2m peptide
(derived from human β2 microglobulin 52-64: SDLSFSKDWSFYL, an irrelavent
peptide specifically bound by class I MHC proteins) (Abgent, Inc., San Diego, CA) were
added to a final concentration of 100 µM. Cells were incubated with peptides at 30 °C
for 1 day and then washed twice with 500 µl ice cold PBS + 1% (wt/vol) bovine serum
albumin (BSA) before staining with streptavidin-PE diluted 1:20 in 100 µl PBS + 1%
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BSA on ice for 30-45 min. Cells were then washed with 500 µl ice cold PBS + 1% BSA
twice and finally resuspended in 700 µl PBS + 1% BSA for analysis on a BD
FACSCalibur flow cytometer (BD Biosciences). EBY100 transformed with pCT302,
which will display an irrelavent single chain antibody on the surface, were used as a
negative control.

2.2.6. Surface-stripping assay by DTT or Factor Xa treatment
Approximately 106 yeast cells per sample were harvested by centrifugation after
induction and washed with 400 µl TBS 1–2x.

For DTT treatment, pellets were

resuspended in 20 µl of reducing buffer [50mM Tris-Cl pH 8.0 containing 0.04mM,
0.2mM, or 1mM DTT (added before use, (Sigma)] and incubated at 4°C for 24 h with
gentle shaking. For Factor Xa treatment, pellets were resuspended in 20 µl of Factor Xa
buffer with 20 µg/ml Factor Xa protease (NEB) added right before use. One set of
samples were incubated at 4 °C for 24 h, another set was incubated at 23 °C for 6 h
followed by 4 °C for another 18 h, and a third set was incubated at 23 °C for 48 h. After
treatment, cells were collected by centrifugation and washed at 1–2x with 500 µl ice
cold PBS + 1% BSA before immunofluorescent labeling.

2.2.7. Immunofluorescent labeling of yeast
Labeling was performed in a 2-step manner. After induction or other treatments,
approximately 106 cells were collected by centrifugation and washed with 400 µl ice
cold PBS + 1% BSA 1–2x. Cell pellet was resuspended in 20–50 µl PBS + 1% BSA
with primary antibodies. After staining for 40–60 min on ice or at room temperature,
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cells were spun and washed with 400 µl ice cold PBS + 1% BSA again. For the
secondary labeling, cells were stained with specific reagents in 40–50 µl PBS + 1% BSA
on ice for 30–60 min. A final wash was applied before resuspending cells in 500–700 µl
PBS + 1% BSA for flow cytometry.

2.2.8. Flow cytometric analysis of labeled cells
Fluorescently labeled yeast cells were analyzed by flow cytometry, where forward
scatter, side scatter and fluorescent signals in corresponding channels (e.g. Alexa Fluor
488 in FL1 or PE in FL2) were recorded by acquiring at least 10,000 cell events. Flow
cytometers used in this chapter as well as this thesis work are as follows: Accuri C6
(Accuri Cytometers Inc., Ann Arbor, MI), Beckman Coulter XL (Beckman Coulter Inc.,
Brea, CA), FACSCalibur, FACSVantage (also a cell sorter), and LSR II (BD
Biosciences).

2.3. Results
2.3.1. Classical yeast display of functional HLA-DR1 heterodimer
MHC-II is originally expressed on the surface of APCs for antigenic peptide
presentation. To verify that wild-type MHC-II heterodimers can be expressed in a
functional form competent for binding to soluble peptides in yeast, the extracellular
domain of HLA-DR1 both with and without a covalently fused antigen peptide was
surface displayed by fusion to the N-terminus of the endogenous yeast adhesion receptor
subunit Aga2p, as described previously for HLA-DR4 (with peptide linked to the β
chain N-terminus)102. The antigen used in these studies is a 13 amino acid peptide
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(designated FLU) from a naturally HLA-DR1-presented fragment of influenza
hemagglutinin (HA306-318), a well-studied peptide known to bind tightly to HLADR159. Similar to Z47102, the expression cassettes of plasmids pfluDR1 or pDR1 directs
the expression of HLA-DR1 ectodomain on the surface of yeast, with or without FLU
fused at N-terminus of β chain (Figure 2-2).

Figure 2-2 Expression cassettes for classical yeast display of HLA-DR1 heterodimer. Galactose
inducible bi-directional yeast promoter GAL1-10 initiates the expression of extracellular domains of both
chains for HLA-DR1: DRA*0101 (1-–192) and DRB1*010101 (1–190) in plasmid pfluDR1 (construct A)
or pDR1 (construct B). The α chain (DRα) is expressed solubly and the β chain (DR1β) is fused to the Nterminus of Aga2p so that once correctly assembled, the non-covalent heterodimer can be led to the
secretory pathway and anchored to surface for immunofluorescent detection. Construct A with FLU
peptide covalently linked to DR1β by a flexible linker is used for displaying FLU/HLA-DR1 complexes,
while construct B is for displaying “empty” HLA-DR1 on yeast surface.

Saccharomyces cerevisiae yeast stain EBY100 (URA+, trp-) was used as parent
strain to accommodate either pfluDR1 or pDR1, both containing a TRP1 nutrient
marker, and selectively cultured under ura- and trp- condition for protein expression.
The surface display of peptide-fused or “empty” HLA-DR1 was assessed by
simultaneous immunofluorescent labeling with anti-HLA-DRα antibody and antibodies
specific for the HA epitope tag included at the Aga2p C-terminus (Figure 2-3, Figure 24).
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Figure 2-3 Classical yeast display and immunofluorescent detection of HLA-DR1 heterodimer. This
is a schematic illustration of yeast surface displayed FLU/HLA-DR1 complexes to Aga2p N-terminus
(corresponding to the expression construct A in Figure 2-2). The Aga2p C-terminal HA-tag enables
immunofluorescent labeling using specific antibodies, ensuring determination and verification of Aga2p
fusion expression on yeast surface. Simultaneously, the expression and non-covalent association of
soluble DRα and Aga2p fused FLU-DR1β can be validated by functional DR-specific antibodies.

Yeast displaying either form of HLA-DR1 are exclusively HA positive (Figure 24(iii)), confirming that detected anti-DR signals correlate to the corrected association of
DRα and DR1β or simply the expression of HLA-DR1 heterodimer. The expression
level of FLU-fused HLA-DR1 (Figure 2-4B(ii)) is significantly higher than that of the
“empty” form (Figure 2-4C(ii)), while the expression level of Aga2p in these two
scaffolds are similar, as represented by anti-HA signals (Figure 2-4(i)).

Enhanced

expression of peptide-fused HLA-DR1 suggests that specific peptides might stabilize
MHC-II folding in yeast similarly to in natural APCs63, while the majority of the empty
HLA-DR1 fails to express (~5-fold reduction in cellular fluorescence in Fig. 2-4(ii) and
(iii)), consistent with a prior study134 and putatively due to degradation by the secretory
quality control machinery143.

38

Figure 2-4 Fluorescence intensity from labeled yeast displaying FLU-linked or “empty” HLA-DR1.
Aga2p and HLA-DR1 levels of yeast expressing A. an irrelevant soluble protein, B. Aga2p-fused HLADR1 with FLU-covalently linked to DR1β N-terminus, or C. “empty” Aga2p-fused HLA-DR1. Cells
were double-labeled with H6908 and L243 followed by Alexa Fluor-488 goat anti-rabbit and Alexa Fluor
647-goat anti-mouse highly cross-adsorbed secondary antibodies. Mean fluorescence intensity (MFI) of
HA signal and DR signal for HA positive cell population was indicated. Flow cytometric data collected
on Accuri C6 were plotted in (i), (ii) univariate histograms, or (iii) two-dimensional dot plots.

Detection of FLU-linked HLA-DR1 on the surface suggests the peptide binding
capability of HLA-DR1 expressed in yeast, however, the flexible linker connecting FLU
and DR1β (Figure 2-3) might provide an unknown positive effect on HLA-DR1
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refolding and FLU association. To validate this functionality, post-induced yeast cells
displaying “empty” HLA-DR1 were incubated with synthetic biotinylated peptides and
stained with streptavidin-PE before detection by flow cytometry (Figure 2-5). Synthetic
FLU peptide bound to HLA-DR1-displaying yeast, but not to a control strain displaying
an irrelevant protein, while a control peptide derived from β2 microglobulin
demonstrated no binding to either yeast. Similar results were obtained whether binding
proceeded in citrate buffer at pH 5.0 or several other buffers or growth media at pH 5.0–
7.4 (Figure 2-5), in agreement with the demonstrated pH-independence of peptide
recognition by HLA-DR1144.

Figure 2-5 Peptide binding capability of classical yeast displayed HLA-DR1 heterodimer. Yeast
displaying “empty” HLA-DR1 (solid curve) or an irrelevant protein (shaded) were incubated with 100 µM
biotinylated FLU; HLA-DR1-displaying yeast were also incubated with 100 µM biotinylated control
peptide (dashed curve). Peptide incubation was carried out in different media or buffers at various pH: A.
YPG (pH 6.5), B. PBS (pH 7.4), C. citrate buffer (pH 5.0), D. citrite buffered SG-CAA (pH 5.0). All
samples were stained with streptavidin-PE and analyzed by flow cytometry on BD FACSCalibur.

Successful expression of functional MHC-II heterodimer as a fusion to yeast surface
proteins enables study and modification of this highly polymorphic molecule using
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directed evolution or other biomolecular techniques, however, difficulties still exist for
characterizing and engineering their functionality, such as peptide binding capability,
which require manipulations of two or more proteins inside or outside yeast.

For

instance, the time and labor intensity and high expense on chemically synthesizing
peptides for binding assay significantly limit the variety of peptide sequences tested; the
variation on mimicking peptide binding conditions outside yeast (on the surface of yeast)
could affect the accuracy of determining peptide binding affinity of MHC-II; the
artificial linker in between DR1β and Aga2 might introduce unknown steric impact on
the folding of HLA-DR1 molecules; etc. Thus, a way to co-express Aga2p-peptide
fusion and soluble heterodimeric MHC-II in yeast, which allows interaction of peptide
and MHC-II taking place inside ER and display of the peptide/MHC-II complex on the
surface, would be an alternative strategy to overcome most of these problems.

2.3.2. Surface display of FLU peptide and their capability for
anchoring soluble HLA-DR1
As mentioned in Chapter I, proteins of interest can be attached to either terminus of
Aga2p; hence, two plasmids ptFLU and ptNFLU with a LEU2 nutrient marker (Figure 26A) were constructed: the former one directs expression of Aga2p C-terminal FLU
peptide flanked by two epitope tags (HA-tag and V5-tag), whereas the latter one enables
FLU peptide attached at N-terminus of Aga2p. In both expression constructs, fused
epitope tags allow immunofluorescent labeling by specific antibodies, which indirectly
represent the display level of Aga2p-linked FLU peptide.
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Figure 2-6 Map of yeast shuttle vectors for yeast co-display. A. A LEU2 nutrient marker bearing
plasmid is constructed for displaying peptide fusion covalently linked to Aga2p either at its C-terminus
(Construct a in plasmid ptFLU) or at the N-terminus (Construct b in plasmid ptNFLU). In construct a,
FLU peptide is flanked by HA and V5 epitope tags, whereas in construct b, FLU is overhung at the Nterminus of Aga2p with a 6His epitope tag fused in between. B. The plasmid ptsDR1 with a TRP1
nutrient marker allows simultaneous expression of DRα [DRA*0101(1-192)] and DR1β
[DRB1*010101(1-190)] extracellular domains in secreted forms from separate cassettes under the control
of a bi-directional promoter GAL1-10.

EBY100 (URA+, trp-, leu-) transformed with ptFLU or ptNFLU (both LEU+) was
selectively grown up and induced under ura-, trp+, leu- condition. Immunofluorescent
labeling against HA-tag and flow cytometric analysis of labeled yeast demonstrates the
successful surface display of FLU peptide using either construct, but a better surface
expression level by construct b (Figure 2-7A).

To evaluate HLA-DR1-binding

probability of surface-displayed FLU, another plasmid ptsDR1 with a TRP1 nutrient
marker (Figure 2-6B) for secreting soluble HLA-DR1 heterodimer was constructed and
transformed into yeast displaying either form of FLU peptide fusion. The resulting yeast
strains were cultured under ura-, trp-, leu- condition and labeled using DR-specific
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antibodies.

The overlay of flow cytometric data indicates that HLA-DR1 can be

anchored on the surface of yeast no matter which terminus of Aga2p was used for FLU
displaying, but an obvious difference of detectable HLA-DR1 amounts between these
two strains exists (Figure 2-7B). Construct a (Figure 2-6A) with lower FLU expression
level actually leading to the higher DR1-anchoring capability was chosen for performing
yeast co-display in the rest of this thesis work.

Figure 2-7 Surface levels of two FLU fusion constructs and anchored soluble HLA-DR1. A. Yeast
displaying FLU peptide as a Aga2p C-terminal fusion (solid curve) or N-terminal fusion (dashed curve)
were induced in SG-SCAA + tryptophan at 30 °C and labeled sequentially with HA-tag-specific H6908
and Alexa Fluor 488 conjugated secondary antibody and analyzed on BD FACSVantage. B. The same
yeast strains as in A were transformed with plasmid expressing soluble HLA-DR1, induced in YPG at 20
°C and labeled sequentially with DR-specific L243 and a tandem dye PE-Alexa Fluor 647 conjugated
secondary antibody and analyzed on Beckman Coulter XL. In both cases, yeast labeled with
corresponding secondary antibody only (shaded) represents an auto-fluorescent background cell
population in the overlayed histograms.

To further confirm the display of FLU to Aga2p C-terminus on the surface of yeast
using construct a, HA-tag and V5-tag flanking FLU peptide were simultaneously stained
with corresponding antibodies. In comparison to non-peptide displaying strain (Figure
2-8A), yeast expressing FLU fusion exhibit comparable HA-tag and V5-tag display
levels, which is independent to the expression of soluble HLA-DR1 (Figure 2-8B and
C).

The FLU display level on the surface of yeast can be represented by the
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background-corrected mean fluorescence intensity value normalized to the background
intensity:
cMFI =

MFI( HA +) " MFI( HA -)
MFI( HA -)

Equation 2-1

where MFI(HA-) and MFI(HA+) represent mean fluorescence intensity of the HA-tag
! Alexa Fluor 647 emission for negative and positive cell populations,
coupled

respectively (Figure 2-8 (i)). Analysis using anti-V5-tag staining resulted in equivalent
cMFI values (Figure 2-8 (ii)), confirming the surface display of FLU peptide.
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Figure 2-8 Simultaneous detection of both HA and V5 epitope tags flanking FLU peptide. Yeast
expressing A. soluble HLA-DR1, B. Aga2p-fused FLU, or C. both were induced in YPG at 20 °C and
labeled with antibodies specific for (i) HA-tag or (ii) V5-tag and analyzed on BD FACSCalibur. cMFI
was calculated using MFI measured by Flowjo software (Tree Star Inc.) for positive and negative cell
populations.
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2.3.3. Yeast co-display of FLU and FLU-anchored soluble HLA-DR1
It was suggested previously that a two plasmids based co-display methodology
(Figure 2-1) can be derived from the classical yeast display approach such that the
MHC-II and target peptide are expressed from separate yeast shuttle vectors (Figure 26). MHC-II heterodimers that bind the Aga2p-fused target peptide are thus anchored to
the cell surface via Aga2p (Figure 2-7), whereas MHC-II that do not bind the target
peptide or bind instead to endogenous peptides present in the secretory pathway will be
either secreted as soluble species or potentially degraded by the secretory quality control
machinery, as suggested by our classical surface display results. To verify the peptidebinding-dependent cell surface display of HLA-DR1, plasmids directing expression of
HLA-DR1 or Aga2p-FLU were transformed into EBY100.

Yeast expressing

combinations of these proteins were immunofluorescently co-stained to detect the level
of FLU peptide and HLA-DR1 on the surface and analyzed by flow cytometry (Fig. 29).

Yeast expressing only the soluble HLA-DR1 ectodomain show no detectable

staining, while those co-expressing soluble HLA-DR1 and surface-displayed FLU
demonstrate correlated signals for both (Fig. 2-9B and D). Based on the known peptidebinding motif of HLA-DR190, 145, Ala was substituted for Tyr at the P1 major anchor
position of the FLU peptide (peptide P1-Ala; PKAVKQNTLKLAT; see Figure 4-1). As
anticipated, this substitution abolished detectable HLA-DR1 on the cell surface (Figure
2F) without affecting peptide display level (Figure 2C and E), confirming the specific
anchoring of HLA-DR1 to the surface via interaction with FLU.
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Figure 2-9 Yeast co-display and surface detection of FLU peptide and FLU-bound soluble HLADR1. A. Yeast parent strains or yeast expressing B. HLA-DR1, C. Aga2p-fused FLU alone, D. Aga2pfused FLU with HLA-DR1, E. Aga2p-fused P1-Ala alone, or F. Aga2p-fused P1-Ala with HLA-DR1
were induced in corresponding galactose-containing minimal media at 30 °C, co-stained by anti-HA and
anti-DR antibodies, and analyzed on BD LSR II. MFI of DR signal was generated using Flowjo for HA
positive cell population. Proportions of the whole cell events were indicated at the corner of each quad.
P1-Ala is a FLU analogue with Tyr308 replaced by Ala.
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2.3.4. Stripping of FLU/HLA-DR1 complex off the surface of yeast
Anchorage of all Aga2p fusions to Aga1p is through two disulfide bonds, which is
reducible by reducing reagents (Figure 2-10), such as Dithiothreitol (DTT) and βmercaptoethanol (βME). Other than that, reducing reagents can also degrade HLA-DR1,
which contains three disulfide bonds (one on α chain and two on β chain).

Figure 2-10 DTT and Factor Xa reacting sites in two FLU/HLA-DR1 displaying schemes: A. codisplay, and B. classical surface-display.

To evaluate the effect of reducing reagents, different concentrations of DTT were
applied to yeast strains displaying FLU/HLA-DR1 complexes by co-display or classical
surface display. Cells before or after DTT treatment were co-stained to detect HA-tag
and HLA-DR1 by flow cytometry (Figure 2-11).

As expected, mean fluorescence

intensity of either anti-HA-tag or anti-DR signal decreased as increasing DTT
concentration (Figure 2-12 and Table 2-12), indicating the surface anchorage of
FLU/HLA-DR1 complexes by Aga2p for both displaying schemes. It is worthy of
noticing that almost all FLU/HLA-DR1 complexes were stripped off the surface of codisplaying yeast at the concentration of 1 mM, while the negative showed little influence
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by DTT except for a small population moving towards higher intensity possibly due to
contamination from DTT preparation.

Figure 2-11 Effect of DTT on surface display of Aga2p or FLU/HLA-DR1 complexes. Yeast
expressing an irrelevant soluble protein (left column), co-displaying Aga2p-FLU and FLU-anchored
soluble HLA-DR1 (middle column) or displaying FLU-linked HLA-DR1 by classical approach (right
columnw), collected before (top row) or after (other rows) DTT treatment, were double labeled using
antibodies specific for HA-tag and HLA-DR1 and applied to Accuri C6 for dot-plot analysis.
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Table 2-1 MFI for HA or DR signal on the surface of yeast before or after DTT treatment.
EBY100 co-transformed with
ptsDR1 and ptFLU
MFI(HA)

MFI(DR)

MFI(HA)

MFI(DR)

192000

2721

149000

19439

0.04mM

138000

1902

110000

10613

0.2mM

12290

1618

37300

2231

1mM

6471

1336

22857

1232

Non-treated
Treated
with DTT

EBY100 transformed with
pfluDR1

NOTE: MFI represents mean fluorescence intensity for the major cell population shown in Figure 2-11.

A short peptide (Ile-Glu-Gly-Arg) constructed in between Aga2p and HA-tag
enables removal of Aga2p C-terminal protein fusion by Factor Xa cleavage (Figure 210).

To examine this effect, yeast strains displaying FLU/HLA-DR1 by either

displaying scheme were collected and incubated with Factor Xa protease at two different
temperatures (4 °C and 23 °C). Flow cytometric data of yeast co-displaying FLU and
HLA-DR1 (Figure 2-12 (middle column)) exhibits a noticeable decrease for both HA
and DR signals, as suggested by calculated MFI values (Table 2-2). Longer treatment
(~2 days) by Factor Xa at 23 °C resulted a substantial decline of the amount of
FLU/HLA-DR1 complexes (Figure 2-13 and Table 2-3), further confirming the fact that
FLU peptide is fused to the C-terminus of Aga2p and HLA-DR1 is bound by FLU
peptide (or at least peptides to the C-terminal downstream of Aga2p//HA-tag cassette,
which do not confirm previous results). On the other hand, the data of yeast displaying
FLU-linked HLA-DR1 by classical approach (Figure 2-13 (right column)) shows
decrease only for HA signal but not DR signal (see Table 2-2), demonstrating that
FLU/HLA-DR1 complexes were linked to the other terminus of Aga2p, where Factor Xa
cleavage had no impact on. Effect of both DTT and Factor Xa protease confirmed
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previously conclusion that soluble HLA-DR1 was specific anchored on the surface of
yeast by interaction with FLU peptide.

Figure 2-12 Effect of Factor Xa protease on surface display of FLU/HLA-DR1. Yeast expressing an
irrelevant soluble protein (left column), co-displaying Aga2p-FLU and FLU-anchored soluble HLA-DR1
(middle column) or displaying FLU-linked HLA-DR1 by classical approach (right columnw), collected
before (top row) or after (other rows) Factor Xa treatment were double labeled for HA-tag and HLA-DR1
and applied to Accuri C6 for flow analysis.
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Table 2-2 MFI for HA or DR signal on the surface of yeast before or after Factor Xa treatment.
EBY100 co-transformed with
ptsDR1 and ptFLU
MFI(HA+)

MFI(DR)

MFI(HA+)

MFI(DR)

192000

2721

149000

19439

4 °C

201000

1983

123000

13712

23 °C

125000

1498

50682

14489

Non-treated
Treated with
factor Xa

EBY100 transformed with
pfluDR1

NOTE: MFI represents mean fluorescence intensity for HA-positive cell population shown in Figure 2-12.

Figure 2-13 Effect of Factor Xa on FLU/HLA-DR1 display level after longer incubation at 23 °C.
Yeast displaying Aga2p-FLU (left column) or co-displaying Aga2p-FLU and FLU-anchored soluble
HLA-DR1 (right column), collected before (top row) or after (bottom row) Factor Xa treatment, were
double labeled using antibodies specific for HA-tag and HLA-DR1 and applied to BD FACSVantage (cell
sorter) flow cytometric analysis.
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Table 2-3 MFI for HA or DR signal on the surface of yeast before or after longer Factor Xa
treatment.
EBY100 co-transformed with
ptsDR1 and ptFLU

EBY100 transformed with
pfluDR1

MFI(HA+)

MFI(DR)

MFI(HA+)

MFI(DR)

Non-treated

394

3.27

442

18.1

Treated with factor Xa

21.4

3.34

29

4.71

NOTE: MFI represents mean fluorescence intensity for HA-positive cell population
shown in Figure 2-13.

2.3.5. Verification of genotype-phenotype linkage between plasmids
and co-displayed proteins
In order to extend the co-display approach to library screening, the genotypephenotype linkage between plasmids and displayed proteins must be maintained;
therefore, experiments were performed to determine whether HLA-DR1: (1) bound to
FLU intracellularly and was subsequently exported to the surface, (2) was secreted
“empty” into the culture medium (or with weakly bound endogenous peptides) and then
bound to FLU, or (3) a combination of these mechanisms.
Yeast cells displaying FLU peptide (Figure 2-9C) or P1-Ala analogue (Figure 2-9E)
were co-cultured with yeast expressing soluble HLA-DR1 ectodomain (Figure 2-9B) and
double labeled using anti-HA and anti-DR antibodies before flow analysis (Figure 214A). Approximately 50% HA-positive cell population shown in the dot-plot indicates
an unaffected peptide expression level on the surface of either peptide-displaying strain,
whereas no obvious DR-positive cell population were observed, suggesting failure of
secretion of soluble HLA-DR1 by corresponding yeast strain or failure of interaction
between surface-displayed FLU and soluble HLA-DR1 outside yeast under the culturing
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condition.

Furthermore, yeast cells displaying FLU were incubated in conditioned

medium from a culture of soluble HLA-DR1-expressing yeast (Fig. 2-14 B and C),
including the co-displaying strain that ensured secretion of soluble HLA-DR1 (Fig. 214B(i)). In all cases, no significant binding of HLA-DR1 to the surface of any yeast was
observed regardless of media used, indicating that resorting of secreted HLA-DR1
between different cells in the same culture fails to occur and suggesting that HLADR1/FLU binding occurs intracellularly within the secretory pathway.

Figure 2-14 Control experiments for examining possible switching of soluble HLA-DR1 molecules
among different yeast cells in the same culture. A. Co-culturing. 107 yeast cells expressing (i) Aga2pFLU or (ii) P1-Ala were co-induced with 107 yeast cells expressing soluble HLA-DR1 in 2 ml SG-CAA +
TRP at 30 °C. B. Medium switching. After induction in minimal media, 2.5 × 106 yeast cells displaying
FLU peptide were incubated in 500 µl medium preconditioned by growing yeast (i) co-expressing Aga2pFLU and HLA-DR1, (ii) expressing soluble HLA-DR1, (iii) co-expressing Aga2p-P1-Ala and HLA-DR1,
or (iv) expressing Aga2p-FLU peptide at 30 °C. C. Minimal media used in (B) for induction was replaced
by rich medium YPG. Cells were all double labeled for HA-tag and HLA-DR1 molecules by H6908 and
L243 before applied on BD LSRII for flow cytometric analysis.
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2.4. Discussion
2.4.1. Yeast is suitable for expressing functional heterologous
multimeric protein complexes
The eukaryotic protein displaying and engineering system, Saccharomyces
cerevisiae has been demonstrated to have the ability to assemble heterologous
multimeric proteins either as recombinant single chain derivatives74, 132, 133, 146, or more
natively as non-covalently associated heterodimers, such as MHC-II alleles DR4102, Fab
antibody fragments88. In this chapter, we also showed that the heterodimeric HLA-DR1
can be displayed on the surface of yeast with or without covalently linked FLU peptide
(Figure 2-4). The noticeablly better expression level of FLU-linked form on yeast
surface agrees with the stabilization effect of FLU peptide on assembly of DR1
molecules67, 68, suggesting a similarity of the in vivo environments between yeast and
human cells. Furthermore, we confirmed the peptide binding ability of “empty” form of
HLA-DR1 on yeast surface (Figure 2-5), which indicates the potential of yeast surface
display as a strategy for characterizing peptide/MHC interaction. However, the time and
labor consumed on chemically synthesizing peptides individually would eventually
restrain this method to generate high throughput results. Another disadvantage of most
available strategies used for characterizing peptide/MHC-II interactions (including the
one just mentioned and those mentioned in introduction of this chapter) is the in vitro
laboratory environments where interaction between peptides and MHCs takes place. As
we all know, in their native biological environments, proteins are not independently
existing but mostly within a complex network, where molecular interactions among
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proteins, nucleic acids, lipids, chemicals, etc. are occurring all the time (known as
interactome147, 148), so, the simple in vitro peptide binding condition might not accurately
reflect the true scenario for peptide/MHC-II association happening inside ER of
professional APCs.

2.4.2. Yeast co-display contains a variety of advantages for studying
peptide/MHC-II interaction
Most of above problems can be solved by the novel method – yeast co-display – we
developed in this chapter. Intensive characterization and validation were performed for
an interacting pair: HLA-DR1 and DR-specific FLU peptide. These two molecules are
translated from gene cassettes carried by two separated yeast vectors, both of which can
be accommodated by the same yeast cell. Under regulation of secretory signal peptides,
both molecules will enter endoplasmic reticulum, where the association between FLU
and HLA-DR1 starts occurring at a more in vivo like environment. Along with exocytic
process, the Aga2p fused FLU/HLA-DR1 complex will be delivered outside yeast and
anchored on the surface of yeast as design (Figure 2-1). In this genetic design, we took
advantage of the fact that the binding groove of MHC-II is more open and allows both
ends of peptide extended outside60, and covalently attached FLU peptide to the yeast
surface protein, a-agglutinin.

This small trick not only provides a linkage for co-

displaying FLU and soluble HLA-DR1, but also eliminates possible artifacts caused by
covalently linking HLA-DR1 to anchoring proteins in other display strategies, such as
Aga2 protein for yeast display74, gIII or gVIII coat proteins for phage display139, hybrid
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produces of lipoproteins and membrane proteins for E.coli display80, envelope
glycoprotein gp64 for baculovirus-insect cell display76.
By site directed mutagenesis and enzymatic cleavage (Figure 2-9E and F, Figure 210 ~ 2-13, and Table 2-1 ~ 2-3), the surface anchorage of soluble HLA-DR1 by FLU
peptide but not other yeast surface structural molecules has been evaluated and
confirmed. The fact that a single substitution in the FLU peptide sequence was able to
disrupt the binding of HLA-DR1 obviously implies the peptide specificity of HLA-DR1
produced in our co-display system, which we will further examine in the following
chapter more quantitatively.
It is worth noticing that the display level of FLU/HLA-DR1 complexes by codisplaying yeast is significantly lower than using classical surface display (Figure 2-11
top row). This could be a direct reflection for the non-covalent association of FLU to
HLA-DR1 in yeast, because there is no artificial linker introduced in between these
molecules any longer. Another interesting result is that no intercellular switching of
soluble HLA-DR1 molecules via FLU anchoring on the surface of yeast is detectable
(Figure 2-14), validating that the interaction of these two molecules mainly takes place
inside yeast cells and both dissociation and re-association kinetics happened outside
yeast is probably slow enough such that phenotype on the surface of a yeast cell is
directly related to its genotype but not others. This observation not only clarifies the
binding location but also suggests FACS as an appropriate screening and sorting strategy
for discovering HLA-DR1 mutants specific for target peptide by directed evolution.
As a new in vitro technology for studying in vivo interaction between peptide and
MHC-II, yeast co-display bears most advantages described earlier for other methods,
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such as the ability to perform quantitative analysis of peptide binding (the analysis in
Figure 2-8 has already set up an basis), the potential to generate peptide libraries and/or
MHC mutant libraries for high throughput assay, etc. In chapter III, we will discuss how
to quantify peptide binding and how to maintain optimal experimental conditions so as
to ensure the reliability of the quantitation. In the following two chapters, we will show
some applications of this quantitative, high throughput methodology for identification of
HLA-DR1 binding motif and prediction of HLA-DR1-specific ligands and for
characterization and engineering of peptide binding specificity of MHC-II allelic
variants.
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Chapter 3. Optimization of yeast co-display for quantitative
analysis
3.1. Introduction
Yeast co-display provides us a powerful tool to study the interaction between at least
two molecules. It has been shown in chapter II that, by doing some simple cloning work
we could culture yeast to produce both FLU peptides and HLA-DR1 proteins, in return,
yeast will give a feedback about the interaction between these two molecules via
presenting them on the surface for detection by flow cytometry. Only knowing whether
a given MHC-II molecule can bind a target peptide or not is not enough sometimes, we
would also like to know how well they bind with each other so that we can understand
which residue at which position will favor or inhibit the interaction and what kind of side
chain of a anchor residue is preferable to the peptide binding, etc. Indeed, yeast codisplay system does have the potential to quantitatively determine the relative peptide
binding affinity for MHC-II molecules. As demonstrated by experiments in Chapter II,
the expression level of peptide on yeast surface is independent and supposed to be
constant if yeast is always induced for a certain time, so theoretically, the better an
MHC-II can bind a peptide, the more MHC-II should be anchored and displayed on the
surface of yeast after being induced for a certain time.
Although the direct counting of how many peptides each yeast can display and how
many MHC-II molecules are anchored by peptides on yeast surface is impossible, we
can always get some related information about them by immunofluorescently labeling
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MHC-II or peptide and measuring the fluorescence intensity using some detection
techniques, such as flow cytometry as described in Chapter I. Due to the morphology
and diverse size of budding yeast, the integrated fluorescence intensity of each yeast will
be different, so measuring thousands or millions of yeast by flow cytometer and
generating a distribution of global fluorescence intensity of different yeast cells is
relatively more meaningful. The mean value of the distribution (MFI) can properly
represent the relative number of MHC-II or peptides on the surface of the average yeast
cell.
It is clear that the biological expression system will never tell us the exact amount of
proteins produced and associated inside the cell before the result is turned out on its
surface, so in order to quantitatively characterize peptide binding specificity of MHC-II
by yeast co-display, optimal yeast culturing and labeling conditions have been
determined so that the generated MFI from flow data with apparently small standard
deviation could be used to accurately reflect how well an MHC-II binds to a peptide.
This optimization actually contains two meanings. First one is to investigate appropriate
experimental conditions for better proteins expression and interaction as well as more
accurate labeling and surface detection. The expression of FLU peptide essentially is an
indicator of protein expression level in yeast cells and an optimal expression level
obviously provides enough binding blocks for efficient protein-protein interaction. A
better interaction between FLU peptide and HLA-DR1 molecule in yeast will result in
more detectable HLA-DR1 anchored for easier surface detection. Consequently, proper
labeling for proteins on yeast surface will largely decrease the inaccuracy and variance
of fluorescent detection by flow cytometry. Second meaning is that the optimized
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working condition has no need to be the best, but at least a local optimum with relatively
broad resistance to variations caused by different reagents and instrument parameters so
that the quantitative assay generated later on can be more reliable. This will also ensure
that mutagenesis introduced to FLU and HLA-DR1 molecules in the following chapters
have no significant impact on quantitation by yeast co-display. Normally, an optimum
should provide some resistance to small errors, so we will mainly focus on seeking for
optimal experimental conditions in this chapter without worrying about the second
meaning too much as it could be obtained automatically once working condition is
optimized.
Variables for culturing yeast such as medium, temperature, time length, and cell
density, etc, are direct effectors controlling the expression and association of proteins in
yeast. Variables for fluorescent labeling including choices of primary antibodies and
secondary fluorescently labeling reagents, concentration or dilution of reagents used, etc,
are factors probably introducing errors for flow detection but not affecting the real
amount of proteins on yeast surface. Actually, all these variables are more or less
connected with each other, which makes the evaluation really difficult. As mentioned
previously, we do not have to find out the best condition, so to make things easier and
still reasonable, the number of variables were grouped and varied a few at a time to
maximize the efficacy of the whole optimization process.
The most direct and reasonable phenotypic signal for evaluating the optimum of
experimental conditions is the amount of HLA-DR1 on the yeast surface.

In this

chapter, we proposed a quantitative way to measure the relative HLA-DR1 amount in
the materials and methods section and then evaluated several sets of variables based on
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the HLA-DR1 measurement for searching an optimal experimental condition in result
section. First of all, issues about medium, time and temperature selected for inducing
yeast to produce proteins for interaction were analyzed. Following that, cell densities at
different stages were evaluated for eliciting better detectable DR-signals on yeast
surface.

Finally, proper antibodies and labeling reagents were selected and the

concentrations of them were titrated for an accurate surface detection.

3.2. Materials and Methods
3.2.1. Media for yeast growth and induction
SD-SCAA was used for cell enrichment. Either a minimal medium SG-SCAA or a
rich medium YPG was picked for induction of GAL1-10 promoted protein expression.
Both SD-SCAA and SG-SCAA were filter sterilized. For YPG, five different batches
were used in experiments done in this chapter (Table 3-1).
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Table 3-1 Different batches of YPG media used in this chapter.
Batch Number

YPG 1

Component

Vendor

Yeast extract

BD Biosciences

Peptone

Fisher Sientific

Galactose

Acros Organics

Yeast extract
YPG 2

Peptone

Fisher Sientific

Galactose

Acros Organics

Peptone
Galactose
Yeast extract

YPG 4

Filtered

Invitrogen

Autoclaved

Acros Organics

Filtered

BD Biosciences

Peptone
Galactose

Autoclaved

Acros Organics

Yeast extract
YPG 5

Autoclaved

BD Biosciences

Yeast extract
YPG 3

Sterilization method

Peptone
Galactose

BD Biosciences

Autoclaved

Acros Organics

Filtered

3.2.2. Primary and secondary labeling reagents
Immunofluorescent labeling for induced yeast cells was carried out mostly in a 2step manner, and primary antibodies and secondary reagents with fluorophores
conjugated are listed in the following.
One of the following DR-specific mouse Mab: L243 or biotinylated LB3.1 (purified
from hybridoma culture supernatant at National Jewish Center, Denver, CO) was used to
specifically label functional HLA-DR1 in the primary labeling step. Different secondary
reagents used for labeling corresponding primary antibodies are Alexa Fluor 488 or 647
conjugated goat anti-mouse antibody (all Alexa Fluor dyes were purchased from
Invitrogen), tandem dye PE-Cy5 conjugated streptavidin (BD Biosciences Pharmingen).
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Polyclonal antibody H6908 and Alexa Fluor 488 - goat anti-rabbit were used as
primary and secondary labeling reagents, respectively, for detecting FLU-linked HA-tag.

3.2.3. General culturing procedure for yeast co-display
Colonies for EBY100 transformants with two plasmids containing both TRP1 and
LEU2 nutrient markers are first selectively grown up on SD-SCAA agar plates
(containing 1 M sorbitol) under trp-, leu-, and ura- condition and then inoculated into 2
ml SD-SCAA liquid medium in an autoclaved glass test tube. The yeast culture was
then enriched to a proper OD600 (an optimal range of the density will be determined in
this chapter) in a 30 °C shaker at 225 rpm. To induce the expression of both FLU fusion
and sDR1, enough yeast cells (an optimal amount will be determined in this chapter) are
collected by centrifugation for ~1 min at maximum speed in a microcentrifuge. After
withdrawing the supernatant, cell pellet was resuspended by 2 ml of either SG-SCAA or
YPG medium and transferred to a new glass tube. Induction is carried out at some
temperature for a certain time length before harvest for surface detection (optimal
induction condition will be determined in this chapter).
Above is just a general yeast cultivation procedure, specific OD600, medium, time
length, temperature are indicated in each experiment stated later on.

3.2.4. General fluorescent labeling procedure
After induction, a pellet of 106 yeast cells were collected from each sample by
centrifugation into a 1.5 ml Eppendorf tube and washed once with at least 300 µl ice
cold PBS + 1% BSA. Cells were then stained with a proper dilution of a primary
antibody specific for either DR or HA epitope tag in PBS + 1% BSA at room
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temperature (RT) or on ice for 30-60 min. Following that, cells were spun and washed
once again with ice cold PBS + 1% BSA and then incubated with corresponding
secondary labeling reagents diluted in PBS + 1% BSA at RT or on ice for 30-60 min.
Finally, cells were washed with PBS + 1% BSA one more time and resuspended in
500~750 µl ice cold PBS + 1% BSA for analysis by flow cytometer.
Above is just a general labeling procedure, specific antibody chosen and exact
dilution used will be indicated in each experiment stated later on.

3.2.5. Quantitative analysis of flow cytometric data
A direct way of evaluating one working condition versus another is to compare the
relative amount of HLA-DR1 on the surface of yeast prepared using different conditions,
because the only reason one can detect HLA-DR1 molecules by yeast co-display is due
to the association and anchorage of HLA-DR1 by FLU peptide expressed on yeast
surface. Herein, we proposed one quantitative approach for determining relative amount
of HLA-DR1 on the surface of yeast by flow cytometric analysis. In most experiments
carried out in this chapter, both a DR-positive and a DR-negative co-displaying yeast
strain were used under each working condition. After flow cytometry, data were first
plotted by SSC vs. FSC for checking and gating the right yeast cell population (Figure 31 (i)). Then the fluorescent signal for labeled HLA-DR1 molecules on the surface of
gated cells was displayed as a cell event distribution in a histogram (Figure 3-1 (ii)). By
using Flowjo, one can measure the mean fluorescence intensity for the distribution. The
HLA-DR1 display level on the surface of yeast can be estimated by the backgroundcorrected mean fluorescence intensity value normalized to the background intensity:
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cMFI(DR ) =

MFI(DR ) (+) " MFI(DR ) (")
MFI(DR ) (")

Equation 3-1

where MFI(DR)(+) and MFI(DR)(-) represent mean fluorescence intensity of DR signals on

!surface of DR-positive and negative yeast strains, respectively.
the
The cMFI(DR) value can be used to reflect the relative HLA-DR1 amount on the
surface of yeast cultured and labeled under a certain condition. The negative subtraction
and normalization are both necessary to set up a base line for comparing data collected at
different experimental condition and minimize unnecessary errors introduced by
different parameters set up on flow cytometers. It is worthy of noticing that due to the
difficulty to discriminate negative and positive, the measurement of MFI (Figure 3-1 (ii))
includes the whole cell population, which actually brings down all absolute values of
cMFI after the background subtraction in Equation 3-1, but has no impact on relative
value when we compare them with each other. Additionally, due to the truth that
negative strain could change its surface turning-out at different culturing condition as
well, there is actually no exact base line to compare data collected on different flow
cytometers or even on different dates. Therefore, most comparison was done for flow
data collected on the same flow cytometer in the same day, and results from different
dates were then put together to draw a final conclusion.
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Figure 3-1 Quantitative analysis of relative HLA-DR1 amount on yeast surface using flow
cytometric data generated from anti-DR-labeled yeast. Data of both A. DR- and B. DR+ cell samples
were first plotted in (i) a dot plot by side scatter (SSC) vs. forward scatter (FSC) representing information
of cell morphology and intracellular organelle complexity, and then gated for the majority of cell
population (red line, ~90% of total) in order to separate real yeast from contaminants. The gated cell
subset was then plotted in (ii) a histogram for fluorescence intensity of fluorophore labeling HLA-DR1
molecules. Mean fluorescence intensity (MFI) of the whole subset was measured for both A and B.

3.3. Results
3.3.1. Evaluation of medium, temperature and time for induction
The growth and induction of yeast cells are usually sensitive to a couple of things
which people might not notice most of the times, such as air flow inside the shaker,
shaking speed, size and shape of the flasks or tubes, which will affect the aeration for the
cell culture and thus the cell growth. To minimize the influence of these factors, all
yeast strains used for quantitative analysis were inoculated and induced in a constant
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volume - 2 ml of medium in an autoclaved glass culture tube, and the shaking speed was
set to 225rpm for all experiments. By setting other effectors unchanged, we will evaluate
medium and temperature chosen for induction at different time length first.
Co-displaying yeast strains were first selected out on SD-SCAA agar plates, which
will inhibit the growth of background or parent strains. After being enriched in the
minimal liquid medium SD-SCAA, cells were switched to different induction media for
expressing proteins. Herein, we tested two kinds of media: a rich medium YPG and a
minimal medium SG-SCAA both containing galactose with the ability to turn on the
GAL1-10 promoter for expression of both Aga2-FLU fusion and soluble HLA-DR1.
The cell growth rate in YPG is dramatically faster than that in SG-SCAA, so the
induction in YPG was tried mainly at 20°C. Occasionally, huge difference between the
final densities of induced cells was observed when different batches of YPG media were
used (OD600 not shown). To determine whether YPG, made of components bought from
different vendors and prepared differently by autoclaving or filtering, would affect the
expression and interaction of FLU and HLA-DR1, different batches of YPG were
examined in some experiments (Table 3-1, Figure 3-2A~C and Figure 3-3D). Results
suggest that not only the final cell density is different, but the HLA-DR1 amount on cell
surface is also different. However, there is no obvious relationship between different
batches and the detectable HLA-DR1 amounts. For example, YPG 3 can provide a
much higher cMFI than YPG 2 when induced for 90 h (Figure 3-2A), but a lower cMFI
when induction time became shorter (Figure 3-3D). In contrast with using other bathes,
cells in YPG 3 didn’t show obvious loss of DR signal after 90 h induction comparing
with 20 h (Figure 3-2A, B and Figure 3-3D), where the yeast extract and peptone
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purchased from Invitrogen for making YPG 3 could have an impact. Hence, it is
difficult to predict which batch of YPG will give the best expression or the highest
association of proteins. Theoretically, YPG provides the most nutrients and materials
for cells to make proteins, however, the uncertainty and richness of components in YPG
will lead to an unpredictable cell growth behavior, which we would like to avoid when
performing quantitation. On the contrary, although not rich, SG-SCAA indeed provides
enough nutrients to keep cells growing slowly while making proteins as well as to inhibit
background cells growing. Henceforward, we will characterize the induction in SGSCAA more intensively.
It was suggested that induction in YPG with shorter time tends to favor the detection
of HLA-DR1 molecules on yeast surface (Figure 3-2B and C), so we tried to induce
yeast in SG-SCAA at two different temperatures using shorter time frames. Within 2
Days, cells induced in SG-SCAA at 30 °C can display an equivalent amount of HLADR1 in comparison with those induced in YPG at 20 °C and both exhibited a similar
feature that the longer they were induced, the fewer HLA-DR1 we can detect on cell
surface (Figure 3-2B and C, also see Figure 3-3A~C), whereas cells induced in SGSCAA at 20 °C do need longer time to present more HLA-DR1 (Figure 3-2C),
suggesting that protein expression in minimal media is slower than in rich media.
Considering higher temperature could favor the protein binding kinetics, we stuck to 30
°C induction in SG-SCAA and explored behaviors at even shorter time frames, where
DR signal no longer increased with increasing time (Figure 3-2D). Together with
previous results (Figure 3-2C), a local optimum for induction time can be searched out
between 14 h and 20 h when inducing co-displaying yeast in SG-SCAA at 30 °C.
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Figure 3-2 Effect of medium, temperature and time length used for yeast induction on HLA-DR1
surface display level. Shown are four separate experiments. cMFI(DR) were calculated as described in
Equation 3-1 for the co-displaying yeast strain prepared at different conditions. A. Cells were induced in
different batches of YPG at 20 °C for 90 h. B. Time lengths for induction were varied when using two
different YPG media. C. Induction was carried out in different media at different temperature for various
time lengths. Biotinylated LB3.1 and PE-Cy5 conjugated streptavidin were used for DR-labeling. D. The
initial cell density (OD600) for inoculation and the time length for induction were both varied. Another
change in this set of experiment is that cells collected for induction were not spun down but with some
volume of SD-SCAA carried over to the medium for induction. (Other than noted, L243 and Alexa Fluor
488 conjugated goat anti-mouse antibody were used for the two-step yeast labeling. The staining was
carried out on ice and flow cytometry was done on Beckman Coulter XL.)

3.3.2. Optimization of cell density for induction
We introduced another factor – cell density when seeking for a local optimum of
induction time when performing induction in SG-SCAA at 30 °C to broaden the
applicability of the optimized condition. Since most of the time yeast is inoculated from
plates directly into culture tubes, it is impossible to check the starting yeast age. Indeed,
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a little more HLA-DR1 molecules were detected when inoculating at a higher density
(OD600~0.4) than lower one (OD600~0.05) (Figure 3-2D), partially reflecting that starting
with fresh cells tends to result better than older ones for a certain growth length, because
old ones normally contain more dead cells which won’t divide. This postulation was
also confirmed by the experimental result being talked about in Chapter IV (Figure 4-3).
Bearing this in mind, we tried to inoculate yeast as fresh as possible henceforward.
However, if cells are too old, several passages using fresh medium will always dilute out
older ones, so it is not necessary to control the starting cell density for inoculation.
Densities of cells collected and initiated for induction are parameters that could
affect the final HLA-DR1 surface display level. Yeast collected from SD-SCAA culture
at both an OD600 of 3.0 and 6.0 exhibit optimal DR signals after being induced for 16 h
regardless of what OD600 used for initiating induction (Figure 3-3A and B), suggesting
that an optimal induction time could be somewhere closed to 16 h. A direct comparison
of these two local optimums (Figure 3-3C) further confirms that cells collected at a
smaller OD600~3.0 and induced in SG-SCAA at a smaller OD600~0.5 will display more
detectable HLA-DR1 than those with bigger OD600. Additionally, serving as a parallel
control, results of yeast induced in YPG at different initial densities (Figure 3-3D)
confirmed that collecting cells at a relatively earlier growth stage helped to display more
HLA-DR1. This makes us to speculate that cells should be collected and induced within
the exponential phase of growth or before stationary phase, after which the changes in
cell wall structure could possibly influence surface display and detection of target
proteins.
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Figure 3-3 Effect of densities of cells collected and initiated for induction on HLA-DR1 surface
display level. Co-displaying yeast grown up in SD-SCAA were collected at either A. OD600 ~ 3.0 (open
symbols) or B. OD600 ~ 6.0 (filled symbols), spun down and resuspended in SG-SCAA to various densities
at an OD600 of 0.5, 1.0 or 2.0 as indicated, and then induced at 30°C for various time lengths. C. Further
comparison of the DR signal from yeast collected at the two different OD600 and induced with a starting
OD600 of 0.5. D. Cells collected at different OD600 after enrichment were also resuspended in different
batches of YPG media to an OD600 of 1.0 and induced at 20 °C for 20 h. After induction, all samples in
were collected and labeled at the same time for flow cytomeric analysis. cMFI(DR) were calculated as
described previously for yeast prepared at different conditions.

Before performing more experiments searching for optimal densities of cells
collected and initiated for induction, we defined the growth pattern for co-displaying
yeast strain in SD-SCAA medium. 2 ml of SD-SCAA fresh media in glass culture tubes
were inoculated by two-day-old cell cultures (used to be kept at 4 °C) to an OD600 of
0.02 and incubated in a 30 °C shaker at 225rpm. OD600 measured at different time
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points plotted in log scale against growth time (Figure 3-4) reveals a curve for yeast
growing in SD-SCAA medium. The curve is actually linear before 20 h (OD600~4.0),
reflecting an exponential growth phase, and then starts to tilt down a little bit, indicating
the beginning of stationary phase or a deceleration stage for entering stationary, where
apoptosis of older cells in the culture tube emerges. Furthermore, the doubling time for
yeast cells growing in SD-SCAA can be determined using this curve, which is around
3.5 hours. It is clear that OD600~3.0 (~19 h post-inoculation) is within the exponential
phase whereas OD600~6.0 (~24 h post-inoculation) is towards the end of this partial
growth curve closed to the stationary phase, confirming our assumption that cells
collected in exponential growth stage tended to display more HLA-DR1 than those
collected outside.

Figure 3-4 Cell growth curve for co-displaying yeast cultured in SD-SCAA.

To further evaluate the effect of growth stage and starting cell density on induction
of proteins expression and association, more OD600 were examined (Figure 3-5). It is
suggested that as long as not collected too early, the yeast will always display a similar
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amount of detectable HLA-DR1 after proper induction, while a relative higher cMFI is
observed at OD600~5.2 (Figure 3-5A). The suggested range of OD600 is about 2.0 to 6.0,
which is a little broader than that obtained from previous results. Meanwhile, the
checking for different initial cell densities of induction culture shows an optimum
around OD600~0.5 (Figure 3-5B), which is consistent with previous observation (Figure
3-3A).

Figure 3-5 Further evaluation for the effect of cell age and initial cell density. A. Cells were grown up
to various ages (OD600), and then switched to SG-SCAA to an OD600 of 0.75. B. Cells were collected at an
OD600 of 3.7 and resuspended in SG-SCAA to various densities (OD600). In both experiments,
immunofluorescent labeling was performed using biotinylated LB3.1 and streptavidin-PE-Cy5. cMFI(DR)
were calculated and plotted against OD600 measurements representing densities of cells collected or
initiated for induction.

In sum, one local optimum condition for culturing co-displaying yeast would be:
inoculate a 2 ml SD-SCAA medium by a single colony (or an aliquot from a few days
old culture) in a culture tube and grow cells in 225 rpm shaker at 30 °C for 16~20 h until
the density reach an OD600 of 2.5 to 5.0, then switch cells into 2 ml SG-SCAA to an
OD600~0.5 and incubate in 225 rpm shaker at 30 °C for 16~18 h before harvest.
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3.3.3. Optimization of immunofluorescent labeling
Using the culturing method optimized in previous section, we can have yeast to
express and display an optimal amount of HLA-DR1 for surface detection. In this
section, different immunofluorescent labeling conditions will be evaluated for
maximizing the detectable signal for flow cytometric analysis.

Two-step labeling

procedures are wildly used for indirect immnofluorescence methods, because of their
higher specificity and better fluorescence intensity. Thereby, all labeling procedures
stated in this thesis work are in a two-step manner. In previous experiments, small
changes have already been tried for evaluating different labeling conditions, such as
using different amount of wash buffers, using different time length for incubations, and
using different labeling reagents, etc. It turned out that washing 106 cells with 200–400
µl PBS + % BSA once or twice, incubating cells with different DR-specific antibodies
for 30–60 min and using different fluorophores, all showed no obvious impact on yeast
labeling and HLA-DR1 detection. However, Alexa Fluor dyes149, 150 are said to be more
stable, brighter, and less pH-sensitive than common dyes such as fluorescein, rhodamine
and the newer cyanine series, so we will use them for the rest of this thesis work.
First, antibodies used for labeling HLA-DR1 were titrated for a better working
dilution. L243 and Alexa Fluor 488 – goat anti-mouse antibodies were selected because
both antibodies are commercially available with suggested concentration and working
dilutions (Table 3-2). A series of dilutions for both were prepared around a reasonable
range and tested for labeling and surface detection of sDR1 (Figure 3-6A and B). The
roughly horizontal curve indicates that within the range tested, both L243 and Alexa
Fluor 488 – goat anti-mouse are sufficient to couple most detectable DR molecules on
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yeast surface without losing essential information. For L243 (Figure 3-6A), the result
basically agree with the suggested dilution by supplier (Table 3-2), and more casespecifically, dilutions around 1:4–1:2 seems to be an optimum for yeast co-displaying
FLU and HLA-DR1. For Alexa Fluor 488 – goat anti-mouse, dilution as low as 1:200 is
still enough to cover all DR proteins labeled by primary antibodies L243 on the whole
yeast surface, due to the high concentration of the antibody itself (Table 3-2).
Table 3-2 Antibodies with working dilution recommended by corresponding suppliers.
Antibody name

Concentration

Working dilution

L243

0.025 mg/ml

1:1

H6908

0.5 mg/ml

1:25

Alexa Fluor dye-secondary labeling reagents

2 mg/ml

NR

NR, no recommendation.

Up till now, we have already constructed a working condition for producing and
detecting an optimal amount of HLA-DR1 on co-displaying yeast surface. To
quantitatively determine the relative binding of FLU by HLA-DR1, the relative amount
of FLU peptide on the surface needs to be calculated using Equation 2-1 and used as a
comparison base line (will explain this in the discussion section in detail). Here, we
evaluated the titration of antibodies used for labeling FLU-fused HA-tag so that more
accurate amount of FLU peptide on yeast surface can be determined later for
quantitation. Again, commercially available antibodies, H6908 and Alexa Fluor 488 –
goat anti-rabbit were examined at a series of dilutions for HA signal by flow cytometry
(Figure 3-6C and D).

The Alexa Fluor dye conjugated secondary shows similar

horizontal curve to that used to label HLA-DR1 (Figure 3-6D), whereas H6908 has to be
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used in a relatively smaller dilution to stay concentrated enough for coupling all HA
epitopes on yeast surface (Figure 3-6C). It also suggests that an optimum might be
achieved while using a dilution around 1: 25, consisting with the vendor’s suggestion
(Table 3-2).

Figure 3-6 Titration of antibodies used for immunofluorescent labeling of HLA-DR1 and HA-tag on
the surface of yeast. Yeast co-displaying FLU and HLA-DR1were induced using the culturing condition
optimized in previous sections and labeled for either A and B. HLA-DR1, or C and D. HA epitope tag. A
and B. L243 and Alexa Fluor 488 goat anti-mouse antibodies were used for labeling HLA-DR1. Staining
was performed at room temperature (RT) for 40–50 min. C and D. H6908 and Alexa Fluor 488 goat antirabbit antibodies (highly cross-adsorbed with lowest cross-reactivity to mouse antibodies) were used for
labeling HA-tag. Staining was performed at room temperature (RT) for 30 min followed by on ice for 10
min. Flow cytometric data was collected on BD LSR II flow cytometer.
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3.4. Discussion
3.4.1. Optimal working condition for yeast co-display
Optimization for cultivation and post-induction manipulation of yeast co-displaying
FLU peptide and HLA-DR1 protein has been carried out.

Variables possibly

determining or affecting the detectable DR-signal have been tested in groups in a
reasonable manner searching for a local optimum that can be used reliably for
quantitation. Quantitative analysis of flow cytometric data confirms that differences do
exist when disturbing certain factors, so it is essential to adjust variables and optimize
experimental conditions so that consistent and reliable flow cytometric results can be
generated for quatitation.
Results suggest that the immunofluorescent labeling of HLA-DR1 or FLU on the
surface of yeast cells is not a big factor for introducing errors for flow cytometry, as long
as the concentration of labeling reagents used every time is closed to the optimal or
exceed the saturation amount.

The labeling procedure is relatively robust without

causing too much variance when performing at different temperatures (RT or on ice) for
a certain range of time lengths. Actually, the vessels used for labeling also have no
impact on the data at all as suggested in the following chapters, where labeling were
largely performed in 96-well plates instead of 1.5 ml eppendorf tubes. In those cases,
more wash steps were included to remove as many non-specific coupling reagents as
possible.
Indeed, cultivation of yeast is the dominant part, where significant differences
between MFI values calculated from flow data could emerge. Therefore cares need to be
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taken when growing and inducing yeast cells. First of all, minimal media is better than
rich media on keeping the constancy of nutrient combination and providing the time
efficiency at higher temperature (for example, 30 °C instead of 20 °C). Next, cells are
better to be collected at the exponential growth stage before switching for induction (for
example, OD600~3.0), where too early or too late is neither recommended. Then, initial
cell density of the induction culture should not be too high so that plenty of nutrients
could be used for protein assembly (for example, OD600~0.5). Finally, temperature and
time length selected for induction should enable both optimal protein expression and
protein-protein interaction (for example, 16h). An optimized protocol for yeast codisplaying FLU peptide and sDR1 is suggested as follow:
•

Culturing:
1) Inoculate a 2 ml SD-SCAA medium by a single colony (or an aliquot from an old
culture, but not too old) in a culture tube
2) Put the tube into a 225 rpm shaker with an angle and grow cells at 30 °C for 16–
20 h until the density reaches an OD600 of 2.5 to 5.0
3) Collect 107 cells by centrifugation and withdraw most medium
4) Resuspend cell pellet in 2 ml SG-SCAA medium to an OD600~0.5
5) Put the tube back to the same shaker and induce cells at 30 °C for 16–18 h
6) Harvest enough cells by centrifugation and withdraw as much medium as
possible for fluorescently labeling. (Alternatively, cell culture can be stored at 4
°C for a couple of days without significantly affecting the flow cytometric
results, but this is not recomended)

•

Labeling (for 106 cells):
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1) Resuspend 106 cells by 300–400 µl ice cold PBS + 1% BSA in a 1.5 ml
eppendorf tube and wash cells by thoroughly vortexing
2) Spin cells down and withdraw as much supernatant as possible
3) label cells by primary antibodies appropriately diluted in PBS + 1% BSA
(specifically, 1:2.5 for L243 and 1:25 for H6908) at room temperature for 30 min
and then on ice for 10 min
4) Spin cells down and repeat step 1) and 2)
5) label cells by secondary reagents appropriately diluted in PBS+1%BSA
(specifically, 1:80 for all kinds of Alexa Fluor dye conjugated secondary
reagents) at room temperature for 25–30 min followed by on ice for 10 min
6) Repeat step 4)
7) resuspend cell pellet by 500–700 µl ice cold PBS + 1% BSA for flow cytometry
NOTE: these procedures are actually case sensitive, so for cultivation and labeling of yeast cells under
other nutrient dropout conditions, they might not be suitable and another optimum might need to be
characterized.

3.4.2. Quantitative analysis of co-displayed FLU and HLA-DR1
We now proposed a quantitative analysis for defining the relative binding of peptide
to MHC-II molecules using optimized yeast co-display. First of all, both a co-displaying
yeast strain and a peptide-only-displaying strain have to be simultaneously stained for
peptide-fused HA epitope tag and MHC-II for flow detection. As described in Chapter 1
(1.4.2), cross-reactivity of labeling reagents and fluorescent signal overflowing are both
issues we should pay attention to when performing double labeling. Henceforward,
L243/Alexa Fluor 647 – goat anti-mouse and H6908/Alexa Fluor 488 – goat anti-mouse
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will be used for labeling HLA-DR1 and FLU respectively when performing quantitative
analysis.

Both secondary reagents purchased form Invitrogen are ‘highly cross-

adsorbed’ with lowest cross-reactivity for other species, ensuring no cross-reaction
taking place during labeling (this has been checked and proved in some experiments
with data not shown).

The far separation of excitation and emission wavelengths

between these two fluorophores also minimizes signal overflowing, where no
compensation required at all.
Next, flow cytometric data (take the two samples in Figure 2-9C and D for example)
were analyzed using Flowjo (Figure 3-7). The display level of FLU peptide on yeast
surface can be determined by calculating cMFI for HA signal using Equation 2-1.
Different from Equation 3-1, the background correction here is based on the same
sample. One reason is that there are two distinct populations in the same culture,
indicating an obvious population of negative cells missing FLU-displaying plasmids and
having no contribution to the surface display of FLU at all. Another reason is that in
contrast with the dependency of detectable amount of HLA-DR1 on FLU expression,
displaying and detecting FLU peptide on yeast surface is apparently independent.
Therefore, eliminating the background will not affect analysis of DR signal at all, but
increase the accuracy as shown in the following. To reflect how well HLA-DR1 bind to
FLU peptide on the surface of yeast, the ratio of MFI(DR) to cMFI(HA) instead of MFI(DR)
(in Equation 3-1) was used for negative subtraction and normalization in the following
equation:

81

[
DR - ratio =
where

!
!

[

MFI ( DR )
cMFI ( HA )

](+) " [ ](")
[ ](")

MFI ( DR )
cMFI ( HA )

](+) and [

MFI ( DR )
cMFI ( HA )

MFI ( DR )
cMFI ( HA )

MFI ( DR )
cMFI ( HA )

](") represent

Equation 3-2

the ratio on the surface of the co-

displaying yeast and peptide-only-displaying yeast, respectively.
! can generate relative binding values for different MHC-II proteins to
This equation

different peptides by comparing DR-ratio of corresponding co-expressing yeast. In the
following two chapters, we are going to introduce mutations in FLU peptide and HLADR1 protein to evaluate relative binding of different DR mutants to different FLU
variants, where DR-ratio normalized by that of the wild type co-displaying strain will be
compared frequently.
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Figure 3-7 Quantitation for relative binding of MHC-II to peptides on the surface of yeast. Flow
cytometric data of A. peptide-only-displaying yeast or B. co-displaying yeast were first assessed (i) to gate
the gate the correct cell population (red line). Gated cells was then analyzed in (ii) a dot plot showing
FLU and HLA-DR1 surface display level respectively, where HA+ and HA- populations can be further
gated. An easier way to gate and generate mean values (MFI(HA+) and MFI(HA-)) for the two populations is
using (iii) a univariate histogram for HA signal only. Detection of HLA-DR1 on yeast surface is largely
due to their binding to the displayed FLU peptide, so HA+ subgroup was further plotted in (iv) the
univariate histogram for generation of MFI(DR)(+) in B and MFI(DR)(-) in A.
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Chapter 4. Identification of P1 pocket profile and prediction of
HLA-DR1-specific ligands
4.1. Introduction
Naturally evolved immune systems can function properly for detecting, preventing
and eliminating foreign pathogens without influencing most of self bio-systematic
balances, predominantly due to their capability to specifically recognize and associate
with epitopes (usually short peptides) in a target pathogen. Hence, immunotherapy and
vaccination used to rely on the original form of pathogens for initiating immune
responses now have an alternative strategy via directly applying epitope-based reagents
to stimulate specific immune responses28. Identification and prediction of pathogenic
epitope-like peptides have become more and more essential.
CD4+ T cell-mediated immune responses are restrictedly initiated by TCR-specific
epitopes associated and presented by MHC-II molecules. Thus, epitope-specificity of
CD4+ T cells is largely determined by antigenic peptide binding specificity of MHC-II
proteins. A few MHC-II alleles expressed by an individual able to present peptides
derived from many kinds of self or foreign antigens indicates the fact that one MHC-II
allele is supposed to recognize and bind a group of structurally similar peptides for
selection by T cell receptor, as a result of which CD4+ T cell-mediated immune
responses will be initiated. Investigating the promiscuous peptide sequences recognized
by MHC-II molecules will greatly help to define peptide-binding specificity of CD4+ T
cells and predict T cell specific epitopes, which can be used for vaccine design and
immunotherapeutic application.
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The earliest and most directly method of defining MHC-specific epitope peptides is
to analyze and pool-sequence peptides eluted off peptide/MHC-II complexes purified
from specialized APC cell lines22, 60, 151-156. This method provides enormous information
for defining binding motif of MHC-II molecules by aligning naturally processed
peptides, but lack of freedom on manipulation of residues at positions of interest for
determining side chain preference and detecting unknown MHC-II ligands. Thereafter,
people started to synthesize soluble peptides and assay for their capability to bind
“empty” MHC-II molecules on the surface of APCs124 or solubly produced from an
EBV-transformed homozygous B cell line18, 118-123. Theoretically, one can examine the
binding of any peptide to a given MHC-II, but the disadvantage of labor intensity on
synthesizing peptides actually makes it a really high cost and low throughput method
even with a modern peptide synthesizer. In addition, the difficulty on acquiring and
culturing mammalian cell lines could be another problem, which was partially solved by
expressing and purifying soluble “empty” MHC-II proteins in other easily manipulated
expression systems106, 108.
Investigation of various peptides with different sequences and lengths for MHC-II
binding requires high throughput experimental approaches and probably computational
prediction. For example, libraries of peptides can be constructed by using phage display,
and screened by mixing phage particles with biotinylated HLA-DR120,

90

.

This

engineering system allows generating information of hundreds of DR-specific peptide
sequences, which is suitable for identifying peptide binding motif and anchor
preferences of MHC-II proteins145 or even predicting promiscuous MHC-II ligands and
T cell specific epitopes with the help of computational programs TEPITOPE23. As one
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of the most successful experimental approaches, phage display and peptide screening
have little to no ability to tell the difference of affinity between different peptides bound
by HLA-DR1, which, complimentarily, has to be further determined by synthesizing
peptides screened out of phage library and mixing them with soluble produced HLADR1 molecules for binding assay. This greatly limits the applicability of phage display
on quantifying peptide-binding specificity of given MHC-II molecules.
Other than above experimental approaches, people have also developed several
computational methods for predicting immunogenic epitopes157. Some are algorithms or
programs such as TEPITOPE, depending on binding motifs and ligand matrices of
MHC-II determined by experimental data. Others are models based on 3D structure and
molecular dynamic simulation, for example, a predictive computational model by global
minimization of potential energy between interacting atoms was proposed for examining
interactions between the entire array of naturally occurring amino acids and the P1
pocket within the binding groove of HLA-DR1158. However, these estimations based on
simplified models are less meaningful without support of experimental data.
Yeast co-display we have developed and optimized in previous chapters on the
contrary, not only has the ability to create libraries of various peptides for screening
MHC-binders experimentally, but also contains a potential to quantitatively determining
relative binding of each peptide to MHC-II. In this chapter, we will examine these
features of the novel engineering system and show its applicability in characterization of
side chain preference of HLA-DR1 and in prediction of MHC-II ligands.
Experimental results from other work20,

90, 145

as well as predictive molecular

dynamic calculations158 confirm the observation obtained from X-ray crystallographic
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studies of HLA-DR159 that there are five pocket-like regions within the peptide-binding
site of HLA-DR1 molecule (Figure 4-1), which are critical for holding specific side
chains of anchor residues in peptide and determining peptide binding specificity.
Among these pockets, the largest and deepest one closed to N-terminus of the bound
peptide (named as P1), is demonstrated to be the dominant position for peptide-HLADR1 interaction. The hydrophobic feature of P1 pocket demands most accommodated
peptides containing an anchor residue with a large hydrophobic side chain towards their
N-terminus.

Specifically, aromatic residues such as Trp, Tyr, Phe show the most

favorability to P1 pocket, followed by other hydrophobic residues such as Met, Ile, Leu,
and Val.

The known anchor preference of P1 pocket can be used to validate the

applicability of yeast co-display for quantitatively determining peptide-binding motif.
Pockets other than P1 are consecutively accommodating the fourth, sixth, seventh and
ninth residues from P1 anchor residue of the associated peptide and designated as P4,
P6, P7, P9 respectively, which exhibit less importance than P1 pocket but noticeable
additive effects on peptide binding145.
In this chapter, site directed mutagenesis was first coupled for replacing and
saturating P1 anchor of FLU peptide with all natural amino acids and yeast co-display
was used for quantifying the relative binding of these P1 variants to HLA-DR1.
Subsequently, a small library of peptides was constructed and screened by directed
evolution approaches allowing isolation and identification of HLA-DR1-specific
peptides in a high throughput manner.
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Figure 4-1 Anchor-Pocket regions in the structure of HLA-DR1 associated with FLU peptide. A.
Top view of the peptide-binding groove formed by α1 and β1 domains of HLA-DR1, represented by green
and purple cartoon structures respectively. Residues in FLU peptide are shown as spheres, where red ones
depict anchors with side chain buried inside pockets formed by residues in the binding groove, represented
by green or purple dots. B. Side view perpendicular to the FLU peptide extending direction with side
chain of all peptide residues shown. Red ones again suggest the five main anchors and yellow ones either
point up to bind T cell receptor (especially the four in the middle) or extend out of the binding groove.
The deepest anchor (P1) near the amino-terminus of FLU peptide dominates the peptide association.

4.2. Materials and Methods
4.2.1. P1 variant-expressing plasmid construction and yeast
transformation
Site directed mutagenesis following “Quikchange II” protocol (as described in
Chapter 2 section 2.2.1) was used to introduce residue substitutions at P1 anchor of FLU
peptide for construction of ptFLUX (X denotes any single letter designation for amino
acids).

For example, ptFLUF was generated via PCR using a pair of reverse

complementary primers W53 (5’–GCTAGCCCTAAGTTCGTGAAGCAGAATAC) /
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W54 (5’–GTATTCTGCTTCACGAACTTAGGGCTAGC) carrying mutated nucleotides
(underlined) encoding Phe at P1 anchor.
Plasmid ptFLUX was transformed into either EBY100 or EBY100 with ptsDR1 by
electroporation for expressing P1-variant of FLU peptide or co-expressing P1 variant
and soluble HLA-DR1 in yeast.

4.2.2. P1 anchor preference assay via yeast co-display
Yeast were prepared using previously optimized culturing and labeling conditions
with a minor modification. 96-well plates instead of 1.5 ml Eppendorf tubes were used
sometimes for a high throughput labeling. For washing steps, cells in each well of the
plate were spun down by centrifugation of the plate at 4 °C, 3000 × g for 5 min and
washed with more than 200 µl ice cold PBS + 1% BSA at least twice. In the final step,
cells were resuspended in 150–300 µl PBS + 1% BSA for flow cytometric analysis. DRratio (using Equation 3-2) was then calculated for each co-expressing yeast strain and
normalized by wild type (FLU peptide) for quantitatively determining the relative
binding of MHC-II to different peptide variants on the surface of yeast.

4.2.3. Construction of peptide library
An oligonucleotide mixture W124 (5’–TGGTGGTGGTTCTGCTAGCNNSNNSNN
SNNSNNSNNSNNSNNSNNSNNSNNSNNSNNSNNSNNSGGAGGTGGACCCGGG
AAGCCTATAC, PAGE purified; IDT) with 15 degenerate NNS codons was designed
for generating a library of 15 amino-acid-long random peptide sequences. Another two
primers W123 (5’–CGCTCTGCAGGCTAGTGGTGGTGGTGGTTCTGGTGGTGGTG
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GTTCTGGTGGTGGTGGTTCTGCTAGC) and W125 (5’–TTGGCATGCTTAAGTAG
AATCGAGACCGAGGAGTGGATTTGGTATAGGCTTCCCGGGTCC)

allowed

amplification and extension of the degenerate oligonucleotides by PCR such that both
ends had at least 50 base pairs (bps) sequence homologous to the linear backbone vector,
separately prepared by digesting ptFLUD with NheI and XmaI. Both the PCR generated
insert and the open backbone vector were prepared at a large scale and concentrated by
Microcon YM-10 cartridges (Millipore, Billerica, MA) before the final purification by
agarose gel electrophoresis. Purified DNAs were precipitated using Pellet Paint CoPrecipitant kit (Novagen) following the manufacturer’s instructions after estimating the
concentration by absorption at 260 nm. Approximately 2.25 µg degenerated gene inserts
and 1.5 µg linear vectors were mixed in 2 µl of sterile nuclease-free water and
transformed into 100 µl freshly made electro-competent cells (EBY100 previously
transformed with ptsDR1) via two separate eletroporation reactions. Transformants
were recovered from the two cuvettes (Fisher) and transferred into 80 ml SD-SCAA
liquid medium for construction of a yeast library co-expressing randomized peptides and
HLA-DR1. Samples of the yeast culture were plated at different dilutions on SD-SCAA
agar plates for estimation of peptide library size (number of distinct transformants), after
which the culture was incubated at 30 °C to enrich real transformants. Once the library
size was determined, the grown up culture (OD600~7.0) was passaged at least twice in
50–150 ml fresh SD-SCAA medium to eliminate non-transformants.

During each

passage, number of cells transferred to fresh medium was at least 10 fold larger than the
library size to maintain the diversity. A separate electroporation reaction was performed
by transforming only 0.75 µg vector but no insert into 50 µl competent cells, which were
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plated at different dilutions as well for estimation of background caused by nonlinearized vector transformants.

4.2.4. Library screening and FACS sorting
After non-transformants being diluted away, the combinatorial library of yeast
transformants bearing both random peptide sequence-expressing plasmid and ptsDR1
were prepared under the optimal condition as described in a larger scale. Briefly, library
culture was enriched in SD-SCAA to an OD600 around 4.0 and transferred to 50 ml SGSCAA in a 250 ml baffled flask to initiate induction at an OD600 of 0.5 for 17–18h. A
scaled up double staining was performed for 1.5 × 107 cells from the yeast library using
antibody pairs H6908/Alexa Fluor 488 – goat anti-rabbit and L243/Alexa Fluor 647 –
goat anti-mouse at similar dilutions as suggested in the discussion of Chapter 3. Labeled
yeast was then sorted on a FACSVantage flow cytometer (Becton-Dickinson) with
sorting gate set to collect double-positive cells and sorting speed set around 3,000
events/s.

Sorted cells in citrate buffered SD-SCAA (pH 5.0, to minimize bacterial

contamination) were enriched and prepared in an enough scale to cover the diversity for
next round of sorting until yeast with desired phenotype (double-positive for Alexa
Fluor 488 and 647 signals) occupies a constant proportion of the total cell population.

4.2.5. Positive clone isolation and plasmid recovery
A dilution of cell samples were spread on SD-SCAA agar plates after the fourth
round of sorting for isolation of individual clones. 10 colonies were picked randomly
from the plate and inoculated for growth and induction followed by labeling for flow
cytometric analysis as described. Plasmids in clones with the desired phenotype were
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rescued using Zymoprep Yeast Plasmid Miniprep Kit (Zymo research, Orange, CA) and
transformed into electro-competent DH5α for discrimination of peptide-expressing
plasmids from ptsDR1 by E. coli colony PCR using vector-specific primer pairs 0118 /
W126 (5’–GTACGAGCTAAAAGTACAGT).

Peptide-expressing plasmids were

finally isolated from the right E.coli cells by normal miniprep and sequenced as
described in section 2.2.1. All recovered plasmids were retransformed into fresh yeast to
verify that plasmids conferred the observed binding phenotype.

4.3. Results
4.3.1. Quantitative mapping of P1 pocket profile by saturation
mutagenesis
Side chain preference for anchor residues accommodated by pockets in the peptidebinding site of MHC-II (defined as “anchor preference” or “pocket profile”) can be
determined by amino acid saturation of selected anchor position for a target MHC-IIspecific peptide. For instance, P1 anchor-pocket position was chosen to be further
characterized for its anchor preference in this section. Tyr308 at P1 anchor of FLU
peptide was replaced by all other natural amino acids (except for Cys, which could form
disulfide bond) using site-directed mutagenesis. The sequence of resulting P1 variantexpressinging plasmids ptFLUX (X refers to any single letter designation for amino
acids) were confirmed by sequencing gene of interest portion of these plasmids.


Verification for expression of P1 variants on yeast surface
Yeast expressing P1-variants only (Figure 4-2) or co-expressing P1-variants and

HLA-DR1 (Figure 4-3) co-stained for HA and V5 epitope tags indicates that HA-tag and
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V5-tag are always present on the surface of yeast simultaneously and the relative ratio of
these two tags is constantly closed to 1 for all P1 variants, which is independent of HLADR1-secretion. Double-positive cell population also represented a relatively constant
percentage of total cells for both types of stains: 60–80% for the one without expression
of HLA-DR1 and 40–60% for the one with. The HLA-DR1-expressing yeast cells used
in this experiment were inoculated from relatively old plates, so the expression level of
P1 variants was a little lower than that of strains without HLA-DR1 expressing plasmid,
confirming previous conclusion in Chapter 3 that inoculation of older cells tended to
result in lower detectable signals of displayed proteins. Other independent experiments
suggested that expression level of P1 variants has no difference for yeast expressing
HLA-DR1 or not (data not shown).
These results and observations convinced that mutation at P1 anchor of FLU peptide
and introduction of HLA-DR1-expressing plasmid both have no impact on proper
expression and display of various Aga2-P1-variant fusions by yeast.
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Figure 4-2 Fluorescent detection of HA-tag and V5-tag simultaneously on the surface of yeast
displaying P1 variant of FLU peptide. The specific residue substitution at P1 anchor position of
surface-displayed FLU peptide is indicated to the top left of each plot using the single letter designation of
amino acids. Alexa Fluor 488 and 647 were used for labeling HA-tag and V5-tag respectively. Data were
collected on BD LSR II flow cytometer.
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Figure 4-3 Fluorescent detection of HA-tag and V5-tag simultaneously on the surface of yeast coexpressing Aga2p-P1-variant and HLA-DR1. The specific residue substitution at P1 anchor position of
surface-displayed FLU peptide is indicated to the top left of each plot using the single letter designation of
amino acids. Alexa Fluor 488 and 647 were used for labeling HA-tag and V5-tag respectively. Data were
collected on BD LSR II flow cytometer.
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Relative binding of HLA-DR1 to P1 variants determined by yeast co-display
Knowing the proper expression of P1 variants, yeast cells co-expressing one P1

variant (except for Cys) and HLA-DR1 molecules were double labeled using anti-HAtag and anti-DR antibodies in order to detect variant-binding dependent DR signal. A
two-dimensional dot-pot (Figure 4-4) exhibits two separated cell populations for all
samples,

where

the

double-negative

auto-fluorescent

background

occupied

approximately 20–30% of total cell population, indicating that all P1 variants were
displayed as expected on yeast surface. However, some strain shows only HA-positive
while others contain a double-positive cell population. The double-positive population
bearing yeast strains were displaying following P1 variants: Phe, Tyr, Trp, Met, Leu, Ile,
Val respectively, which all contain hydrophobic side chain, consistent with the side
chain preference of P1 pocket found elsewhere145.
The relative peptide binding of HLA-DR1 to all these P1 variants can be further
estimated by using the quantitative analysis proposed in the discussion of Chapter 3. An
average generated from four independent flow experiments (Figure 4-5) suggests that the
peptide binding affinities follow the order Phe ≥ Tyr ≥ Trp > Met ≥ Leu ≥ Ile ≥ Val, with
other amino acids tested yielding much weaker or no binding to DR1, in agreement with
the peptide binding motif of DR1 determined using phage display and/or other
methods145. However, compared to other methods, our system is even more sensitive for
detecting the subtle differences between all those weaker or non-binders, which would
be especially useful for characterizing naturally existing weak interactions between
epitopes and epitope-specific MHCs.
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Figure 4-4 Simultaneous detection of P1-variant and HLA-DR1 on the surface of co-expressing
yeast. Yeast Co-expressing HLA-DR1 and a peptide with the indicated P1 residue were co-stained for
HA-tag and HLA-DR1 to determine the surface level of both peptide and HLA-DR1 and analyzed by flow
cytometry.
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Figure 4-5 P1 pocket profile of HLA-DR1 analyzed by yeast co-display. DR-ratio was calculated
using Equation 3-2 based on flow cytometric data (Figure 4.4) of yeast co-expressing HLA-DR1 and FLU
analogues with the indicated P1 anchor residue. Relative binding level of HLA-DR1 to different peptide
variants were generated by normalizing DR-ratio by the value for yeast co-displaying FLU with Tyr at P1
and HLA-DR1, indicated as the dashed line. Error bars represent standard error of the mean (SEM)
determined from four independent experiments.

The ability to discriminate the difference of peptide binding among P1 variants also
confirms that yeast co-display is an appropriate approach for quantitatively
characterizing peptide/MHC-II interaction. Using similar method, determining anchor
preference of any pockets of a selected MHC-II molecule will be straightforward.
Theoretically, a matrix could be generated for all possible combinations of anchor
residues allowing peptides to bind any given MHC-II protein, which will be greatly
helpful for predicting MHC-II specific ligands.

4.3.2. Determination of HLA-DR1 specific ligands by screening
peptide library
By saturation mutagenesis at a specific anchor of peptides, information such as
anchor reference of a specific pocket can be generated, however, the labor intensity will
limit the output once more anchors are involved. To generate more information about
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the whole amino acid sequence of peptides bound by MHC-II molecules or to further
determine peptide binding specificity, alternative approaches can be screening of yeast
co-expressing HLA-DR1 and library of randomized peptides for DR-positive clones.


Construction and screening of peptide library
Degenerate oligonucleotides encoding randomized peptides with 15 amino acids in

length were used for amplification of mutated gene of interest cassettes [(SGGGG)3
linker//randomized peptide//V5-tag] by PCR. These mutated gene inserts along with
enzymatic-linearized vector (from ptFLUD instead of ptFLU in order to minimize false
positive caused by wild type FLU peptide) were then co-transformed into yeast strain
bearing HLA-DR1-expressing plasmid by electroporation. The insert and vector were
ligated to form randomized peptide-displaying plasmids by homologous recombination
inside yeast cells. After several passages, yeast cells displaying millions of distinct
peptides were selectively enriched with background or parent strains all diluted out.
Size of the yeast library was estimated by plating a series of diluted samples of the
library culture on agar plates. For the first trial, the library size was designed to be 1–2 ×
106, which is amenable by FACS screening and later characterization.

Once the

procedure was approved to be applicable, the size of yeast library can be scaled up easily
to 108 or even 109 by increasing the concentration of insert and vector DNA and the
number of electroporation reactions to obtain more information.
The combinatorial peptide library was cultured and double labeled for HA-tag and
HLA-DR1 signal using the same procedure as that for wild type co-displaying strain at a
bigger scale, and sorted by fluorescent-activated cell sorting (FACS) on a FACSVantage
cell sorter for four rounds. The sorting gate was set for HA and HLA-DR1 double99

positive cell population and the sorting stringency was increased gradually (not too
much) every round by moving the gate toward higher fluorescence intensity. Significant
amount of double positive was already observed after the second around (Figure 4-6).
Ratios of sorted cells to total cells in the four rounds are 0.6%, 5.8%, 14.8%, and 7.9%
respectively. The percentage of cell population within the sorting gate increased each
round for the first three rounds and stayed constant (dropped a little due to the restrict
stringency) after the third one, suggesting no more sorting rounds needed. According to
the ratio of sorted cells in each round, we can also estimate that the real number of
distinct positive clones sorted out of peptide library with a size of 1–2 × 106 is roughly
10–102.

Figure 4-6 Fluorescent-activated cell sorting of a library of randomized peptides for HLA-DR1
specific ligands by yeast co-display. Wild type (yeast co-displaying FLU and HLA-DR1) was used as a
double positive control for each round. The original sorting gate was draw with a little relaxed stringency
to ensure the recovery of all possible genuine HLA-DR1 binders in the library.
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Characterization of HLA-DR1-specific ligands extracted from yeast libray
Samples of the sorted cells were plated on SD-SCAA agar plates to isolate individual

clones. Ten colonies, a proper sample number representing the sorted positive strains,
were inoculated and induced for further characterization of the interaction between
HLA-DR1 and the displayed peptide. The ten selected yeast clones were double labeled
for HA-tag and HLA-DR1 and applied for flow cytometric analysis (data not shown).
cMFI(DR) values corresponding to the amount of HLA-DR1 anchored by peptides on the
surface of these ten clones were calculated based on the flow data (using Equation 3-1),
and cMFI(DR) of yeast co-displaying FLU/HLA-DR1 was used for normalization (Figure
4-7). Seven of these ten clones display peptides with improved HLA-DR1-anchoring
ability than FLU peptide, and only one clone shows no detectable HLA-DR1 on its
surface.

Figure 4-7 Relative HLA-DR1 amount on the surface of selected clones from yeast library coexpressing randomized peptide sequences and HLA-DR1. By using flow data, cMFI for DR coupled
fluorophores was generated using Equation 3-1 for all selected clones (designated as S4DR1pep1.n, where
n refers to clone number) and normalized by that of yeast co-displaying FLU/HLA-DR1 (dashed line).
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Plasmid rescuing and DNA sequencing enables further analysis of these peptides.
Plasmids were recovered from the seven positive yeast clones by yeast mini-prep, which
normally contains two kinds of plasmids: one for displaying peptide (ptFLU based
plasmid), the other for secreting soluble HLA-DR1 (ptsDR1 based plasmid). To screen
the plasmid prep and select out the one for displaying peptide, the prep was transformed
into E. coli strain DH5α by electroporation and a portion of the transformants was
spread on LB agar plates with ampicillin added. Colony PCR allows discrimination of
these two kinds of plasmids because each E. coli cell can only accommodate one
plasmid. It is worthy of noticing that DH5α containing peptide-expressing plasmid
tends to grow faster than the one containing HLA-DR1-expressing plasmid, so bigger
colonies on the plate would always be the right ones.

Plasmids encoding peptide

sequences were then isolated from the right E. coli colonies by normal mini-prep and
sequenced to acquire sequences of sort-out peptides (Fig 4-8). Six of these seven clones
gave distinct sequences while one sequence showed up twice, which suggested that the
original ten clones represented a good sample of the whole sort-out strains.

Figure 4-8 Sequences of peptide fusions displayed by sorted DR-positive clones. The sequence starts
from Factor Xa cleaving site (IEGR) followed by HA-tag (pink), (SGGGG)3 linker, randomized peptide
(underlined), and V5-tag (orange).

To verify that higher HLA-DR1 amount on yeast surface is due to peptide binding
but not other positive effect introduced by cell sorting and to compare relative binding of
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HLA-DR1 to these sorted peptide and FLU peptide, plasmids encoding the six distinct
peptides were re-transformed back to yeast strain containing HLA-DR1-expressing
plasmid and tested for the phenotype by flow cytometry again. As a control, these
plasmids were also transformed into parent strain EBY100 for checking false positives
obtained by sorting yeast co-displaying library. Strains without HLA-DR1-secretion
will give a value close to zero for genuine HLA-DR1 binders because there is no HLADR1 produced and anchored by these yeast at all, while those with HLA-DR1
expression should generate higher DR-ratio due to their apparently stronger HLA-DR1binding ability than FLU as suggested from previous results (Figure 4-7). Five out of six
re-transformed clones show true phenotypes in agreement with expectation (Figure 4-9).
On the contrary, one clone shows no difference between strains with and without HLADR1 expressing plasmid, indicating that the DR-signal detected by flow cytometry is
actually a false positive probably due to the interaction between displayed peptide and
DR-labeling antibodies or fluorophores.
The whole trial experiment suggests that, a combinatorial yeast library of
randomized peptides with 1–2 × 106 distinct clones will yield 10–20 distinct peptide
sequences with the capability to bind HLA-DR1, excluding 10% false positives.
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Figure 4-9 Relative binding of HLA-DR1 to peptides sorted out of yeast library. Plasmids encoding
randomized peptides were recovered from selected positive clones and re-transformed into parent strain
with (filled bar) or without (open bar) HLA-DR1-expressing plasmid. Double labeling and flow detection
of these transformants (data not shown) were performed for generation of DR-ratio values. DR-ratio for
yeast co-displaying HLA-DR1 and FLU (dashed line) was used for normalization.

4.4. Discussion
In last two chapters, we have developed yeast co-display for characterizing and
engineering peptide binding specificity of MHC-II molecules and optimized its working
condition for quantitatively determining the interaction between peptides and MHC-II.
In this chapter, one application of this quantitative, high throughput method has been
explored for characterization of peptide binding specificity.

4.4.1. Yeast co-display can quantitatively determine pocket profiles
The ability of defining anchor preference or pocket profile by yeast co-display has
been proved by substituting Tyr at P1 anchor of FLU peptide with all natural amino
acids and calculating relative binding level of P1 variants to HLA-DR1 displayed on
corresponding yeast surface (Figure 4-5). Specifically, expression of P1 variants on the
surface of yeast has been demonstrated to be irrelevant to the reside substitution within
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FLU peptide and also independent of possible binding by HLA-DR1 as well (Figure 4-2
and 4-3). The equivalent amount of HA-tag and V5-tag detected by flow cytometry
confirms the relatively constant display level of peptide variants and suggests a standard
for quantitative analysis (refer to Figure 2-8, Figure 4-2 and 4-3). Relative binding of
HLA-DR1 to all 19 P1 variants (except for Cys) generated using flow cytometric data of
corresponding co-displaying yeast shows perfectly agreement with the P1 pocket profile
obtained by soluble HLA-DR1/peptide binding assay145. Our quantitative analysis also
shows an preferable binding order for favorable anchor residues: Phe ≥ Tyr ≥ Trp > Met
≥ Leu ≥ Ile ≥ Val, confirming that anchor preference of P1 pocket is restricted, where
aromatic side chains are most favorable to be accommodated followed by other larger
hydrophobic side chains.
Due to the relatively independent and additive nature of different pockets of HLADR proteins contributing for peptide binding145, anchor preferences of other pockets of
HLA-DR1 can be similarly defined using yeast co-display simply by saturating other
anchor residues with all natural amino acids. To extend this application, pocket profiles
of other DR alleles can be determined likewise by yeast co-display, which would largely
broaden the predictability of software such as TEPITOPE for evaluation and
identification of DR-specific ligands.

4.4.2. Potential of yeast co-display for determining binding motif of
DR-specific ligands in a high throughput manner
Other than performing anchor preference analysis as discussed above, another
feature of yeast co-display for generation of high throughput informative results has
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been tested by constructing a library of peptides in an easily manipulative scale. This
can also be used as an alternative method for determining pocket profile or generally
identifying binding motif of MHC-II proteins. From this initial attempt, we can estimate
that a combinatorial library of randomized peptides with 106 distinct yeast clones will
yield 10–100 HLA-DR1 specific peptide sequences with 10–20% experimental errors
introduced by false positives.

Theoretically, information of 103–104 DR1-specific

ligands can be generated if a yeast library (with a size up to 109 as stated in Chapter 1) is
properly designed and sorted. Comparison of these peptide sequences will help to
discover most correlation between peptide binding groove of HLA-DR1 molecules and
specific peptides.
Although only a few peptides were sorted out from the small yeast library, the
alignment of their sequence (Figure 4-8) did exhibit some common features which are
consistent with the binding motif determined elsewhere. For example, first, the Nterminal residue of all five genuine DR1 binders has a large hydrophobic side chain,
which has the potential to serve as the putative P1 anchor for their binding to HLA-DR1.
The whole sequence of each peptide is relatively hydrophobic due to the existence of
more hydrophobic residues, which agrees with the truth that most DR1 pockets favor for
accommodating hydrophobic residues59 though FLU has a Asn at P4 anchor. However,
the false positive also show all these features, indicating that more intensive
characterization is needed to clarify the exact anchors for these peptides, so that binding
motif based on these anchor preference information could be statistically determined if
more genuine binders were sorted and characterized.
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The work in this chapter has shown evidences of the quantitative and high through
put features of yeast co-display on characterizing peptide-MHC-II binding.

It is

suggested that discovery of the database for promiscuous HLA-specific ligands would
become possible within decades.
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Chapter 5. Engineering HLA-DR1 by directed evolution for
altered peptide binding specificity
5.1. Introduction
Intensive study of anchor preferences or binding motifs of certain MHC-II alleles
(e.g. results in Chapter 4) discovers their peptide-binding specificity, but the molecular
basis and evolutionary motivation eliciting these kinds of properties remains unclear.
Therefore approaches such as crystallography, NMR, and molecular modeling, etc., have
been widely applied attempting to learn the rules and limitations governing the
architecture of peptide/MHC-II complexes by isolating them from all the other
biological constraints imposed on the naturally occurring proteins55-59,

159-165

.

Introducing mutations at interested sites of these molecules and analyzing the structurefunction relationship with the help of X-ray crystal structures or stimulated models are of
great value for understanding the significance of specific residues to peptide binding and
presentation69,

119, 165-167

.

However, information in protein crystal structures is not

sufficient to guide decisions for mutagenesis studies, so a high throughput screening of
MHC-II allelic variants for altered peptide binding specificity is required to help
narrowing down criteria important for peptide association. A few attempts performed in
other work suggested a potential of using classical yeast surface display to screen
libraries of single-chain MHC-II mutants, but none of them successfully expressed wild
type proteins or suggested useful information about mutation sites in regard of peptide
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binding133, 168. Therefore, a robust high throughput in vitro screening method is of great
demand.
In addition, screening DR-variants for altered or desired peptide binding properties
could find application in immunotherapy and vaccine design. For example, applying
soluble MHC-II or its multimeric products to associate epitope peptides and present
them to CD4+ T cells169-174 has been demonstrated to be an efficient strategy in therapy
of autoimmune diseases46-48, 71, 175, 176 and in initiating antitumor immune responses38, but
the restricted set of peptides that can be presented by available solubly produced MHC-II
allelic proteins hamper widely clinical application of peptide/MHC-II complexes. The
possibility of genetically engineering peptide-binding site of some MHC-II protein so
that they can specifically bind and present designed target peptide could help expand
recently limited MHC-II presenting capability.
Alignment of known natural selected MHC-II proteins shows that most polymorphic
residues locate at or have their side chains involved in forming pockets and stabilizing
peptide binding or contacting T cell receptors15 (e.g. Figure 5-8), suggesting an
evolvability of MHC-II proteins for altered peptide specificity. Protein Engineering via
experimental evolution and selection imposes a possible path to select better fitness of
MHC-II functionalities. Yeast co-display actually represents such an high throughput
engineering and screening method.
Since P1 anchor-pocket region is known to be the determinant for peptide binding59,
90, 145

, the initial trial will be focused on this region. According to the pocket profile

generated in Chapter 4, some P1 variants are not bound by wild type HLA-DR1. These
variants are proper representatives that emerge outside the restricted group of HLA109

DR1-specific peptides.

To possibly bind these targets, specific modifications or

mutations of HLA-DR1 need to be introduced (or in nature, we would say evolved).
Therefore, a combinatorial library of HLA-DR1 mutants will be constructed using yeast
co-display system and screened for positive alones regaining P1 variant binding ability.
Based on the structural and polymorphic information of HLA-DR1 in complex with
FLU peptide, mutation sites will be intensively evaluated within the P1 pocket of the
peptide-binding site, where residues are mainly involved in peptide association.
In this chapter, we will first show a laboratory strategy for in vitro engineering HLADR1 protein for altered peptide association properties by construction and screening two
generations of co-displaying yeast libraries, and then discuss the possible evolutionary
significance of polymorphic peptide binding regions where essential substitutions could
take place in the lab or in the nature.

5.2. Materials and Methods
5.2.1. Construction of HLA-DR1 mutants library in yeast
The GAL1-10 promoter flanked by fragments of DRA*0101 and DRB1*010101
genes encoding the α1 and β1 domains, respectively, was amplified from plasmid
ptsDR1 via 20 cycles of PCR reactions using two synthetic oligonucleotides: W90 (5’–
CGCCAGACCGTCTCCTTCTTTGCCATATCCACATGSNNSNNCTCATCACCATC
AAAGTCSNNCATAAACTCGCCTGATTGGT, PAGE purified; IDT) carrying three
NNS degenerate codons enabling saturated mutations at positions α 24, α 31, and α 32
on α1 domain, and W93 (5TGGGTCTTTGAAGGATACACAGTCACCTTAGGCTCA
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ACTCGCCGCTGCACSNNSNNGCTCTCSNNAACCCCGTAGTTGTGTCTGC,
PAGE purified; IDT) carrying three NNS codons at positions β 86, β 89, and β 90. The
mutagenized PCR products were agarose gel purified and extended twice each by PCR
with another two pairs of primers. Primers for the first extension were W89 (5’–
TTTGTCCACAGCTATGTTGGCCAATGCACCTTGAGCCTCAAAGCTGGCAAAT
CGTCCAAATTCTTCAAGCCGCCAGACCGTCTCCTTCTT, PAGE purified; IDT)
and an ultramer W92 (5’–TCCAATCTCCATTCTGGATCAGGCCTGTGGACACCAC
CCCAGCCTTCTCTTCCTGGCCGTTCCGGAACCACCTGACTTCAATGCTGCCTG
GATAGAAACCACTCACAGAGCAGACCAGGAGGTTGTGGTGCTGCAGGGGCT
GGGTCTTTGAAGGATACAC, PAGE purified; IDT). The second pair, W88 (5’–
GTTGGAGCGCTTTGTCATGATTTCCAGGTTGGCTTTGTCCACAGCTATGTTGG)
and W91 (5’–CTGTTTCCAGCATCACCAGGGTCTGGAAGGTCCAATCTCCATTC
TGGATC) added 50 bps of sequence homologous to the linearized yeast shuttle vector
prepared by MscI/StuI enzymatic digest of ptsDR1. Both the PCR generated insert and
the open backbone vector were prepared at a large scale to ensure enough DNA for
highly efficient homologous recombination and concentrated by Microcon YM-10
cartridges (Millipore) before the final purification by agarose gel electrophoresis.
Purified DNAs were precipitated using Pellet Paint Co-Precipitant kit (Novagen)
following the manufacturer’s instructions after estimating the concentration by
absorption at 260 nm. Approximately 24–30 µg insert and 6 µg vector were mixed in 6
µl sterile nuclease-free water and transformed into EBY100 bearing a plasmid directing
surface display of P1-mutated FLU via six separate electroporation reactions.
Transformants were pooled into 150 ml SD-SCAA liquid medium and aliquots were
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plated at different dilutions on SD-SCAA agar plates for determination of library size.
Yeast cultures were enriched at 30 °C and passaged twice by transferring at least 109
cells into 250 ml fresh SD-SCAA medium to dilute background cells and maintain the
HLA-DR1 mutant library diversity.

A separate reaction of electroporation by

transforming only 1µg vector but no insert into competent cells served as the
background control.

5.2.2. FACS Sorting for Library of HLA-DR1 mutants
Culturing, labeling and screening of HLA-DR1 mutants’ library were similar to
methods described in Chapter 4 section 4.2.4, except:

1) The primary/secondary

labeling reagent pair: Biotinylated L243 (BD Biosciences) or Biotinylated LB3.1 / Alexa
Fluor 647 – streptavidin (Invitrogen), instead of L243 / Alexa Fluor 647 – goat antimouse antibody, were used for labeling HLA-DR1 when performing cell sorting for Valand P1-Ala-binding HLA-DR1 mutant libraries in some rounds, which provided no
impact on phenotype detection and positive recovery at all; 2) In the first round,
approximately 108 cells were examined using enrich mode with an event rate of 5,000–
10,000 s-1 to recover as many positive cells as possible.

5.2.3. DNA shuffling and backcrossed library screening
Yeast cells recovered after the fourth round of sorting were enriched in SD-SCAA
and applied directly for yeast miniprep using Zymoprep Yeast Plasmid Miniprep Kit.
Plasmids isolated from the culture were used as template for PCR amplification of
mutagenic gene inserts encoding cassettes ((DRα(1–61)//GAL1-10//DR1β(1–146)) by
primers W88 and W91. At the same time wild type gene inserts were cloned from
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ptsDR1 by similar PCR reactions using primer pairs: W88/W91, W120 (5’–
GGAGGTACATTGGTGATCG) / W121 (5’–CAGGTGTAAACCTCTCCAC) or just
0117 (5’–GTTACATCTACACTGTTGTTAT), products of which had a little different
lengths but all cover the whole mutated cassette sequence. After concentration and gel
purification, 0.5 mg mutant and 2.5 mg wild type DNA were mixed in 100 µl of Buffer
A (1 mM MgCl2, 50 mM Tris-HCl pH7.4) in an Eppendorf tube and degraded by
quickly adding 1.5 U DNase I (10 U/µl, Thermo Scientific, Pierce, Rockford, IL) and
gently shaking the tube for 14–18 min at room temperature, after which the DNase I
was inactivated immediately by incubating the tube at 90 °C for at least 10 min. The
degraded DNA fragments were mostly shorter than 250 bps as confirmed by 2%
Agarose (Invitrogen) gel electrophoresis.

0.05 U/µl PfuUltra high fidelity DNA

polymerase (2.5 U/µl, Stratagene) in a 25 µl primerless PCR reaction [programmed as
(96 °C, 3 min) for 1 cycle, (94 °C, 1 min, 55 °C, 1 min, 72 °C, 1 min 40 s + 5 s/ cycle
gradient) for 40 cycles, (72 °C, 10 min) for 1 cycle, 4 °C to infinity] allowed 5 ng/µl gel
purified DNA fragments to reassemble into new gene cassettes with the original length
but different combination of mutations. Another gene piece encoding cassette GAL1-10
amplified from the wild type ptsDR1 was also added in the primerless PCR mixture to
decrease the mutation carry-over within the promoter region. 4 µl raw primerless PCR
products were diluted 50 fold in a modified PCR mixture containing primer pairs
W88/W91 or W120/W121, 1× ThermolPol Reaction buffer (NEB) and two kinds of
polymerases: 0.05 U/µl PfuUltra and 0.05–0.1 U/µl Taq (5 U/µl, NEB) for amplification
of the right shuffled gene cassettes by 20 cycles of reactions. The shuffled DNA was
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confirmed by 1% gel electrophoresis and purified using the Wizard Cleanup Kit
(Promega).
4–5 µg shuffled insert DNA’s along with 0.8–0.9 µg vector (MscI/StuI double cut
ptsDR1, same as the one used in section 5.2.1) were transformed into 100 µl freshly
made competent cells (EBY100 containing a P1-variant-expressing plasmid) via 2
electroporation reactions. Transformants in both cuvettes were transferred into 50 ml
SD-SCAA to construct the backcrossed library of HLA-DR1 mutants. Culturing and
labeling of this library was the same as described in Chapter 4 section 4.2.3 and 4.2.4.
Backcrossed libraries were only sorted for one round at normal mode on FACSVantage.

5.2.4. Positive clone isolation and characterization
The isolation of positive clones and recovery of corresponding plasmids were carried
out in a similar manner as described in Chapter 4 section 4.2.5, with clone numbers
varied. E. coli transformation was used again as mentioned previously but followed by
Colony PCR with [DRα(1–61)//GAL1-10//DR1β(1–146)] expression cassette-specific
primers

W7

(5’–AAGGATACACAGTCACCTTAGGCTCA)

and

W10

(5’–

AACTCGGCCTGGATGATCACAT) for discriminating HLA-DR1 mutant-expressing
plasmids from P1-variant-expressing plasmids in the yeast miniprep mixture. Recovered
plasmids were retransformed into EBY100 by electroporation for false positive
evaluation and resulting transformants were subsequently transformed with ptFLUX for
P1 anchor preference analysis as described in Chapter 4 section 4.2.2.
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5.3. Results
Different from the peptide library constructed in Chapter 4, HLA-DR1 mutant
library results in non-directly tethered protein variants outside yeast cells, where possible
self-neighbor interchange raises certain issues. It has already been demonstrated that
HLA-DR1 molecules secreted and anchored by FLU peptide on the surface of yeast are
rather self-specific than intercellular switchable, indicating that in the library each yeast
will mainly present HLA-DR1 mutants secreted by its own via P1-variant-anchorage.
This genotype-phenotype linkage will greatly favor for yeast library screening and DR
positive clone recovery by flow cytometry or FACS sorting.

5.3.1. Construction and screening of HLA-DR1 mutant library
In order to edit HLA-DR1 molecules for altered peptide-binding specificity,
nonspecific peptides will be set up as targets and a combinatorial library of HLA-DR1
mutants need to be screened against these target peptides for sorting of target-binding
mutants. From results described in Chapter 4, yeast co-display system has already
discovered some P1 variants of FLU peptide showing lower or no binding ability to wild
type HLA-DR1 proteins (Figure 4-5), which can be used as proper target peptides for
screening HLA-DR1 mutant-containing yeast library. Herein, initial trial was taken
placed by selecting three representative peptides: 1) P1-Val (PKVVKQNTLKLAT) –
weak

binder

with

hydrophobic

side

chain

at

P1

anchor;

2)

P1-Ala

(PKAVKQNTLKLAT) – non-binder with hydrophobic side chain at P1; and 3) P1-Glu
(PKEVKQNTLKLAT) – non-binder with hydrophilic side chain at P1. It is obvious
that screening difficulty increases one after another for these three variants, because P1
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pocket of wild type HLA-DR1 protein favors for larger hydrophobic side chain as shown
in Figure 4-5.
Different purposes of protein engineering by directed evolution require different
criteria for designing and screening library of protein mutants. In this trial, we are
testing the possibility of altering minimum residues of HLA-DR1 molecules so that only
the peptide binding specificity will be modified but not other properties or function.
Accordingly, criteria for construction HLA-DR1 mutants-secreting library include: 1)
mutations should be focused within regions related to peptide-binding site, e.g., pockets,
which specially serve as functional group for peptide recognition and association; 2)
mutations should not greatly affect structural stability of HLA-DR1 protein, e.g.,
disulfide bonds, non-covalent interactions; 3) mutations should not inhibit peptide
presenting ability of HLA-DR1 mutants to T cell receptor, so that the HLA-DR1 mutant
remains a potential for immunotherapeutic application; 4) mutations should not
influence other functional regions of HLA-DR1 molecules, e.g., CD4 reactive region,
DM binding region. Based on the crystal structure of HLA-DR1 in complex with FLU
peptide59, residues chosen to be saturated to all natural amino acids are Phe α24, Ile α31,
Phe α32, Gly β86, Phe β89, Thr β90, all located around P1 pocket of the binding site
containing at least one atom within 5 Å of at least on atom of P1 anchor residue
(Tyr308) of FLU peptide (Figure 5-1). All these residues were closed to the floor of
peptide binding groove, where is far from the TCR accessible peptide-presenting surface
as well as HLA-DR1 heterodimer-associating interface.
Three pairs of nested primers were used to amplify mutagenic PCR product encoding
expression cassette [DRα(1–61)//GAL1-10//DR1β(1–146)] bearing the six designed
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mutation sites via 60 reaction cycles totally.

More PCR cycles actually provide

undersigned random mutations within the insert gene cassette, which might help
stabilize folding of HLA-DR1 mutants interfered by the six modified residues and
provide more structure-function linkage related to peptide binding.

Figure 5-1 P1 pocket in peptide binding site of HLA-DR1. A. Top view of P1 pocket formed by HLADR1 residues surrounding P1 anchor (red sphere) of FLU peptide. B. side view of how P1 pocket holds
the side chain of P1 anchor residue, Tyr308. C. Residues in P1 pocket have at least one atom within 5 Å
of at least on atom of Tyr.

Mutated gene cassette mixture and cut vector were concentrated and co-transformed
into yeast strain expressing P1-Val, P1-Ala, or P1-Glu peptides to construct three HLADR1 mutant-secreting yeast libraries for sorting P1-variant-binding HLA-DR1 mutants:
P1-Val-bing mutants, P1-Ala-bing mutants, or P1-Glu-bing mutants.
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Homologous

recombination of insert and vector DNA took place inside yeast cell to form a HLA-DR1
mutant-expressing plasmid, millions of which were then selectively enriched after
several passages in minimal growth medium. Plating of diluted samples from each
library suggested an estimation of their sizes: 3 × 107 (P1-Val), 6 × 107 (P1-Ala), and 2 ×
107 (P1-Glu). Size of background determined by transformants with vector only is three
orders of magnitude less. Consequently, each library constructed includes almost all
combinations of 20 natural amino acids in the six selected positions, which is supposed
to be 206.
The three combinatorial yeast libraries were cultured and double labeled for HA and
DR signal using the same procedure as that for wild type co-displaying strain at a bigger
scale, and sorted by FACS on a FACSVantage cell sorter for four rounds. Sorting gates
were all set for HA and DR double positive population with variations in each round.
Enrichment mode and relaxed stringency were set up for the first round to collect as
many positive clones as possible. Normal mode and a little more stringent sorting were
used for the rest rounds. Ratios of sorted cells to total cells in each round (Table 5-1)
suggest that roughly 103, 102, and 10–102 distinct positive clones were sorted out of P1Val, P1-Ala, and P1-Glu -displaying yeast libraries, respectively. It is also worthwhile
noticing that the sorting of P1-Val-displaying library is relatively easier than the other
two as suggested by the percentage in the third round of sorting, wherein significant
numbers of positive clones had already been screened out for P1-Val-displaying.
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Table 5-1 Ratios of sorted cells to total cells after each round of sorting.

Sorting rounds

Libraries
P1-Val-displaying

P1-Ala-displaying

P1-Glu-displaying

1

2.2%

5.1%

0.5%

2

0.6%

0.5%

0.3%

3

9.1%

0.3%

1.1%

4

21.6%

22.2%

ND

ND, not determined.

5.3.2. Characterization of positive clones containing target HLA-DR1
mutants
After the fourth round of sorting, samples of sorted clones from each of the three
libraries were plated on agar plates. Individual colonies were randomly selected and
inoculated for induction and further characterization. Number of colonies picked for P1Val, P1-Ala, and P1-Glu -displaying libraries are ten, ten, and eighteen respectively.
Flow analysis of these yeast clones (data not shown) indicated most of them carrying the
phenotype as sorted, except for some from P1-Glu-displaying library. Additionally, the
detectable DR-positive signal indicates that mutations within these sorted HLA-DR1
mutants have no impact on the binding and coupling of DR-specific mAb L243.
cMFI(DR) representing the amount of HLA-DR1 mutants anchored by P1 variants on the
surface of these clones were calculated (using Equation 3-1), and normalized by wild
type (Figure 5-2). Most HLA-DR1 mutants show improved corresponding P1-variantbinding ability than wild type FLU peptide, and it is easier to find out mutants with
higher binding affinity to weak binder (P1-Val, Figure 5-2A) than non-binder (P1-Ala or
P1-Glu, Figure 5-2B or C). In addition, not all clones derived from the P1-Glu-diplaying
119

library exhibit detectable HLA-DR1 molecules (e.g., clone S4E1.10 in Figure 5-2C) or
display HLA-DR1 with improved binding affinity (e.g. clone S4E1.1, S4E1.16 and
S4E1.17 in Figure 5-2C), again indicating that the hydrophilic side chain is not as
favorable as hydrophobic ones in P1 pocket even with designed residue substitutions.
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Figure 5-2 Relative HLA-DR1 amount on the surface of selected positive clones co-displaying HLADR1 mutants and target P1 variant: A. P1-Val, B. P1-Ala, or C. P1-Glu. The wild-type-normalized
cMFI value representing relative HLA-DR1 amount was generated using flow data for selected clones
(designated as S4X1.n, where X refers to A. V, B. A, or C. E, and n refers to clone numbers) from
corresponding HLA-DR1 mutant libraries. The dashed line indicated cMFI value of yeast co-displaying
wild type HLA-DR1 and FLU peptide.
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In order to find out more sequence-structure-function related information, plasmids
were rescued from selected positive yeast clones by yeast mini-prep. As mentioned in
Chapter 4, the prep is a mixture of two kinds of plasmids, which can be distinguished by
screening of E. coli transformants on LB agar plates. This time, the plate was incubated
at 37 °C a little longer allowing the smaller colonies to grow big enough for colony PCR
and inoculation. E. coli mini-prep of grown-up culture was performed to isolate the ones
containing HLA-DR1 mutant-expressing plasmid, which can be used as template for
DNA sequencing. However, the yield of these plasmids was sometimes not high enough
for sequencing; alternatively, gene cassettes encoding mutated regions of HLA-DR1
mutants were amplified from yeast mini-prep or E. coli mini-prep by PCR, and then
cleaned up by electrophoresis gel extraction and purification before DNA sequencing.
Sequences of selected HLA-DR1 mutant clones obtained by DNA sequencing (Table
5-2) suggest that other than the six selected mutation sites, random mutations do exist
within the PCR amplified gene cassette. The observation that all P1-Val and P1-Alabinding mutants are different from each other confirms that the number of distinct clones
sorted out of these two libraries is larger than the sample number. In contrast, the same
clone was sequenced multiple times for P1-Glu-binding mutants, indicating a relatively
small number of distinct clones sorted out of this library. This is consistent with the
estimation made by sorted cell percentage as described previously, confirming the
difficulty for sorting P1-Glu-binding mutants. Another interesting result is that most P1Val-binding and P1-Ala-binding mutants bearing an Aα61S mutation located at the
restriction enzyme recognition site used for linearizing vector ptsDR1. This mutation
may be result from homologous recombination, but provide no positive effect on peptide
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binding (actually, this assumption was confirmed by sequence analysis after
backcrossing shown in table 5-3). Except for this mutation, consensus mutations or
single mutation bearing mutants are seldom observed by alignment of these sequences,
but besides the six heavily mutated sites, α54, β11, β30, β37, β57, β81 show certain
importance on peptide binding. Backcrossing of these multiple-mutation sequences with
wild type HLA-DR1 can be used to pinpoint the most essential mutations that contribute
to the altered peptide binding capability and to derive more conclusive results.
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Table 5-2

71

81

86

89

90

91

100
92

105

108

109

112

113

114

β chain
57

a chian
51

54

60

61

11

17

18

25

26

30

32

37

52

53

55

H
S

V

V
V

Y L
A L
C L
L L

S L

T L

L S
I

I

M L
L

L

S

L L
S
S

H
Y

L

L

M

M
M

S
S
S
S
S

S
S

F

H

I

R

F
L

L
S

Q F

Y
Y

N

F

T

F

K

M
Q
Y

Y
Y
Y

M

T A L
I R M
L V F
L
S
F N P
M L A
L M S E
Q L G I
F L A
F N L
L P H
F R H
F S K
F S L
Y M W
F T L
F H P
F A M
F L L
L L L
L Y P
L H H
L I Y
I

I M
I Y
I Y

I L L
L L A
L
L
L

K

R S N

X

Q

X

K

V

32
G

31

F L R F F L A L F F R L C Y S E L R D R H G F T V Q T K P L H N L

50

I

45

P F F

24

Mutations in selected HLA-DR1 mutants.

s4V1.1
s4V1.2
s4V1.3
s4V1.4
s4V1.5
s4V1.6
s4V1.7
s4V1.8
s4V1.9
s4V1.10
s4A1.1
s4A1.2
s4A1.3
s4A1.4
s4A1.5
s4A1.6
s4A1.7
s4A1.8
s4A1.9
s4A1.10
s4E1.1
s4E1.2
s4E1.3
s4E1.6
s4E1.8
s4E1.11
s4E1.12
s4E1.15
s4E1.18

22

16

Shaded: designed mutation sites. X: deletion.
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WT HLA-DR1

P1-Val-binding
P1-Ala-binding
P1-Glu-binding

Three representative HLA-DR1 mutants, S4V1.5, S4A1.9 and S4E1.3, with the
highest relevant P1-variant-binding ability were chosen from these three characterized
mutant pools for P1 anchor preference analysis. EBY100 was first transformed with the
plasmid secreting one of these three HLA-DR1 mutants, and then transformed with one
of 19 P1-variant-displaying plasmids ptFLUX to generate corresponding co-expressing
strain. All resulting strains were cultured and double labeled with H6908 and L243 for
flow analysis as described before. Relative binding of each mutant to any P1 variant
(Figure 5-3) determined using Equation 3-2 followed by normalization shows
significantly higher overall peptide binding ability of all HLA-DR1 mutants than wild
type, which is supposed to be the result of sorting for better binding signal. Other than
that, P1 anchor preferences of these three HLA-DR1 mutants (Figure 5-3B~D) are all
different from that of wild type (Figure 5-3A or Figure 4-5), indicating a possibility of
engineering peptide binding specificity of MHC-II protein using yeast co-display by
directed evolution.

Among these mutants, S4V1.5 and S4A1.9 still prefer to

accommodate hydrophobic side chains in their P1 pockets; however, residues with
smaller hydrophobic side chains tend to be more favorable because sorting was set for
against peptide variants with smaller hydrophobic side chain (Val or Ala) at P1 anchor.
S4E1.3 on the other hand, shows a hyper bidning promiscuity, suggesting the P1 pocket
is no longer dominant for determining peptide-binding specificity.
The ability of screening co-expressing yeast library by FACS for acquiring HLADR1 mutants with improved peptide binding ability and altered specificity validates the
fact that the interaction between peptide and MHC-II molecules does occur inside yeast
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cells and the switching of MHC-II proteins among different yeast cell surface is a rare
event or flow non-detectable in our experimental circumstance as evaluated in Chapter 2.

Figure 5-3 P1 anchor preference for HLA-DR1 and its variant-binding mutants. DR-ratio was
calculated using Equation 3-2 based on flow cytometric data of yeast co-expressing HLA-DR1 mutant and
one of the indicated P1-variants. Relative binding level of A. wild type HLA-DR1, or B. P1-Val-binding
mutant S4V1.5, or C. P1-Ala-binding mutant S4A1.9 D. P1-Glu-binding mutant S4E1.3 to indicated P1variant were generated by normalizing DR-ratio by the value for yeast co-displaying FLU with Tyr at P1
and HLA-DR1 (dashed line). Error bars represent standard error of the mean (SEM) determined from four
independent experiments.
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5.3.3. Backcrossing and new library construction and screening
Although P1-variant-binding mutants with changed peptide binding properties were
obtained from previously constructed yeast libraries, mutations in these mutants are too
diverse, which brings too much difficulty to structure-function analysis.

Shuffling

mutagenized gene cassettes with extra amount of wild type provides an effective
approach to separate these mutations and enables construction and screening of yeast
library containing single mutation bearing mutants177, 178.
Three plasmid mixtures were recovered from three sorted mutant pools, respectively,
by yeast mini-prep and used as templates for amplifying mutated gene portions [DRα(1–
61)//GAL1-10//DR1β(1–146)], which carrying all mutations to be shuffled. After gel
purification, each of the three PCR products was mixed with five folds more
concentrated wild type DNA and was chopped up into small fragments by DNase I.
Primerless PCR drives these small fragments to reassemble into longer pieces DNA,
which were then selectively amplified using specific primers to recover shuffled gene
cassettes. Enough shuffled insert and cut vector (same as the one used to construct
previous three HLA-DR1 mutant libraries) were co-transformed into corresponding P1variant-displaying yeast strain, respectively, to construct backcrossed HLA-DR1 library
by homologous recombination. Combinations of all mutations after shuffling is not too
many due to the small amount of essential mutations found in previous libraries, so the
size of new libraries was designed to be a little smaller: 8 × 106 (P1-Val), 7 × 106 (P1Ala), and 1.5 × 107 (P1-Glu). The three backcrossed libraries were sorted against the
three P1-variants individually by FACS. Different from previous ones, only one round
of sorting yield significant amount of double positive clones for all three libraries.
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5.3.4. Characterization of positive clones of backcrossed libraries
Spreading sorted clones on agar plates enabled isolation and characterization of
individual colonies. More than twenty clones were randomly picked from each of these
three libraries for flow cytometric characterization. Similar results were observed by
comparing the normalized cMFI(DR) histograms generated before (Figure 5-2) and after
DNA shuffling (Figure 5-4), suggesting a correlation between these two sets of mutants.
Because of fewer rounds of sorting were carried out, more negative clones without
phenotype of interest (normalized cMFI(DR)≈0) were included.
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Figure 5-4 Relative HLA-DR1 amount on the surface of clones sorted out of wild type-backcrossed
libraries for co-displaying of HLA-DR1 mutants and target P1 variant: A. P1-Val, B. P1-Ala, or C.
P1-Glu. The wild-type-normalized cMFI value representing relative HLA-DR1 amount was generated
using flow data for selected clones (designated as S1X2.n, where X refers to A. V, B. A or C. E, and n
refers to clone numbers) from corresponding backcrossed libraries. The dashed line indicated cMFI value
of yeast co-displaying wild type HLA-DR1 and FLU peptide.
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Similarly, to obtain sequence information, plasmids were rescued from selected
positive yeast clones by yeast mini-prep, and either used for E. coli transformation and
plasmid isolation or used as template for amplifying PCR product for DNA sequencing.
Comparing with previous one (Table 5-2), alignment of sequences of more HLA-DR1
mutants from backcrossed libraries (Table 5-3) discovers less mutations or single
mutation bearing clones with improved P1-variant-binding ability, which helps to
determine more essential mutations, such as α22, β11, β26, β30, β37, β57, β86. Of
particular interest is the phenomenon that much less mutations in α chain, including the
three designed mutation sites, were carried over to backcrossed mutants than β chain
from previous mutant pools, indicating neutral or negative contributions of most
mutations in α chain, which agrees with the fact that α chain is more conserved under
natural evolution whereas most polymorphic regions are located at β chain. Stop codon
observed at the end of β1 domain of some mutant (mutant S1V2.10) implies that β2
domain may be unnecessary for peptide binding. Same sequences can be found in all
three mutant pools, especially for those bound by P1-Ala and P1-Glu, suggesting that
proper sample number was chosen to acquire enough information from each pool.
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Table 5-3 Mutations in HLA-DR1 mutants after being backcrossed with wild type.
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Shaded: designed mutation sites. *: stop codon. X: deletion.
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Like previous characterization, seven mutants: S1V2.1, S1V2.3, S1A2.1, S1A2.10,
S1E2.6, S1E2.16 and S1E1.18, most of which show multiple times in table 5-3, were
chosen for P1 anchor preference analysis (Figure 5-5). Only S1V2.3 and S1A2.10
exhibit different P1 anchor preferences from wild type HLA-DR1, and the patterns of
their relative binding histograms look very similar, indicating some correlation between
these two clones. S1V2.3 is a single mutation-bearing mutant, the mutation Gα86F,
which is also include in S1A2.10, is likely to be responsible for the changed P1 anchor
preference. Therefore, other mutations within S1A2.10 might just provide some effect
on stabilizing protein folding or just neutral mutations. In contrast with the two with
altered peptide binding specificity, the other five selected mutants just show an
increasing overall binding ability to all variants without changing the preference, which
suggest that DNA shuffling and backcrossing against wild type may get rid of some
positive contributions from rare mutations which cell sorting can not tell and recover.
These results also tell us that fewer mutations outside a specific pocket region have the
potential to alter anchor preference of that pocket.
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Figure 5-5 P1 anchor preference for selected HLA-DR1 mutants from backcrossed libraries: A. P1Val-binding B. P1-Ala-binding and C. P1-Glu-binding. Relative binding level of different mutants to
FLU analogues with indicated residues at P1 anchor were determined as decribed previously. The dashed
line again represents the value for yeast co-displaying wild type FLU peptide and HLA-DR1.

5.3.5. Evaluation for false positive sorted from yeast library
S4V1.5, S4A1.9 and S1V2.3, S1A2.10 obtained before and after DNA shuffling,
respectively, show obvious altered P1 anchor preferences, which demonstrate the
applicability of using yeast co-display to engineer peptide binding specificity of HLADR1. However, the observation that S4E1.3 has no binding preference to all P1 variants
and five out of seven mutants sorted out of backcrossed libraries exhibit a similar
increase for binding to each P1 variant, suggesting that the phenotype might due to false
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positives, for instance, possible binding of mutagenized HLA-DR1 molecules to yeast
surface proteins. To evaluate this possibility, parent strain EBY100 was transformed
with plasmids encoding these mutants and tested for HA and DR double positive signals
without including any peptide-expressing plasmid. Because S4V1.5, S4A1.9, S1V2.3
and S1A2.10 have already shown no binding to several P1 variants (Figure 5-3 B and C,
Figure 5-5A and B), there is no need to test these true positives; on the other hand, they
can be used as controls (Figure 5-6A and B) to evaluate other ones. Five of the other six
mutants gave similar flow cytrometric results (Figure 5-6C~H), whereas only S1E2.18expressing plasmid transformed yeast shows a small DR-positive population.

It is

interesting to notice that S1E2.16 and S1E2.18 share most mutations but Lβ26F only
found in S1E2.18 (Table 5-3), which could be the one bringing in the false positive
phenotype. However, S4V1.5 containing the same mutation Lβ26F still represents a true
positive clone, suggesting that the false positive observed for S1E2.18 is possibly due to
an overall false positive effect added up by non-obvious ones contributed by single
mutations. Nonetheless, the percentage of false positive is only 10% or less, which will
not significantly affect the accuracy of applying yeast co-display for manipulation of
HLA-DR1 molecules.
Along with the checking for false positives performed in chapter 4 (Figure 4-9), this
control experiment again points out that directed evolution using the high throughput
yeast co-display system normally provides conclusive information with 90% accuracy,
which is statistically high enough for quantitatively evaluating characteristics of
interaction between MHC-II proteins and various peptides.
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Figure 5-6 Flow cytometric analysis for examination of false positive. EBY100 transformed with one
of these HLA-DR1 mutant-expressing plasmids was cultured under corresponding nutrient dropout
condition and double labeled to detect both HA and DR signal. Data was collected on Accuri C6 flow
cytometer.
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5.4. Discussion
5.4.1. Appropriate strategy for engineering peptide binding
specificity of MHC-II
Following previous chapter, we have examined another more profound application of
yeast co-display on engineering peptide binding specificity of HLA-DR1, product of a
well-characterized MHC-II allele, in order to explore the possibility of tailoring the
antigen presenting spectrum for MHC-II molecules evolved under laboratorial situation.
Directed evolution strategy such as constructing and screening a combinatorial yeast
library of tens of millions of HLA-DR1 mutants has been applied throughout this chapter
for selecting novel binding phenotypes in a high throughput manner.
Although HLA-DR1 mutants are secreted solubly and bound by yeast-surfacetethered P1 variants non-covalently, no intercellular switching of these soluble
molecules was observed, which enables recovery of the mutagenic genotype
corresponding to screened phenotype easily. This genotype-phenotype linkage has been
further confirmed for clones sorted out of both the original libraries and the backcrossed
libraries by recovering the HLA-DR1-expressing plasmid from positive clones and
retransforming them into corresponding parent strains (for example, after transforming
the plasmid encoding S4V1.5 back into parent strain displaying P1-Val peptide, the
same phenotype (Figure 5-3B) was observed just as the positive clone sorted out of P1Val-displaying library (Figure 5-2A), so it is reliable to use FACS for screening positive
phenotype in co-displaying yeast libraries and obtaining corresponding genotype
information.
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The laboratorial evolution of HLA-DR1 discussed in this chapter includes two
generations of yeast libraries. The original yeast libraries were constructed for screening
HLA-DR1 mutants bearing mutation sites concentrated near P1 pockets against a DR
non-specific P1 variant. Sequence analysis of selected P1-variant-associated HLA-DR1
mutants indicates that although a little more leucine’s (which should be more because it
can be encoded by six codons) appearing among mutated residues, the whole
mutagenesis strategy did not cause too much bias and if combining different sites,
mutations almost include all possible amino acids (Table 5-2). Indeed, this generation
has already yield significant amount of mutants capable of associating with FLU variants
used to escape the recognition of HLA-DR1 molecules and these mutants have started to
exhibit altered peptide specificity (Figure 5-3), but most mutants contain multiple
substitutions. If time permitted, one could test these substitutions one by one to define
their effects on defining peptide binding motifs and pocket profiles by making single
mutation bearing mutants. To accelerate the process for selection and determination of
useful mutations, backcrossed libraries aiming for pinpointing the most essential
substitutions within the mutagenized gene cassette were constructed and screened for
similar phenotypes against corresponding P1-variants.

Alignment of genotypic

sequences suggests an obvious correlation between the two generations of libraries
(Table 5-2 and 5-3), where the backcrossed ones significantly shrink the range of
mutation sites to regions possibly dominating the altered phenotypes. Characterization
of HLA-DR1 mutants extracted from selected clones also implies the additive
contribution of each single-substitution bearing mutant (Figure 5-5) to the phenotype of
a multi-substitution bearing mutant (Figure 5-3). This overview clearly shows that the
137

searching strategy herein is appropriate for engineering HLA-DR1 molecules and
discovering important sites within peptide binding groove, which will imply more
structure-function relationship with the help of crystallographic analysis.

5.4.2. Common features of essential mutations in HLA-DR1
By simply comparing the sequence alignments in Table 5-2 and Table 5-3, we found
that mutations in β chain are more diverse while those in α chain are more conserved,
and the number of mutations in α chain dramatically declines after backcrossing such
that even the three designed mutation positions have no more mutations left, especially
for P1-Val and P1-Ala-binding mutants (the case of P1-Glu-binding mutants is a little
special and we will further discuss this in detail later). The more conserved feature of
DRα on defining peptide anchor preference nicely agrees with the discovery in nature
that there is only one single extracellular domain of HLA-DRA protein known till today
comparing with more than six hundred HLA-DRB proteins (Table 1-1). This again
indicates the outstanding capability of yeast co-display to reflect and mimic the natural
evolution of MHC-II proteins.
In contrast to the total decreased number, mutations are significantly enriched after
backcrossing in a few sites: α22, α60, β11, β26, β30, β37, β57, β86, most of which have
been observed in mutants binding to different P1 variants.

Other than these,

α54 and β81 also imply certain importance as both of them show up for both P1-Val and
P1-Ala-binding mutants in original libraries (Table 5-2). Together with α31, α32, β89,
β90, which are designed to be intensive mutated, almost all these essential mutation
positions suggested by yeast co-display are either located in P1 pocket or on the floor of
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peptide binding groove (Figure 5-7A, α31, α32, β81, β89, β90, responsible to form P1
pocket, are not shown in this figure). Space spanning of these residues in wild type
HLA-DR1 suggest a direct contact or correlation between side chains of peptide anchors
and these residues, except for α60, which is further away from the peptide-binding site
(Figure 5-7B). Mutation Lα60M observed in S1V2.12, S1E2.9 and S1E2.12 is actually
coexisting with other essential mutations at sites mentioned earlier, so this site might not
critical on its own or just a neutral mutation carried over from original libraries, so we
will not consider it when further discussing the structure-function correlation.
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Figure 5-7 Essential mutation sites implied by directed evolution via yeast co-display for altering
peptide binding properties. A. Location of these positions corresponding to HLA-DR1 structure. B.
Space spanning for side chains of wild type residues at these positions. In all images, greens and purples
represent α1 and β1 domains of HLA-DR1 or corresponding residues in either domain. FLU peptide is
shown as stick-connected red or yellow spheres, where reds represent anchor residues with side chain dots
also dipicted in B. In A and B, top view (i) and side view (ii) are both presented.

An alignment of dozens of representative protein sequences for extracellular domain
encoded by naturally discovered DRB alleles indicates that most polymorphic sites are
concentrated in β1 domain, and responsible for peptide binding or TCR binding (Figure
5-8). All essential mutation sites (β11, β26, β30, β37, β57, β86) found in β chain
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suggested by yeast co-display are right among these polymorphic regions, and several
substitutions (Lβ11R, Lβ26F, Cβ30Y, Sβ37F, or even Hβ81Y) even exist in some
genuine alleles. Except for the relatively conserved bimorphic position β86 in P1 pocket,
all other essential mutation sites allow various alterations (up to 8) in nature (red
rectangles in Figure 5-8). In addition, it seems none of these sites affect the interaction
between MHC-II and TCR, DM or CD4 molecules. Because mutants isolated by yeast
co-display appear consistent with the natural evolution of MHC-II molecules, yeast codisplay seems like a potent tool for probing the molecular basis for MHC-II evolution in
defining peptide specificity.

Figure 5-8 Polymorphic sites of protein encoded by DRB alleles. Alternative residues at variable
positions of DRB extracellular domain (β1 and β2) are listed under corresponding position of protein
sequence for DR1β chain (DRB1*010101) by alignment of selective mature protein sequences in each
subgroup of DRB alleles (DRB1*010101, DRB1*030101, DRB1*040101, DRB1*0411, DRB1*070101,
DRB1*080101, DRB1*090102, DRB1*100101, DRB1*110101, DRB1*120101, DRB1*130101,
DRB1*140101, DRB1*150101, DRB1*160101, DRB3*01010201, DRB3*0201, DRB3*030101,
DRB4*01010101, DRB5*010101, DRB5*0202). Putative peptide contacting residues are shaded.
Essential mutation sites implied by directed evolution via yeast co-display are illustrated in red rectangles.
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5.4.3. Residues in P1 pocket defining peptide binding specificity
The conserved feature of α chain in nature, where little or no neutral drift is
suggested, implies that this chain is structurally or functionally intolerant to mutations;
here, α chain mutations were isolated from the primary libraries, suggesting that
mutations at these sites were not highly detrimental to folding, assembly or function of
the heterodimer. However, most mutations found at α24, α31, α32, and α54 disappear
after backcrossing, implying that these mutations were not important for binding to the
target peptide. In contrast, the three intensively mutated sites on β chain almost carry
alterations all the time, where β89, β90 permit various substitutions though a little
hydrophobic prone after backcrossing, while β86 mainly allows hydrophobic residues
even for accommodating P1-Glu with a negative charged side chain at P1 anchor. After
backcrossing, phenylalanine was greatly enriched at β86 in mutants specific for
hydrophobic P1 variants, especially for P1-Ala (Table 5-3), which agrees perfectly with
the fact discovered in other work that the β86 Gly-Val dimorphism plays an substantial
role in affecting peptide binding69, 119, 152, 179-181. This enrichment results in a single
mutation-bearing mutant S1V2.3 (Gβ86F), which exhibits a significant different side
chain preference for its P1 pocket (Figure 5-5A) and tends to lose binding ability to
aromatic side chain and bigger side chain bearing residues including the wild type Tyr in
comparison with the P1 pocket profile of wild type HLA-DR1 (Figure 4-5 or Figure 53A), which is also confirmed by previous characterization of a similar mutation at β8669.
Furthermore, S4V1.5 (Figure 5-3B), S4A1.9 (Figure 5-3C) and S1A2.10 (Figure 5-5B)
bearing the mutation Gβ86F are all exhibiting a similar P1 pocket profile to S1V2.3
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though minor differences exist among them, probably resulting from the non-shared
mutations in these clones.
As shown previously, in naturally-occurring DRB proteins, the bimorphic site β86
has either Gly or Val (Figure 5-8), whose small hydrophobic side chains allow P1 pocket
to have enough space for aromatic or bigger hydrophobic side chain to fit in (Figure 53A, 5-7B). This also explains why Val and Ala at P1 anchor of FLU analogues are less
favored, and mutants specific for them need longer side chain substitutions in order to
occupy the space and provide enough attractive force to hold small anchors (e.g. Figure
5-9A). These characterizations all support the fact that β86 is one of the dominant
residues within P1 pocket of HLA-DR1 for defining the pocket profile, or even suggest a
possible role of β86 in defining the significantly different peptide binding specificity of
another MHC-II allele, HLA-DQ, whose product has a hydrophilic β86 residue22, 58, 122,
154, 155

. Substitutions for other residues forming P1 pocket such as Hβ81Y, Fb89L,

Fbb89A, or even Fa32L, Fα54L found in conserved chain in Table 5-2, seem not
necessary but could presumably donate positive contribution to maintain the
hydophilicity and to stabilize P1 pocket by saving more space for the Phe-substitution at
β86 (e.g. comparing Figure 5-9B to Figure 5-7B).
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Figure 5-9 Selected examples of substitutions at essential mutation sites within P1 anchor-pocket
region dominating or affecting P1 Pocket profile. A. Gβ86F/P1-Val. B. Fα54L/P1-Val. Same as
shown previously, greens and purples represent essential residues in α1 and β1 domains of HLA-DR1
respectively, presumably responsible for peptide binding. P1 variants of FLU peptide is illustrated as
spheres either in red for anchors or yellow otherwise, connected by yellowish sticks with P1 anchor
residue replaced by corresponding variant (carbon/hydrogen, nitrogen and oxygen atoms are shown in
white, blue and red respectively). Space spanning for side chains of all residues at essential mutation sites
and all peptide anchors are indicated using dots. Cyan suggests specific mutations at different sites in
HLA-DR1 mutants. Mutagenesis was performed by using the software PyMOL. Briefly, wild type amino
acids was replaced by mutated residues arbitrarily first, and then one of the two conformations predicted
by PyMOL was selected to simply illustrate the putative side chain space spanning.

However, due to hydrophobic nature of P1 pocket59, 145, hydrophilic or charged side
chains such as Glu are much less favored such that replacing Gly itself at β86 by Ile, Leu,
Phe, or Thr would not be enough any more, alterations around P1 pocket especially in
the conserved chain become inevitable. Few phenotypic positive clones sorted out of
original P1-Glu-displaying library also confirm the difficulty for HLA-DR1 mutants to
accommodate P1-Glu peptide. Although most mutations in mutants bound by P1-Glu
are only shown once in table 5-2 and possibly neutral, Fα31L, Fα32S, Fα32L Lα45H,
Rα50G, Fα51Y are all located at P1 area. Along with Gβ86T, Fβ89Q, Tβ90M, all these
putative alterations in P1 pocket tend to convert the hydrophilicity of P1 pocket, which
potentially favor anchors such as Glu. Therefore, DNA shuffling and backcrossing
actually limit the carry-over of contributions from all these mutations and lead mutants
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even harder to prefer binding to P1-Glu (Figure 5-5C).

The only example in our

characterized clones that suggests a possibility to make Glu a preferred P1 anchor is
S4E1.3 (Fα22V, Fα32S, Lα60M, Dβ57Y, Gβ86I, Fβ89Q, Tβ90M), which unselectively
bind to all P1 variants with similar binding affinity (Figure 3D). This ultra promiscuity
implies an intermediate state from where if more alterations being introduced, resulting
mutants could specifically prefer Glu instead of hydrophobic residues. To compromise,
dominating nature of P1 pocket on peptide specificity may be dramatically disturbed and
importance of other pockets possibly arise, because several changes outside P1 pockets
are observed in S4E1.3 and these changes remain after backcrossing.

5.4.4. Significance of essential mutations occurred outside P1
pocket
Clones selected from the original three libraries all contain multiple mutations (Table
5-2), which makes structure-function relationship harder to interpret, but of particular
interest is that random mutations outside the six designed mutation sites have been
extensively observed throughout the whole mutagenized gene cassette [DRα(1–
61)//GAL1-10//DR1β(1–146)], especially along the β chain even considering the more
residues included in the cassette. A couple of these mutations were remaining in the
cassettes as the only mutation after DNA shuffling and backcrossing against wild type
sequence (Table 5-3), a process that theoretically would eradicate most nonessential
substitutions. Therefore, these sites found by sorting original libraries appear to convey
significant influence on peptide binding even they are not directly engaged in association
with P1 anchor. Based on the screening and characterization of phenotypic positive
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clones selected from two generations of yeast libraries, residues outside P1 pocket that
might introduce important contribution to P1 variant associations include α22, β11, β26,
β30, β37, β57 (Figure 5-7). Mutations occurring in these sites are more or less favorable
for accommodation of other anchor residues on peptide regardless of alteration in P1
anchor-pocket region. For example, Lβ11R, Cβ30Y (not single mutation, but clearly
important), Sβ37F and Dβ57Y found in S1A2.1, S1V2.4, S1V2.1 and S1E2.6 actually
exhibit larger space occupancy (Figure 5-10A~D) than wild type (Figure 5-7B), which
could provide stronger molecular interaction between the mutated residues and P6, P7,
P9 anchors respectively.

Other than that, even though Fα22V and Lβ26F are not

observed as single mutations, their contributions for peptide binding can be judged by
comparing S1E 2.21 or S1E2.18 versus S1E2.16 (Figure 5-5C). The effect of Fα22V is
possibly connected to stabilization of P4 anchor Gln by replacing the aromatic side chain
to smaller hydrophobic one (Figure 5-10F). The effect of Lβ26F is not obvious due to
the simple mutagenesis analysis by PyMOL (Figure 5-10E), but could also be due to
some correlation with P4 anchor considering its importance in some other DR proteins
with Phe at β26 (e.g. DR2182), though a little bit false positive was observed for S1E2.18
(Figure 5-6H).
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Figure 5-10 Substitution at essential mutation sites outside P1 anchor-pocket region favoring for
accommodation of P1 variants. A. Lβ11R/P1-Ala. B. Cβ30Y/P1-Val. C. Sβ37F/P1-Val. D.
Dβ57Y/P1-Glu. E. Lβ26F/P1-Val. F. Fα22V/Glu-variant. Color illustrations are the same as previous
figure. Mutagenesis was performed by PyMOL in a similar manner to previous figure.
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Relative binding assay shows HLA-DR1 mutants containing only these mutations
rather obtain stronger overall binding ability than altering P1 anchor preference (Figure
5-5).

Alternative explanation of this observation is that higher expression level

(probably related to stability) instead of better peptide binding occurred due to these
mutations, which agrees with the hypothesis proposed in other work that mutations
Lβ11H, Lβ26F and Dβ57A are responsible for increasing the stability of a single-chain
derivative of HLA-DR1 displayed by yeast133. The fact that the anchor preference
governed by P1 pocket can hardly be changed by introducing substitution outside this
pocket confirms the dominance of P1 pocket on determining peptide binding specificity
and the relatively independent peptide-binding nature of P1 pocket region to elsewhere.
However, different from S1V2.1 (Sβ37F), the ability of mutants S1A2.1 and S1E2.6
to associate with variants that are not bound by wild type HLA-DR1 suggests that
substitutions Lβ11R and Dβ57Y occurring in P6 and P9 pockets could compensate a
little affinity loss caused by P1 anchor alteration, such that weak- or non-binder could
associate. Although due to a lack of single mutation in P4 and P7 pockets we did not
characterize whether such substitution could provide similar compensation, essential
mutations around all these four anchors indeed have been identified for altered binding
affinity, suggesting similar effects of all these pockets on acquiring binding ability to P1
variants that wild type does not bind. In addition, elsewhere studies suggest that sitedirected mutations applied at sites β11, β13, β30, β67, β70, β71, β74, β78 forming P4,
P6, and possibly P7 pockets have impact on peptide binding by other DR alleles such as
DR3 or DR7119, 166. The importance of β26, β37 and β57 for P4, P9 pocket of DQ
proteins has also been postulated for determining their specific peptide association56, 58,
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167, 183, 184

. Therefore we postulate that the effect of any of the other four pockets is

roughly equal on stabilization of peptide binding for DR proteins without influencing the
binding specificity determined by P1 pocket, and the contribution for peptide binding
from one of these four pockets can be obtained by modifying residues in others.

5.4.5. Evolutionary hint for MHC-II in peptide binding specificity
Comparing with P1-Val or P1-Ala, the huge hydrophilicity change in P1-Glu peptide
requires more residue alterations in essential positions, which are closely related to
natural evolution of MHC-II molecules. In humans, HLA-DQ, another subclass of
MHC-II alleles, encode some proteins specific for binding and presenting antigenic
peptides with Glu or Gln at P1 anchor, and these proteins have significantly different
residues in their P1 pockets as well as other pockets22, 58, 122, 154, 155. For example, the
structure of HLA-DQ8 in complex with an immunodominant peptide insulin B (derived
from insulin B chain 9-23: SHLVEALYLVCGERG, with the N-terminal Glu as P1
anchor and C-terminal Glu as P9 anchor)58 suggests that Gluβ86, Hisα24 and Gluα31
instead of Glyβ86, Pheα24 and Ileα31 in HLA-DR1 are responsible for forming P1
pocket for DQ8 to hold Glu (P1) in the insulin B peptide. Obviously, the hydrophilicity
of P1 pocket in DQ8 is completely reversed, and P1 is demonstrated to be less important
than some other pockets such as P4 and P9 in determining peptide binding specificity of
DQ molecules, in agreement with our findings for mutants (e.g. S4E1.3) with relatively
better binding to P1-Glu mentioned previously. It is also known that protein sequences
of DQA are not conserved at all (Table 1-1), consistent with the observation in our
results that more alterations are involved in α chain for mutants obtaining P1-Glu
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binding ability (Table 5-2 and 5-3). Particularly, DQ8 has Leuβ26 and Alaβ57 at P4 and
P9 pockets respectively responsible for accommodation of corresponding anchors Tyr
(P4) and Glu (P9) in insulin B peptide. Even though mutations Fα22V, Lβ26F and
Dβ57Y occurred around P4 and P9 pockets in HLA-DR1 mutants S4E1.3, S1E2.1,
S1E2.6, S1E2.9, S1E2.18, S1E2.21 may not contribute to P1-Glu binding the same way
as Leuβ26 and Alaβ57 towards insulin B peptide, β26 and β57 are selected out of yeast
library even though we did not design any of these sites for mutagenesis. All these
similarity between the mutations we found in mutants bound by P1-Glu peptide and the
essential residues in DQ8 specific for Glu (P1) bearing insulin B peptide, gives us an
obvious hint that there is a molecular motivation for evolving MHC-II by switching
peptide binding dominancy in between different pockets to broaden peptide binding
spectrum. This might be the reason why MHC-II molecules have been differentiated
into three major subtypes for recognition and presentation of various antigenic peptide
sequences derived from different sources.
Additionally, the result that single-mutation-bearing HLA-DR1 mutants favor for
binding to P1-Glu is hardly found to exhibit a similar anchor preference to S4E1.3
indicates that single mutation might only lead to a relatively moderate alteration and the
genuine change in peptide specificity can only be obtained by combining multiple such
moderate alterations. This phenomenon can be observed by comparing the relatively
lesser polymorphism among different proteins within a subtype of MHC-II to the more
significant sequence differences between DR and DQ proteins.
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5.4.6. Summary of engineering HLA-DR1 for altering peptide binding
specificity
The peptide binding specificity of HLA-DR1 molecule is predominantly governed
by residues forming P1 pocket, essentially the naturally bimorphic site β86, which is
also responsible for controlling the hydrophilicity of this pocket with significant
contributions dedicated by other residues in P1 pocket. Residues outside P1 pocket
region provide relatively independent and equal importance on stabilizing peptide
association.
To specifically associate with hydrophobic P1 variants, one hydrophobic substitution
at β86 is presumably sufficient and those at other potentially polymorphic sites in or
outside P1 pocket could strength the specificity of this alteration though not necessary.
This indicates the relationship between different alleles found in DR subtype (e.g. DR1,
DR2, DR3, DR7 as mentioned previously). On the other hand, to specifically bind
hydrophilic P1 variants, appropriate alterations applied to β86, conserved sites in α
chain within P1 pocket, and essential sites around other pockets are all required for
accumulating all necessary contributions to this specificity conversion. To maintain
structural stability, more residue substitutions might be needed in other non-polymorphic
sites, as a result of which the dominant feature of P1 pocket could significant altered,
implying a structural rationale for differentiation of different MHC-II subtypes (DR, DQ,
etc.). Another hypothesis is that hydrophilicity might be one critical motivation for the
gradual switching of dominant pocket during natural selection and could possibly guide
the experimental evolution strategies.
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Chapter 6. Conclusions of this thesis work and the future
6.1. Development of a quantitative, high throughput
engineering platform for studying protein-protein interactions
In this thesis work, we developed a powerful in vitro methodology – yeast co-display
for characterizing and engineering in vivo protein-protein interaction by using a wellcharacterized immune response related protein pair FLU/HLA-DR1.

It has been

clarified that the assembly of HLA-DR1 and their baiting by target peptide mainly take
place inside yeast via secretory pathway and dissociation on the surface is a slow process
which will not affect discovering the direct linkage between phenotype on the surface to
genotype inside the same yeast.

Furthermore, the surface display of HLA-DR1 is

actually peptide-binding-dependent.

Therefore, interest phenotype of corresponding

peptide-variants/MHC-II-mutants binding on the surface of target yeast clones recovered
after several rounds of FACS cell sorting in a high throughput manner can be further
analyzed quantitatively via yeast co-display.
On one hand, peptide molecules can be manipulated either by saturating an interested
anchor with all natural amino acids for determination of anchor preference or by
randomizing the entire sequences for characterization of HLA-DR1 binding specificity.
Therefore, both specific pocket profiles and general binding motif can be generated by
yeast co-display. On the other hand, MHC-II molecules can be modified by directed
evolution method for altering their peptide binding specificity, which can be applied for
designing novel proteins for immunotherapeutic purpose or for understanding molecular
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basis of natural evolved polymorphic MHC-II proteins with the help of crystallographic
analysis or molecular modeling.

6.2. Generation of peptide binding spectrum of MHC-II for
various applications
Importance on modification of MHC-II molecules and on identification of MHC-II
ligands has been emphasized several times throughout this thesis.

Herein we are

showing a map of peptide binding spectrum for HLA-DR1 and its mutants generated by
collecting and quantitatively analyzing several yeast co-display data, which would
provide a guidance for future mapping the database of promiscuous HLA-specific
ligands experimentally or computationally (Figure 6-1).
In this three-dimensional map, X-axis starts with the wild type FLU peptide followed
by alternative P1 variants, and to a extend, more randomized peptides. Y-axis lists
HLA-DR1 as well as its mutants, which normally contain more substitutions following
the axis direction. Z-axis represents the relative binding of each peptide to each protein.
Because libraries constructed by yeast co-display would yield false positive, a set of
background controls for each peptide are also included at the origin of Y-axis.
Looking at this map, first, it is easy to tell the false positive such as peptide sequence
S4DR1pep1.6 generated by sorting randomized peptide library against wild type HLADR1. Second, anchor presences for each protein can be compared for further sequencestructure-function relationship analysis. For example, S1V2.3 (Gb86F) prefers smaller
hydrophobic side chains to bigger ones in comparison with wild type HLA-DR1, and
S1A2.1 (Lβ26F) obtains the ability to bind most non-binders of wild type HLA-DR1.
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These findings are directly related to the single substitutions within these two mutants as
we discussed in Chapter 5. Third, relative binding of different DR proteins to a specific
variant can be compared, which could affect the determination of using specific protein
to present target peptide for possible immunotherapeutic applications.

Fourth,

interaction between DR proteins and randomized peptide sequences can be used to
identify and compare peptide motifs of each protein. If more alterations are introduced
into wild type FLU peptide, data can be added in between P1 variants and randomized
peptides and more sequence-function relationship could be acquired.

If more DR

proteins are tested for their association with different peptides, data can also be inserted
in corresponding Y-axis. The potential of constructing and combining peptide libraries
with MHC-II mutant libraries using yeast co-display would accelerate the generation of
peptide/MHC-II interaction data to fill this indefinite binding spectrum, which would be
extremely useful for guiding us to understand peptide binding properties of MHC-II
molecules and applying created MHC-II with defined peptide specificity for vaccine
design or other purposes.
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Figure 6-1 An example of peptide binding spectrum of DR proteins determined by yeast co-display.

6.3. Potential applications of yeast co-display
Interaction of FLU and HLA-DR1 molecules occurring inside yeast cells better
mimics the is in vivo scenario compared to other binding assays, but it belongs to in vitro
engineering methods, which decrease biological complexity and concentrate on the
interested functionality of targets. Therefore, phenomena observed by yeast co-display
could be subtly different from those occurring in original biological environment, where
accessory molecules are extensively involved65. It is suggested that the presence of
HLA-DM is important for acceleration of weaker peptide (e.g. Ii) dissociation185 (Figure
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1-4)

and DM reportedly functions by interacting with DR molecules from the N-

terminal side of accommodated peptides128, 186, which would provide more restraints on
screening HLA-DR1 mutants specific for target P1 variant. The ability to assemble
HLA-DR in a secreted form therefore entering the secretory pathway and to co-express
multiple plasmids simultaneously suggests a potential of this yeast system wherein DM
could be co-expressed (e.g., with an ER retention signal) in a similar way and the
peptide binding of DR molecules would be examined in the presence of this catalyst.
The capability to characterize and modulate protein-protein interactions in yeast
using co-display will also show its promising application in various ligand-receptor
interaction studies. For instance, in the immune system, other than peptide/MHC-II
protein pairs, a lot of other protein pairs like antigen-antibody, peptide/MHC complexTCR, IFA-ICAM, and CD40-CD40L are being intensive studied these days due to their
significant role in CD4+ T cell development and function (Figure 1-2). It is possible to
study the interaction between these protein pairs using yeast co-display system and to
determine the function-structure relationship of them.

However, covalent linker in

between anchor protein Aga2 and at least one protein of these ligand-receptor pairs has
to be introduced most of the times, which could be a drawback in the future.
The success of expressing two heterologous proteins encoded by three genes in yeast
actually extends yeast expression system for engineering more structurally complicated
molecules.

Instead of making single chain derivatives, essential immunity related

membrane proteins such as MHCs, antibodies, and T cell receptors (TCRs), are all able
to be displayed more natively as heterodimer on yeast surface for function studies.

156

Additionally, yeast display of a homotrimer like hemagglutinin would also become
possible.
Yeast co-display remains some other advantages of surface-display technology. One
example is the possibility of direct purification of soluble HLA-DR1. The solubility of
HLA-DR1 produced in this system and the freedom of its dissociation from the surface
though a little slow make routinely purification of recombinant MHC-II from this system
become possible. It is demonstrated that the FLU/HLA-DR1 complex on the surface of
yeast can be stripped off by treatment of Factor Xa (Chapter 2), so some easier
approaches can be developed for extracting soluble HLA-DR1 or FLU/HLA-DR1 from
yeast cells. However, although the affect is not yet shown in our system, the highmannose yeast glycosylation and the low protein expression level are still major
limitations for assembling human glycoproteins. Engineered yeast strains with fully
humanized glycosylation pathway187, 188 would probably help improved the performance
of our system for producing recombinant proteins in the future. Another advantage of
the surface-display system is that yeast co-displaying FLU/HLA-DR1 complexes has the
potential to stimulate T cell response by direct contact of FLU/HLA-DR1 complex and
TCR. This is partially proved by experiments elsewhere134. Finally, applying yeast codisplay technology in the area of whole yeast vaccine design189, 190 would shed light on
development of novel immunotherapeutic strategies.
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